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A la Isa, per l’alegria i amb les llàgrimes del record.
3
31
32
33
34
35
36
37
38
39
40
45
3
446
47
48
49
4
“Do you see the story? Do you see anything? It seems to me I am trying to tell you a dream--making a vain 
attempt, because no relation of a dream can convey the dream-sensation, that commingling of absurdity, 
surprise, and bewilderment in a tremor of struggling revolt, that notion of being captured by the incredible 
which is the very essence of dreams...” 
Joseph Conrad, Heart of Darkness and the Congo Diary 
 
« —Mire vuestra merced —respondió Sancho— que aquellos que allí se parecen no son gigantes, sino 
molinos de viento, y lo que en ellos parecen brazos son las aspas, que, volteadas del viento, hacen andar 
la piedra del molino.
—Bien parece —respondió don Quijote— que no estás cursado en esto de las aventuras: ellos son gigantes; 
y si tienes miedo quítate de ahí, y ponte en oración en el espacio que yo voy a entrar con ellos en fiera y 
desigual batalla ».
"Ninguna ciencia, en cuanto a ciencia, engaña; el engaño está en quien no la sabe."
Miguel de Cervantes
« Au milieu de l’hiver, j’apprenais enfin qu’il y avait en moi un été invincible" 
Albert Camus
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Malaria risk factors for pregnant women and infants in Benin.
Abstract
In Benin malaria and nutritional deficiencies are the main diseases contributing to the disease burden. 
Therefore, preventive strategies targetting both diseases have been deployed for over 10 years.
Pregnancy-associated malaria (PAM) is responsible for maternal anaemia, placental malaria and low 
birth weight (<2500g), contributing to enhance maternal and child morbidity and mortality. To 
prevent PAM, the World Health Organization recommends the intermittent preventive 
treatmentduring pregnancy (IPTp). In Benin it consists in the administration of two curative doses of 
sulfadoxine/pyrimethamine (SP) at least one month apart and starting at the second trimester of 
pregnancy. Considering that IPTp has an effect on PAM, and thereby influences the exposure of the 
fœtus to the parasite, we wanted to investigate the possible effect of IPTp on malaria in infants.
In parallel, iron supplements are recommended during pregnancy to prevent maternal anemia. Some 
pediatricians give iron supplements to infants as well. As there is some epidemiological evidence that 
iron might enhance malaria episodes and their severity we wanted to analyse the association of iron 
levels with malaria in pregnancy and infancy. Therefore, we analysed data from a cohort study of 
1005 pregnant women conducted from 2010 to 2012 in Allada (Benin), and data of the first 400 
infants born to this cohort of mothers, who were followed for a year.
First, we showed that interval length between IPTp doses (the number of days between doses) was 
inversely correlated with malaria risk and P. falciparum parasitemia, possibly due to the reduction of 
the exposure of the fœtus to the parasite in utero, which thereby hinders a possible immune tolerance 
process. 
We also found that iron levels during pregnancy and infancy were associated to increased malaria 
risk and P. falciparum parasitemia, with a possible dose effect.
In a context of growing resistance to SP, a strategy based on more than 2 doses of SP should be 
encouraged to confer an optimal protection to pregnant women. In addition, complementary 
interventional data are needed to determine the benefits and risks of differently dosed iron 
supplements, in order to ascertain their impact on infant health in malaria-endemic regions.
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I. Introduction
Les principales causes de morbidité et de mortalité en Afrique sub-Saharienne sont les maladies 
infectieuses et les déficiences nutritionnelles. Les femmes et les enfants de moins de cinq ans y 
sont particulièrement vulnérables. D’après l’OMS, entre 2000 et 2012, les carences nutritionnelles, 
les maladies infectieuses, ainsi que la morbidité périnatale représentent la plupart des causes de 
mortalité chez les enfants et les jeunes femmes .
L’anémie,  dont  la  première  cause  est  la  carence  en  fer,  est  définie  par  l’OMS par  des  taux 
d’hémoglobine  < 11  g /  l.  C’est  une  des  maladies  liées  aux carences  nutritionnelles  les  plus 
prévalentes  dans le monde :  on estime qu’au début  du XXI siècle,  25 % des enfants seraient 
anémiés . La prévalence de l’anémie gestationnelle au Bénin est très élevée avec une estimation 
dépassant 65 % . Pour pallier ce problème d’anémie chez la femme enceinte, une supplémentation 
en fer  a  été  activement  recommandée par  l’OMS depuis  les années  1990.  De fait,  une méta-
analyse  Cochrane effectuée en 2012 montre que la  supplémentation en fer est  associée à  une 
réduction de 70 % du risque d’anémie et de 57 % du risque de carence en fer . Au Bénin, des 
suppléments de 200 mg de sulfate ferreux et 5 mg de folate jusqu'à 45 jours après l’accouchement 
sont donnés aux femmes enceintes systématiquement.
Cependant  différentes études  épidémiologiques suggèrent que des niveaux de fer élevés auraient 
un  effet  délétère  sur  le  risque  de  paludisme  .  Néanmoins,  l’absence  d’étude  de  cohorte 
longitudinale chez la femme enceinte et chez l’enfant reste un obstacle important pour établir un 
lien entre les niveaux de fer et un risque accru de paludisme.
Etant donné qu’au Bénin  une supplémentation en fer est donnée systématiquement aux femmes 
enceintes, et que le paludisme est endémique dans la région, notre premier objectif était d’analyser 
l’association entre les niveaux de fer et le paludisme gestationnel dans une cohorte prospective de 
femmes enceintes. 
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Chez les enfants béninois des taux d’anémie supérieurs à 80 % ont été reportés . Néanmoins, il n’y 
a pas à ce jour au Bénin de recommandation officielle concernant la supplémentation en fer chez 
l’enfant, même si l’OMS recommande un supplément quotidien de 12,5 mg de fer chez les enfants 
âgés entre 6 et 24 mois dans des contextes où la prévalence d’anémie dépasse 40 % . 
Par ailleurs, au Bénin, la principale cause de mortalité des enfants de moins de cinq ans reste le 
paludisme.  Environ  21  % des  décès  infantiles  dans  ce  pays  sont  dus  au  paludisme,  maladie 
responsable de 22,8 % des années de vie perdues en 2010 . En définitive, malgré une prévalence 
d’anémie  infantile  et  une  mortalité  causée  par  le  paludisme  très  importantes,  aucune 
recommandation nationale concernant  les suppléments en fer n’est  proposée.  Pour ces raisons, 
nous avons cherché à identifier l’accroissement du risque de paludisme chez le nourrisson en lien 
avec des niveaux élevés de fer plasmatique.
En parallèlle, afin de réduir les effets du paludisme gestationnel, le Ministère de la Sante du Bénin 
a mis en place une stratégie de traitement préventif intermittent (TPI) du paludisme pendant la 
grossesse. Ce traitement, par son effet sur le parasite, permet de réduire l’anémie maternelle, mais 
aussi le paludisme placentaire, la prématurité, et le petit poids a la naissance . Ainsi, outre les 
suppléments de sulfate ferreux et de folate, 1500 / 75 mg de sulphadoxine-pyrimethamine (SP) 
sont prescrits aux femmes enceintes béninoises en tant que TPI. Ce traitement s’administre en 
deux doses à un mois d’écart  au minimum, dont la première le plus tôt  possible au cours du 
deuxième trimestre de grossesse. 
Ainsi, le paludisme gestationnel étant associé au paludisme de l’enfant , il est possible que les 
interventions modifiant l’exposition au parasite, aient aussi un effet sur le paludisme de l’enfant. 
Cet  aspect  a  été  peu  investigué  jusqu’à  présent :  notre  deuxième objectif  a  donc  consisté  en 
l’analyse de l’effet du TPI sur le risque de paludisme chez l’enfant pendant la première année de 
vie.
Finalement, des chercheurs travaillant sur la même cohorte avaient trouvé des niveaux élevés de 
plomb chez ces enfants. Les niveaux élevés de plomb, comme le paludisme, ont un effet sévère sur 
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le développement de l’enfant et sont associés à des taux très importants d’anémie. Par ailleurs, 
Nriagu avait trouvé un effet significatif du paludisme sur la plombémie chez des enfants 
nigérians . Pour ces raisons notre troisième objectif était d’évaluer l’effet des niveaux élevés de 
plomb sur le risque palustre.
Afin d’atteindre ces objectifs, nous avons étudié les indicateurs palustres ainsi que les niveaux de 
fer sériques chez 1005 femmes enceintes. Ces femmes étaient recrutées par les études APEC  
(Anemia in pregnancy : etiology and consequences) et MiPPAD (Malaria in pregnancy preventive 
alternative drugs, http://clinicaltrials.gov/ct2/show/NCT00811421). Cette dernière étant plus 
spécifiquement un essai clinique comparant l’efficacité de la sulphadoxine-pyrimethamine 
(1500/75 mg par dose) et la méfloquine (15 mg/kg). Les critères d’inclusion des femmes étaient : 
l’absence de prise de TPI, de traitement anti-helmintique ou de suppléments en fer ou acide 
folique. Un dépistage du VIH était également proposé aux femmes.
Après l’accouchement, nous avons suivi 400 de leurs enfants (200 enfants de mères anémiées à 
l’accouchement, et 200 enfants de mères non-anémiées à l’accouchement) pendant toute leur 
première année de vie. Les niveaux de plomb des enfants ont également été analysés à 12 mois.
Ces études ont été réalisées entre janvier 2010 et mai 2012 dans trois cliniques d’Allada, une 
région sémi-rurale 50 km au Nord de Cotonou, où le paludisme est  principalement dû à 
Plasmodium falciparum. La transmission du paludisme à Allada est pérenne avec des pics 
saisonniers : entre avril et juillet et entre octobre et novembre.
Notre suivi dans le temps de la femme enceinte et de l’enfant comprenant des données répetées, 
nous avons utilisé des modèles multiniveaux avec un intercept aléatoire au niveau individuel. Plus 
précisément, nous avons utilisé comme variables dépendantes : i) la possibilité d’avoir ou pas une 
goutte épaisse positive pendant le suivi et ii) la parasitémie (évaluée par microscopie) au cours du 
suivi.
Pour évaluer l’effet du plomb sur le risque palustre, nous avons utilisé une régression logistique 
sur la possibilité d’avoir ou pas une goutte épaisse positive à 12 mois au cours du suivi, ainsi 
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qu'une régression linéaire en utilisant la parasitémie à 12 mois (évaluée par microscopie) comme 
variable dépendante.
II. Etat de l’art
1. Effet des niveaux de fer de la femme enceinte sur le paludisme gestationnel 
Une méta-analyse Cochrane a montré de manière convaincante les bénéfices associés à la 
supplémentation en fer. En effet, les suppléments en fer pendant la grossesse sont associés à une 
réduction de 70 % du risque d’anémie et à une réduction de 57 % de la carence en fer comparé à 
des contrôles. Cependant, le fer est un cofacteur de la croissance de Plasmodium , et ces 
suppléments pourraient entraîner une augmentation du risque palustre dans les zones d'endémie. 
Bien que les essais cliniques ne montrent pas d’augmentation de la morbidité liée à la 
supplémentation, la carence en fer est associée à un moindre risque d’épisodes palustres . Même si 
les différences ne sont pas statistiquement significatives, les taux de ferritine des femmes avec un 
placenta infecté par Plasmodium falciparum sont systématiquement plus élevés que chez les 
femmes sans infection placentaire dans toutes les études dans des pays avec des transmissions 
aussi diverses que la Tanzanie , le Gabon , le Malawi , la Gambie , ou le Kenya . Une méta-
analyse récente, bien que concluant à l'absence de preuve épidémiologique pour conclure à une 
augmentation de risque palustre liée aux suppléments , montre que la carence enfer, mesurée par la 
ferritine sérique, est associée à un moindre risque de paludisme gestationnel. En outre, la plupart 
des études n'évaluant les niveaux de fer sériques qu'à l'inclusion des femmes ou lors de 
l'accouchement, il serait utile de mener des études de cohortes avec un suivi systématique des 
niveaux de fer pendant tout le déroulement de la grossesse. 
Un autre élément important concerne la manière d’évaluer les taux de fer. Une combinaison 
d’indicateurs est souhaitable d’après l’OMS en dépit de l’existence d’un marqueur «gold 
standard», l'hémoglobine. En conséquence le Comité Technique de l’OMS recommande le suivi 
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des niveaux de fer par l’hémoglobine, le volume corpusculaire moyen (VCM), le récepteur soluble 
de la transferrine (sTfR), la ferritine sérique,  et la protoporphyrine des globules rouges mesurée 
par le ratio zinc protoporphyrine/hémoglobine (ZPP :H) .
2. Effet des niveaux de fer de l’enfant sur le paludisme
Chez le jeune enfant, l’épisode palustre est défini par une température > 37.5 ºC et une goutte 
épaisse positive dans les 48 h. La carence en fer est définie par des niveaux de ferritine sérique < 
12 μg / ml ou < 15 μg / ml dans la plupart d’études. Une première révision d’enquêtes menées 
entre 2001 et 2003 au Kenya d’enfants âgés de 8 mois à 8 ans décrit une protection significative 
contre le paludisme chez les enfants carencés en fer  (ratio d’incidence ajusté (RI) = 0,7 ; IC 95 % 
(0,51; 0,99)).  Une enquête plus récente menée en Tanzanie (2012), a également montré que la 
carence en fer était associée à un moindre risque de parasitémie (OR = 0,15 ; IC 95 % (0,12; 
0,19)), d'hyperparasitémie (définie par un nombre de parasites > 2500 / 200 globules blancs) (OR 
= 0,04 ; IC 95 % (0,02; 0,07)) et de paludisme sévère (OR = 0.25 ; (IC 95 % (0,14; 0,46)). 
Quant aux études sur la supplémentation, un essai clinique randomisé contre placebo en 1995 en 
Tanzanie n’avait pas montré de différences significatives relatives au risque palustre entre les 
enfants de 8 à 24 mois .  Néanmoins, en 2003 l’essai clinique de Pemba (Tanzanie) avait montré 
une augmentation très importante du risque palustre parmi les 2413 enfants âgés de 0 à 35 mois, 
de la cohorte . Plus précisément, le risque d’hospitalisation par paludisme était significativement 
supérieur (RR = 1,18 ; IC 95 % (1,02; 1,36)), ainsi que le risque de paludisme cérébral (RR = 
1,22 ; IC 95 % (1,02; 1,46)) chez les enfants supplémentés. Cette étude avait fait modifier les 
recommandations de l'OMS dans le sens d'une restriction des suppléments en fer uniquement aux 
enfants carencés . 
Concernant l’importance des niveaux de fer de départ pour la supplémentation, lors d’une étude au 
Ghana en 2010, les enfants ayant une carence en fer et de l’anémie avait un risque 
significativement réduit de paludisme comparés aux enfants ayant reçu du placebo (RR = 0,67 ; IC 
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95 % (0,5; 0,88). Cependant, en Tanzanie en 2008  un essai de supplémentation en zinc et autres 
nutriments (dont le fer), avait décrit que les enfants carencés étaient significativement plus à risque 
de paludisme lors de la supplémentation (Rapport de risque =1,41 ; IC 95 % (1,09; 1,82)). En 
effet, la question reste ouverte et les résultats des différents essais cliniques se révèlent a nouveau 
contradictoires. Une revue Cochrane a tenté de trancher ce débat en analysant les données de 
45.353 enfants de 71 essais cliniques différents. Après s’être concentré sur les 13 études les plus 
fiables, cette révision conclut qu’il n’y a pas de différences statistiquement significatives 
concernant les épisodes palustres entre les enfants supplémentés par rapport aux enfant ayant reçu 
un placebo (RR = 0,99 ; IC 95 % (0,9; 1,09). Nonobstant, cette revue décrit un risque de 
paludisme plus élevé chez les enfants supplémentés, en l’absence de surveillance épidémiologique 
ou de traitement. Une évaluation de l’augmentation du risque en prenant en compte les niveaux de 
fer de départ, mesurés par la ferritine, reste également à faire.
En conclusion, l'interprétation dans le sens d'une augmentation du risque de paludisme associée 
aux niveaux de fer diffère entre les études observationnelles et les essais cliniques. Globalement, 
les études observationnelles décrivent une certaine protection contre le paludisme chez les enfants 
carencés en fer. En parallèle, des anciennes études sur l'administration de suppléments en fer 
rapportent un risque de paludisme accru lié a la supplémentation , comme le fait l’étude de Pemba, 
qui a une puissance statistique notable. Pourtant, les essais cliniques les plus récents, réalisés dans 
le contexte d'une prophylaxie anti-palustre effective, ne montrent pas d’augmentation de risque 
significative de paludisme liée à la supplémentation . Pour toutes ces raisons, il est nécessaire 
d’analyser une cohorte prospective on l’on évalue les niveaux de fer lors de chaque épisode 
palustre afin de pouvoir conclure sur l’association entre paludisme et niveaux de fer.   
La révision de la littérature sur l’association entre les niveaux de fer et le risque paluste a fait 
l’objet d’un article actuellement sous révision dans le journal « Nutrition reviews ».
3. Effet du paludisme gestationnel et du TPI sur le paludisme de l’enfant
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Le paludisme gestationnel est défini comme l’infection du sang périphérique ou placentaire par 
Plasmodium falciparum par l’OMS. Ayant un effet délétère sur la santé de la femme enceinte et de 
l’enfant, le paludisme gestationnel constitue un problème majeur de santé publique dans le monde. 
A lui seul, il est responsable de 125 millions de grossesses à risque par an . L’exposition à 
Plasmodium in utero dépend de la transmission et des mesures de contrôle qui modifient cette 
exposition. Le TPI, une des plus importante stratégies de contrôle, diminue la parasitémie 
périphérique de la mère ainsi que le paludisme placentaire, modifiant significativement la réponse 
immunitaire du foetus in utero . 
Une analyse globale de quatre études fondatrices réalisée en 2007 a déterminé que l’administration 
du TPI, constitué de deux doses de SP, est associée à une réduction du risque de paludisme 
placentaire correspondant à un risque relatif (RR) = 0 , 48 comparé à l’administration d’un 
placebo, ou comparé au seul traitement des accès cliniques . 
Le paludisme gestationnel est lié pendant les premiers mois de vie à un risque accru de paludisme 
chez le jeune enfant . En effet, il est associé à un risque augmenté de paludisme congénital, à un 
plus grand nombre d’épisodes palustres pendant l’enfance, à un plus grand risque d’anémie, et 
enfin à des épisodes de fièvre non palustres . 
Comme l’a révélé une étude réalisée en 1997 au Cameroun, le paludisme gestationnel est corrélé 
avec des épisodes palustres plus précoces chez le nourrisson . Plus précisément, cette étude a 
trouvé que l’infection placentaire par Plasmodium falciparum était significativement liée au 
paludisme de l’enfant âgé de quatre à six mois : à six mois, 36 % des enfants avec un placenta 
infecté avaient déjà subi un épisode palustre, alors que seulement 14 % des enfants avec un 
placenta non-infecté avait souffert un épisode palustre  (valeur p < 0.05). En outre, la parasitémie 
était plus élevée chez les enfants issus d’un placenta infecté entre 5 et 8 mois, que chez les enfants 
dont le placenta n’était pas infecté. En 2002-2004, une étude effectuée en Tanzanie a confirmé ces 
résultats et déterminé un hazard ratio (HR) de 1,41 (intervalle de confiance (IC) 95 % (1,01; 1,99)) 
jusqu'à la première parasitémie chez les enfants nés avec un placenta infecté par rapport aux 
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autres. Plus récemment, au Mozambique, il a été observé que les enfants des mères ayant subi des 
épisodes palustres pendant la grossesse et / ou un placenta infecté, présentaient significativement 
plus d’épisodes palustres pendant l’enfance (Odds ratio (OR) = 1,96 ; IC 95 %, (1,13; 3,41), et OR 
= 4,63 ; IC 95 % (2,10; 10,24)), respectivement . Enfin, une étude réalisée en 2009 au Bénin a 
confirmé le lien entre le paludisme placentaire et le paludisme chez l’enfant, en s’appuyant sur un 
suivi entomologique et environnemental rigoureux . Cette étude a montré que les enfants issus 
d’un placenta infecté dormant sous une moustiquaire imprégnée ont significativement plus de 
risques de contracter le paludisme que les enfants dont le placenta n’était pas infecté (rapport de 
risque = 2,13 ; IC 95 % (1,24; 3,67)). Cette étude a considéré également d’autres facteurs de 
risque comme la transmission, la saisonnalité, le nombre d’Anopheles, et des facteurs obstétricaux. 
Cette même étude a montré que les enfants présentaient une sensibilité accrue à des parasites 
possédant les mêmes antigènes que ceux auxquels ils avaient été exposés in utero, ce qui suggère 
l’existence d’un processus de tolérance immunitaire . Enfin, plusieurs études ont mis en évidence 
une réduction du transfert d’anticorps au foetus associée au paludisme gestationnel, ce qui 
augmenterait la susceptibilité de l’enfant au parasite .  Cependant les mécanismes 
physiopathologiques de ce processus n’ont pas encore été élucidés.
En définitive, le paludisme gestationnel détermine l’exposition foetale à P. falciparum et il est 
corrélé à un risque accru de paludisme pendant l’enfance, probablement suite à un processus de 
tolérance immunitaire in utero. Le TPI, en réduisant l’exposition au parasite, pourrait également 
diminuer la morbidité associée au paludisme gestationnel. Ceci implique une réduction des taux de 
petit poids à la naissance, de la prématurité, du retard de croissance intra-utérin et de la mortalité 
périnatale dans des contextes où la résistance à la SP n’est pas encore très présente.
La révision de la littérature sur le lien entre le paludisme gestationnel et le paludisme chez l’enfant 
a fait l’objet d’un article publié dans le journal « Malaria Journal ».
4. Autres facteurs ayant un effet sur le paludisme de l’enfant : le cas du plomb.
En parallèle à notre étude, des collègues ont retrouvé dans la même cohorte d’enfants des niveaux 
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de plomb très élevés. Des niveaux élevés de plomb sont associés à un risque accru d’anémie et à 
des troubles neurologiques , symptomatologie également présente dans le paludisme. Ceci est 
d’autant plus préoccupant que la pathologie se concentre aussi dans la tranche d’âge de 12 à 36 
mois, période particulièrement délicate pour les enfants impaludés . Enfin, Nriagu avait trouvé en 
2008 une effet négatif significatif du paludisme sur les niveaux de plomb , alors que la prévalence 
de niveaux de plomb élevés en Afrique de l’Ouest est très importante . Pour ces raisons, nous 
voulions déterminer la nature de l’association entre les niveaux de plomb et le risque palustre tout 
en considérant d’autres facteurs de risque de paludisme.
III. Résultats
1. Effet des niveaux de fer sur le paludisme gestationnel
A la première consultation anténatale 1005 femmes enceintes ont été inclues et 941 ont été suivis 
jusqu’à l’accouchement. Pendant le suivi, 29 % des femmes enceintes ont eu au moins un épisode 
palustre. La moyenne, de gouttes épaisses postives était de 0,52 (écart-type = 1,23), avec une 
médiane de 0 (1er quartile=0, 3eme quartile=1) et une étendue de 0 à 6. 
Après utilisation de modèles multi-niveaux à intercept aléatoire chez les mères, les valeurs élevées 
de la concentration de fer (approximés par le logarithme en base 10 de la ferritine corrigé par 
l’inflammation) étaient associées significativement au risque d’avoir une goutte épaisse positive 
(OR ajusté = 1,75 ; IC 95 % (1,46; 2,11) ; valeur p < 0,001) et à une parasitémie par P. falciparum 
plus importante (estimateur beta = 0,22 ; IC 95 % (0,18; 0,27) ; valeur p < 0,001). De plus, les 
femmes carencées en fer étaient significativement à moindre risque d’avoir une goutte épaisse 
positive et une parasitémie élevée (valeur p < 0,001 dans les deux cas). Plus précisement, ces 
modèles comprennent les résultats de 2227 gouttes épaisses et 2227 frottis sanguins de 826 
femmes. Des niveaux élevés de fer étaient également significativement associés au risque de 
paludisme placentaire (OR ajusté = 2,02 ; IC 95 % (1,43; 2,86) ; valeur p < 0,001) et de petit poids 
à la naissance (OR ajusté = 1,69 IC 95 % (1,28; 2,22) ; valeur p < 0,001).
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En parallèle, des niveaux élevés de folate étaient significativement associés à un moindre risque 
d’avoir une goutte épaisse positive (OR ajusté = 0,37 ; IC 95 % (0,19; 0,70) ; valeur p = 0,002), et 
à une moindre parasitémie (estimateur beta = -0,20 ; IC 95 % (-0,37; -0,08) ; valeur p < 0,001). Un 
statut socio-économique élevé était associé à un moindre risque de paludisme et à une moindre 
parasitémie par P. falciparum (OR ajusté = 0,82 ; IC 95 % (0,69 ; 0,96) ; valeur p = 0,02, et 
estimateur beta = -0,05 ; IC 95 % (-0,09; -0,01) ; valeur p = 0,01, respectivement). Egalement, un 
jeune âge de la mère, un âge gestationnel précoce et un processus inflammatoire actif, étaient 
statistiquement liés au risque palustre et à une parasitémie élevée.
Ces résultats ont fait l’objet d’un article publié dans le journal « Open Forum Infectious 
Diseases ».
2. Effet du TPI et des niveaux de fer sur le paludisme de l’enfant
A l’accouchement, 10,9% des placentas étaient infectés par Plasmodium falciparum, même si 
aucun cas de paludisme congénital n'a été trouvé. Parmi les 400 enfants inclus à la naissance, 324 
ont été suivis au long des 12 mois de suivi. Pendant la première année de vie 40% des enfants ont 
eu au moins un épisode palustre. En moyenne, les enfants ont eu 0,64 gouttes épaisses positives 
(écart-type = 0,92), avec une étendue de 0 eà 4. Plus concrètement, 60,25 % des enfants n’ont eu 
aucune goutte épaisse positive pendant le suivi, 22 % en ont eu 1, 12,5 % en ont eu 2, 4,5 % en ont 
eu 3, et 0,75 % des 400 enfants en ont eu 4. 
Il n’y avait pas de différences significatives entre les femmes ayant reçu un TPI à base de SP et les 
femmes ayant reçu de la MQ. Néanmoins, l’intervalle entre deux prises du TPI était 
significativement associé à un moindre risque de paludisme (OR ajusté = 0,87 ; IC 95 % (0,76 ; 
0,99) ; valeur p = 0,04) et à une parasitémie plus basse (estimateur beta = -0,06 ; IC 95 % (-0,1 ; 
-0,01) ; valeur p < 0,001).
Dans des modèles multi-niveaux à intercept aléatoire réalisés chez les enfants, les niveaux de fer 
de élevés (approximés par le logarithme en base 10 de la ferritine corrigé par l’inflammation) 
étaient associés significativement au risque d’avoir une goutte épaisse positive (OR ajusté = 2,77 ; 
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IC 95 % (1,95 ; 3,96) ; valeur p < 0,001) et à une parasitémie par P. falciparum plus élevée 
(estimateur beta = 0,38 ; IC 95 % (0,29 ; 0,47) ; valeur p < 0,001). ). Plus précisement, ces 
modèles comprennent les résultats de 746 gouttes épaisses et de 746 frottis sanguins de 329 
enfants. Egalement, les enfants carencés en fer étaient significativement à moindre risque d’avoir 
une goutte épaisse positive et une parasitémie élevée (valeur p < 0,001 dans les deux cas). En 
parallèle, la présence d’un processus inflammatoire actif était associée à un risque accru d’avoir 
une goutte épaisse positive (OR ajusté = 4,37 ; IC 95 % (2,20 ; 8,65) ; valeur p < 0,001) et une 
parasitémie élevée (estimateur beta = 0,77 ; IC 95 % (0,53 ; 1,01) ; valeur p < 0,001). 
Par ailleurs, des niveaux de folate maternels élevés et la présence d’helminthes chez la mère à 
l’accouchement étaient significativement associés à un risque accru d’avoir une parasitémie élevée 
pendant la première année de vie (estimateur beta = 0,34 ; IC 95 % (0,01 ; 0,66) ; valeur p = 0,04, 
et estimateur beta = 0,88 ; IC 95 % (0,20 ; 1,57) ; valeur p = 0,03, respectivement). Un statut 
socio-économique bas était aussi lié à une parasitémie élevée (estimateur beta = 0,12 ; IC 95 % 
(0,01 ; 0,23) ; valeur p = 0,03). Le volume des précipitations, indicateur du risque anophélien, était 
marginalement associé à un risque élevé de paludisme (OR ajusté = 1,06 ; IC 95% (0,99 ; 1,11) ; 
valeur p = 0,06) et à une parasitémie plus importante (estimateur beta = 0,03 ; IC 95% (-0,00 ; 
0,06) ; valeur p=0,06). 
Finalement, les enfants avec des niveaux de ferritine dans les deux derniers quartiles étaient 
significativement plus à risque de paludisme.
Ces résultats ont fait l’objet d’un article actuellement sous révision dans le journal « Pediatrics ».
3. Effet des niveaux de plomb sur le paludisme de l’enfant
A 12 mois, 25 des 203 enfants pour qui les niveaux de plomb avaient été évalués (12,5 %), avaient 
une goutte épaisse positive, avec une parasitémie moyenne de 13460 parasites / μl. Les niveaux de 
plomb élevés sont définis par le CDC comme des niveaux de plomb sanguin > 5 µg / dL. Trente-
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neuf enfants (19 %) avaient des niveaux de plomb toxiques, définis par des niveaux de plomb 
sanguin > 10 µg / dL.  Lors de l’analyse multivariée par régressions logistique et linéaire 
respectivement, des niveaux de plomb élevés étaient associés à un moindre risque de goutte 
épaisse positive, (OR ajusté = 0,98 ; IC 95 % (0,96 ; 0,99) ; valeur p = 0,02) et à une moindre 
parasitémie par P. falciparum (estimateur beta = -0,003 ; IC 95 % (-0,006 ; -0,001) ; valeur p = 
0,04). Les niveaux élevés de plomb, étaient aussi statistiquement corrélés à un moindre risque de 
goutte épaisse positive, (OR ajusté = 0,38 ; IC 95 % (0,15; 0,99) ; valeur p = 0,048) et à une 
moindre parasitémie par P. falciparum (estimateur beta = -0,44 ; IC 95 % (-0,84 ; -0,04) ; valeur p 
= 0,03). D’autres facteurs ont ét trouvés associés à un risque accru de paludisme : les niveaux 
élevés de fer (estimés par le logarithme en base 10 de la ferritine) (OR ajusté = 2,46 ; IC 95 % 
(1,01 ; 6,05) ; valeur p = 0,05) et les niveaux élevés de folate, statistiquement liés à une plus 
grande parasitémie par P.falciparum (estimateur beta = 0,0003 ; IC 95 % (0,0001 ; 0,006) ; valeur 
p = 0,04).
Ces résultats ont fait l’objet d’un article actuellement sous révision dans le journal « Plos One ».
IV. Discussion
1. Effet des niveaux de fer sur le paludisme gestationnel
Le fait de retrouver une association très significative entre les niveaux de fer et le risque palustre 
chez la femme enceinte est d’autant plus important qu’une récente méta-analyse avait conclu qu’il 
n’y avait pas d’éléments suffisants pour évaluer ce lien. En effet, les niveaux de fer et le risque 
palustre n’avaient jamais été analysés de manière conjointe tout au long d’un suivi de cohorte 
pendant la grossesse, en dépit de l’importance donnée aux suppléments en fer pour corriger 
l’anémie gestationnelle dans les zones d’endémie palustre. De plus, nous avons également trouvé 
que les niveaux de fer étaient statistiquement associés au paludisme placentaire et au petit poids de 
naissance, ce qui illustre l’effet délétère des niveaux élevés de fer de la mère sur la santé de 
l’enfant également. 
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Le fait que la carence en fer confère une protection contre le risque palustre pendant le suivi et que 
les niveaux de fer n'aient pas été trouvéss significativement associés avec le risque palustre chez 
les femmes carencées suggère l’existence d’un seuil à partir duquel les niveaux de fer 
deviendraient délétères. En effet, une étude a montré une augmentation du risque palustre à partir 
de 30 jours de supplémentation en Afrique. Nos résultats sont en outre cohérents avec la 
littérature, qui décrit une protection conférée la carence en fer, bien que les essais cliniques (menés 
dans le contexte de mesures préventives importantes) ne montrent pas d’augmentation 
significative du risque. 
Des explications plausibles pour expliquer l’augmentation du risque liée à des niveaux de fer 
élevés résultent, au niveau de l’hôte, de l’interférence de Plasmodium avec le système immunitaire 
et de son intervention dans l’inhibition de l’absorption de fer. En outre, les niveaux élevés de fer 
rendraient plus difficile l’activation des macrophages et, de fait, le fer non lié à la transferrine est 
corrélé avec la sévérité du paludisme.
En conclusion, l’interaction entre les niveaux de fer et le risque palustre est complexe et 
ambivalente en raison des besoins augmentés de fer pendant la grossesse et d'autre part de 
l’augmentation de risque palustre que supposent des taux élevés. Pour ces raisons, une recherche 
plus approfondie est nécessaire afin de lever cette ambigüité dans un contexte d’anémie 
gestationnelle fortement prévalente. 
2. Effet du TPI et des niveaux de fer sur le paludisme de l’enfant
L’intervalle entre deux prises de TPI ainsi que les niveaux de fer sont associés au risque palustre 
pendant la première année de vie, en considérant aussi bien la probabilité de survenue d’une 
goutte épaisse positive que la parasitémie par Plasmodium falciparum. 
Le paludisme gestationnel étant connu comme influençant l’état de santé de l’enfant10, il est 
plausible qu’une intervention préventive chez la mère ait également un effet sur le paludisme de 
l’enfant. Nos résultats sont de ce point de vue cohérents avec la littérature. Borgella et al. ont 
trouvé que les infections pendant le dernier trimestre de grossesse étaient associées à un risque 
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accru d’infection (OR = 4,2 ; CI 95 % (1,6; 10,5) ; valeur p = 0,003) ainsi que d’épisode palustre 
(OR = 4,6 ; CI 95 % (1,7; 12,5) ; valeur p = 0,003) . En outre, Huynh et al. avaient décrit que le 
calendrier du TPI et les infections au premier trimestre de grossesse étaient liés à un plus grand 
risque de petit poids à la naissance (-98,5 g; valeur p = 0,03) .  Par contre, Harrington avait trouvé 
en Tanzanie que le TPI était associé à des épisodes palustres plus précoces parmi les enfants issus 
d’un placenta infecté . Néanmoins, on retrouve une résistance très importante à la SP dans le 
Nord-Est de la Tanzanie, et la même équipe a déjà montré que, dans cette région, le TPI se révèle 
inefficace . Dans cette population, le TPI est associé à une grande fréquence d’allèles de résistance 
à la SP, à une densité parasitaire plus importante. Ces arguments renforcent indirectement 
l’hypothèse du processus de tolérance immunitaire in utero. Dans tous les cas, le fait que 
l’augmentation de la durée totale du TPI (par espacement ou ajout de nouvelles prises) ait un effet 
protecteur sur le paludisme de l’enfant est plutôt rassurant à la lumière des nouvelles 
recommandations de l’OMS en faveur d’un renforcement du rythme d’administration de la SP.
En parallèle, nous avons trouvé une association très significative entre les niveaux de fer et le 
risque palustre (prévalence et densité parasitaire) pendant toute la première année de vie en 
prenant en compte d’autres facteurs de risque environnementaux, socio-économiques, et 
obstétricaux. La carence en fer avait en particulier un effet protecteur pendant tout le suivi. Plus 
précisément, les enfants avec de faibles niveaux de fer, dans le premier quartile de l’échantillon, 
étaient significativement à moindre risque d’épisodes palustres et avaient une densité parasitaire 
significativement plus basse que les autres. 
Dans la littérature cet effet protecteur de la carence en fer  est souvent évoqué. Dans une revue 
Cochrane étudiant l’effet de la supplémentation en fer chez les enfants en zone d’endémie palustre 
aucune augmentation de risque palustre n’avait été mise en évidence . Cependant, comme déjà dit, 
les niveaux de fer ne sont pas déterminés longitudinalement. 
Malgré ces résultats, les suppléments en fer ont des bénéfices indéniables pour la santé des 
enfants. Une méta-analyse leur attribue une protection très significative contre l’anémie (RR = 
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0,61 ; IC 95 % (0,50; 0,74), n=4825) et contre la carence en fer (RR = 0,14 IC 95% (0,10;–0,22), 
n=2145) . Etant donné qu’il n’est pas possible de pondérer les risques et les avantage des 
suppléments car très difficilement quantifiables, les mesures antipaludiques doivent être sans 
doute encouragées.  
3. Effet des niveaux de plomb sur le risque palustre
Les proportions très importantes d’enfants avec des niveaux de plomb élevés (63 %) et avec des 
niveaux toxiques (19 %) plaident pour la prise en considération du rôle des niveaux de plomb dans 
la morbidité liée aux maladies infectieuses chez les enfants. L’effet protecteur du plomb associé au 
risque palustre est plutôt rassurant en raison de l’importante prévalence des niveaux élevés de 
plomb en Afrique de l’Ouest. Au Nigéria, on retrouve 55 % d’enfants avec des niveaux toxiques . 
Néanmoins, en dépit de cette étude qui met en évidence en analyse univariée un effet du 
paludisme sur les niveaux de plomb , notre travail est le premier à décrire un effet des niveaux 
élevés de plomb sur le paludisme. Le mécanisme explicatif de l’interférence entre plomb et 
paludisme serait un effet toxique du métal sur le parasite dans le globule rouge, 
l’immunorégulation, et l’inhibition de l’utilisation du fer par le parasite qui se produit dans un 
contexte d’élévation de la plombémie.
En outre, le fer comme le plomb sont associés significativement au paludisme, mais aussi à 
l’anémie. En conséquence, il est nécessaire de considérer l’impact sur la morbidité lié au fer 
comme au plomb dans les stratégies dédiées à la lutte contre l’anémie.
V. Conclusion
L’impact du paludisme gestationnel n’implique pas seulement le paludisme placentaire, la 
prématurité ou le petit poids à la naissance, mais aussi un risque accru de paludisme pendant 
l’enfance, probablement suite à un processus de tolérance immunitaire in utero. Par conséquent, 
les interventions s’attaquant au paludisme placentaire devraient également avoir un effet sur le 
paludisme chez l’enfant. En effet, l’augmentation de la durée d’administration du TPI (par 
exemple par augmentation du nombre de prises) permettrait d’allonger la période pendant laquelle 
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l’enfant est protégé et serait ainsi associée à un moindre risque d’épisodes palustres et à une 
parasitémie par Plasmodium falciparum moins importante. Néanmoins dans notre étude, ni le 
moment d’administration du TPI, ni le type de régime (SP ou MQ) ne paraissent avoir d’effet sur 
le paludisme de l’enfant.
L’association entre les niveaux de fer et le risque palustre pendant la grossesse et l’enfance est 
d’autant plus importante que le contexte d’endémie palustre est associé à une prévalence 
importante d’anémie, rendant les suppléments d’autant plus nécessaires. D’où l’importance de 
montrer ce risque augmenté dans une cohorte prospective chez la femme enceinte et aussi chez 
l’enfant. 
Chez la femme enceinte, même dans le cadre de l'utilisation de moustiquaires et du TPI, nous 
avons montré l’impact des niveaux élevés de ferritine sur le risque d’épisodes palustres et de 
densités parasitaires élevées, ainsi que sur le paludisme placentaire et le petit poids à la naissance. 
Chez l’enfant les mêmes résultats sont retrouvés, ce qui devrait être pris en compte pour élaborer 
les politiques de supplémentation et des nouveaux essais cliniques, qui devraient aussi élargir les 
marqueurs du monitorage du fer.
VI. Perspectives
Compte tenu de l'effet probable du paludisme gestationnel sur le paludisme de l’enfant, de 
nombreux arguments plaident en faveur d'une initiation des stratégies préventives contre le 
paludisme gestationnel dès la période pré-conceptionnelle afin de mieux protéger la mère et 
l’enfant. La recherche opérationnelle sur les différentes stratégies de TPI en fonction du contexte 
de résistance à la SP avec des doses élargies devrait fournir des connaissances supplémentaires. 
Ainsi, des analyses coût-efficacité du dépistage et du traitement au niveau communautaire 
pourraient également se révéler très utiles pour les décideurs en santé publique. Le fait que les 
enfants aient une susceptibilité accrue aux parasites portant les mêmes allèles que ceux auxquels 
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ils avaient été exposés in utero, est également encourageant pour la poursuite de recherches 
explorant le processus de tolérance immunitaire. 
D’autres aspects comme les conséquences neurocognitives du paludisme ou l’effet des 
polymorphismes d’HLA-G sur les symptômes du paludisme mériteraient des recherches plus 
approfondies. 
Sur un plan pratique, la possibilité d’un effet-dose des niveaux de fer sur le risque d'infection 
palustre devrait justifier la réalisation d’essais cliniques de supplémentation avec des doses 
différentes pour en évaluer l'efficacité sur les indicateurs hématologiques. 
Quant à la détermination de méthodes permettant d'obtenir des indicateurs fiables de la charge en 
fer de l'organisme, nous pensons que l'évaluation du fer dans les suivis de populations devrait 
intégrer un dosage de l’hepcidine ainsi que les marqueurs recommandés l’OMS,  et inclure des 
marqueurs de l’inflammation comme la CRP ou l’AGP. 
Finalement, si les femmes avaient des niveaux de fer suffisants avant la grossesse, on pourrait 
envisager de diminuer le dosage des suppléments recommandés, ce qui diminuerait les 
inconvénients liés à l'administration de fortes doses de fer. D’autres pratiques comme le clampage 
retardée du cordon ombilical pourraient être appliquées dans le cas des enfants.
Dans tous les cas, des niveaux de fer suffisants sont vitaux pour la mère et l'enfant, et ils doivent 
être atteints de toutes les manières possibles. En conséquence, les stratégies de contrôle et de 
prévention doivent être optimisées afin d’assurer un risque minimal pendant la grossesse et 
l’enfance. 
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I. Introduction
I. 1. The global burden of disease in Africa
The global burden of disease in the African continent is mainly driven by infectious diseases 
and nutritional deficiencies, the pregnant women and the children under 5 years being the 
most vulnerable groups in the population. In the African region communicable, maternal and 
nutritional conditions gather the largest proportion of the crude death rate by broad cause 
group between 2000 and 2012 (Figure 1). More precisely, in 2012, out of the 1000 deaths per 
100,000 people, approximately 60% were due to communicable, maternal and/or nutritional 
conditions, whereas communicable diseases gathered 30% and injuries 10%, respectively.
Figure 1. Crude death rate by broad cause group between 2000 and 2012, WHO 2013.
Hence, maternal and infant health have been prioritized in public health policies. Indeed, they 
are at the heart of 4 out of the 8 Millenium Development Goals (i.e. to promote gender 
equality and empower women, to reduce child mortality, to improve maternal health, and to 
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     I. Introduction
combat HIV/AIDS, malaria, and other diseases). To be most effective, public health strategies 
need to target the main causes of disease underlying the impaired health status of pregnant 
women and children. 
I. 2. The burden of disease in Benin
In Benin, the three risk factors that account for most of the disease burden (in disability-
adjusted life years (DALYs)) are childhood underweight, household air pollution from solid 
fuels, and iron deficiency (defined by WHO as serum ferritin levels<15μg/l) (Figure 2). The 
leading risk factors for the burden of diseases in children under 5 and adults aged 15-49 years 
were childhood underweight and iron deficiency, respectively, in 2010.
Figure 2. 
Burden of disease 
attributable to 15 leading risk factors in 2010, expressed 
as a percentage of Benin's disability-adjusted life years 
(DALYs). Institute of 
Health Metrics, 2015. The colored portion of each bar represents 
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     I. Introduction
the specific diseases attributable to that risk factor while bar size represents the percentage of DALYs 
linked to specific risk factors.
Albeit the high disease burden gathered by nutritional deficiencies, mortality rates in children 
under 5 years of age in Benin are driven mainly by malaria (Figure 3). Over 21% of child 
deaths are caused by malaria, which, in addition, is also responsible for 22.8% of life years 
lost (LYY) in 2010.
Figure 3. Distribution of causes of deaths in children under 5 years in Benin (2012). 
WHO, 2014.
Therefore, not only globally but also in Benin do nutritional deficiencies and malaria lead 
morbidity and mortality rates in children under 5 years.  For these reasons, substantial efforts 
have been made by to fight these diseases in Benin.
For further knowledge, information on malaria physiopathology is explained in Box 1. 
Complementary information about the epidemiology of malaria in Benin is presented in Box 
2.
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Box 1.   Malaria: Physiopathology and  Plasmodia   life cycle: 
Malaria is a human disease caused by a eukaryotic unicellular parasite from the genus 
Plasmodium. There are 5 different Plasmodia species that can infect Humans: 
P.falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. In Benin the majority of 
the disease burden is caused by P. falciparum, and in this dissertation we will focus on P. 
falciparum malaria. This parasite is transmitted from one infected human host to another 
human by the bite of the mosquito vector, the female Anopheles. P. falciparum has a 
sexual reproduction in the Anopheles and an asexual reproductive phase in the human 
host. After the infectious Anopheles bite, the parasites (known as sporozoites at that stage 
of the life cycle) reach the hepatocytes within which they multiply. After one to two 
weeks, the infected hepatocytes explode and liberate hepatic merozoites parasites into the 
blood. The parasites infect then the red blood cells (RBC), where they develop as 
trophozoites and, after having multiplied, they become schizontes. Upon RBC rupture, 
erythrocytic merozoites are liberated into the blood and will infect other RBC. After 
several cycles of erythrocytic multiplication do gametocytes appear. Gametocytes are the 
sexual form of Plasmodium, and they are absorbed by the mosquito bite.  After sexual 
reproduction and then maturation in the gut and salivary glands of the mosquito, 
respectively, they are injected by the female Anopheles to another human host. 
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Box 2.   Malaria in Benin: Epidemiology  
Benin is a West-African republic whose surface is 114 762 km2. In 2013 the Beninese 
population was about 10.3 million people, half of them living in the countryside. It has a 
low Human Development Index (HDI, ranged 165th according to the HDI). 
In 2013, according to the WHO World Malaria Report, it is still considered a high 
transmission country, i.e., there are >1 case per 1000 population per year. Even if there 
are some infections by P. vivax, WHO considers that in Benin almost 100% of malaria 
cases are due to P.falciparum. The main vectors are A. gambiae, A. funestus, and A. 
melas. In 2014 there were 1,078,834 confirmed cases and 2,288 reported deaths due to 
malaria. Intermittent preventive treatment in pregnancy (IPTp) against malaria was 
introduced in 2005, and Insecticide residual spraying (IRS) started to be implemented in 
2006. The policy of free distribution of insecticide treated nets (ITNs) was adopted in 
2007. The first-line treatment according to Beninese guidelines is arthemether-
lumefantrine (AL), and in case of failure and/or severe malaria quinine (QN) is the 
molecule recommended. Artesunate (AS) is also recommended for severe malaria.
Allada, the site of our research study, is a semi-rural area of 91,778 inhabitants located 50 
km North of Cotonou (Benin). Malaria has a perennial transmission pattern with two 
transmission peaks corresponding to the rainy seasons in April-July and October-
November. As in the rest of Benin, Plasmodium falciparum is the species responsible for 
the majority of infections.  Source: WHO. World Malaria Report 2014. Beninese Ministry of Health.
Figure 4. Map and plan of the disctric of Allada. Source: Institut Géographique National du Bénin.
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I. 3. Preventive strategies to tackle the disease burden during 
pregnancy and infancy in Benin
As stated previously, in Benin the main contributors to disease burden during infancy are 
malaria and nutritional deficiencies. 
However, there are no official preventive strategies regarding malaria in infants. 
With regard to nutritional diseases, underweight and iron-deficiency anemia are the main 
conditions contributing to enhance nutritional deficiencies. 
Underweight is significantly linked to low birth-weight (LBW, defined as birth-
weight<2500g), whose rates in Benin reached 13% in 2012. Indeed, infants with lower birth 
weights are likely to remain shorter and lighter throughout childhood compared to infants 
without LBW, especially those having experienced intra-uterine growth retardation (IUGR, 
defined as birth-weight below the 10th percentile of a reference weight distribution according 
to gestational age). In addition, LBW is significantly associated to increased morbidity and 
mortality. Furthermore, LBW and malnutrition have a synergistic relationship with infectious 
diseases.
From the epidemiological perspective, LBW is correlated with pregnancy associated malaria 
(PAM), low maternal body-mass index (BMI), and maternal micronutrient deficiencies. 
Therefore, interventions during pregnancy to fight LBW include the prevention of PAM, low 
BMI and maternal micronutrient deficiencies. To prevent the consequences of PAM, the 
Ministry of Health implements an intermittent preventive treatment in pregnancy (IPTp) 
against malaria. This intervention consists in 1500/75 mg of sulphadoxine-pyrimethamine 
(SP). Usually, it is joint to the anti-helminth parasitic preventive treatment of 600 mg of 
albendazole, although other treatments are available (appendix 3). Thereby Benin follows 
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WHO recommendations encouraging IPTp with SP for all pregnant women as early as 
possible in the second trimester, and at each scheduled antenatal care (ANC) visit at least one 
month apart in areas of moderate to high malaria transmission. Supplementary information on 
PAM can be found in Box 2, but briefly, PAM by Plasmodium falciparum involves the 
adherence of Plasmodium to the placenta, and it is thought this might entail reduced 
nutritional exchanges between mother and fœtus. Consequently, IUGR and prematurity 
(defined as gestational term less than 37 weeks), the two main mechanisms underlying LBW, 
are more likely to appear. IPTp should reduce plasmodial parasitemia in the mother’s blood, 
and thereby hinder the red blood cells (RBC) sequestration in the placental intervillous space. 
Consequently, foeto-maternal exchanges should improve and, consequently, LBW rates 
should diminish.
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Box 3.   Pregnancy associated  malaria: basic concepts  
In pregnancy associated malaria (PAM) erythrocytes infected with P. falciparum 
accumulate in the placenta through adhesion to molecules such as chondroitin sulphate A. 
Antibody recognition of placental infected erythrocytes is dependent on gravidity, and 
could protect from malaria complications. Moreover, the parasite gene var2csa has been 
associated with placental malaria, suggesting that its protein product might be an 
appropriate vaccine candidate. On the contrary, the understanding of placental 
immunopathology in the context of PAM and how this contributes to anaemia and low 
birth-weight has not been elucidated so far; although we know that inflammatory 
cytokines produced by T cells, macrophages, and other cells play a major role. 
The symptoms and complications of PAM vary according to malaria transmission 
intensity in the given geographical area and according to the individual’s level of acquired 
immunity. In high-transmission settings, where levels of acquired immunity tend to be 
high, P. falciparum infection is usually asymptomatic in pregnancy. Yet, parasites may be 
present in the placenta and contribute to maternal anaemia even in the absence of 
documented peripheral parasitaemia. In high-transmission settings, the adverse effects of 
P. falciparum infection in pregnancy are most pronounced for women in their first 
pregnancy. In low-transmission settings, where women of reproductive age have 
relatively little acquired immunity to malaria, malaria in pregnancy is associated with 
anemia, an increased risk of severe malaria, and it may lead to spontaneous abortion, 
stillbirth, prematurity and low birth weight. In such settings, malaria affects all pregnant 
women, regardless of the number of times they have been pregnant. Sources: WHO, Rogerson 
et al. 
To fight nutritional deficiencies during pregnancy, the Beninese Ministry of Health prioritized 
the prevention of anemia (defined by WHO as hemoglobin (Hb) <11g/l). Therefore, it 
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recommends supplements of 200 mg of ferrous sulphate and 5 mg of folate given daily until 
45 days after delivery.
Indeed, anemia, including iron-deficiency anemia, constitute a public health concern not only 
during pregnancy but also during infancy. Despite the lack of official recommendations, in 
case of iron defiency anemia, Beninese paediatricians give daily supplements of iron of 10 
mg/kg/day and 0.5 mg/kg/day of folic acid during 2 months, every 6 months, starting at 6 
months of age until 5 years. This is similar to WHO guidelines, which recommend 12.5 mg 
iron and 50µg folic acid to prevent anaemia in children 6-24 months. In case of low birth-
weight (LBW), defined by birth weight<2500g, supplements start at 2 months. Concrete 
details on accurate recommendations of the national Beninese program against malaria are 
given in the appendix 3.
However, there is some epidemiological evidence that suggests that iron supplements could 
have an effect on malaria appearance and severity. Considering that iron supplements are 
given systematically during pregnancy in Benin, and that malaria is endemic in the region, we 
wanted to investigate the possible effect of iron levels on PAM. Furthermore, we wanted to 
analyse the effect of the infant iron levels on malaria in infants as malaria is the first cause of 
infant mortality, and there are no national guidelines on the iron supplementation policy in 
infants.
In parallel, as PAM seems to have a significant effect on malaria in infants, and IPTp has an 
impact on secondary malaria outcomes (such as LBW and anaemia), we wanted to investigate 
the possible impact of IPTp on malaria in infants during the first year of life.
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II.1. Effect of preventive public health interventions during pregnancy 
on pregnancy associated malaria: evidence of protective measures and 
iron levels. 
II.1.1. Effect of IPTp on PAM outcomes: clinical malaria in pregnancy, 
placental malaria, and low birth-weight.  
II.1.1.a. Epidemiological evidence
Pregnancy associated malaria (PAM) is defined as peripheral or placental infection by 
Plasmodium, and it constitutes a stake of interest for infant health as its consequences may 
attain 125 million pregnancies at risk of malaria infection every year. More precisely it is 
estimated that 32 million women become pregnant every year in Sub-Saharan Africa endemic 
countries. The prevalence of malaria in pregnancy is influenced by transmission, the 
immunity of the mother and protective measures. The main protective interventions against 
PAM are insecticide-treated nets (ITNs) and intermittent preventive treatment (IPT). IPT is a 
widespread preventive strategy to fight malaria consisting in the administration of a curative 
dose of an effective anti-malarial drug, regardless of the presence of Plasmodium in the blood, 
to prevent the effects of the disease. A landmark review gathering evidence on PAM between 
1985 and 2000 in Sub-Saharan Africa stated a median prevalence of PAM of 27.8% among 
all gravidae. In low transmission African settings the median prevalence peripheral infection 
was 13.7% and placental malaria median prevalence was 6.7%. In general, recent studies 
report a significant decline in prevalence following IPTp implementation since the beginning 
of the XXI century. A systematic review and meta-analysis of trials determining whether 
regimens containing 3 or more doses of SP for IPTp were associated with a higher birth 
weight or lower risk of LBW than standard 2-dose regimens showed that the 3-dose group 
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had less placental malaria (RR=0.51; 95% CI (0.38; 0.68) in 6 trials, 63 vs 32 per 1000; 
absolute risk reduction, 31 per 1000 (95%CI (20; 39)). However, the augmented efficacy 
related to higher doses is mostly observed in the case of clinical trials rather than in studies 
issued from public health program implementations. Finally, the additional protection of the 
joint use of ITNs with IPTp-SP is significant only in certain trials, but reported ITN use 
ranges from 5% to 25%, and it might not be sufficient to show an effect. 
In short the prevalence of PAM has evolved according to transmission and protective 
measures like IPTp or ITN use. Further elements like gestation and the moment of infection 
during pregnancy have shown to influence its pathologic consequences as well. Because 
immunity develops during the first pregnancy, primigravidae are especially at higher risk for 
PAM. 
Finally the timing of high parasitemia infections during pregnancy entails different effects on 
PAM outcomes like anemia or LBW. Therefore, the administration of IPTp at different 
moments determines different protection patterns for the infant. 
As a result of these concurrent realities, we have to consider other determinants of PAM, such 
as transmission, IPTp regime and gestity, to better understand the shades of the influence of 
IPTp on PAM.
II.1.1.b. Effect of IPTp on PAM 
WHO recommends in areas of moderate to high malaria transmission, IPTp with SP for all 
pregnant women as early as possible in the second trimester, and at each scheduled antenatal 
care visit at least one month apart. The different IPTp regimes implemented in the African 
region are described in Figure 4.
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Figure 5. Different IPTp regimes implemented in Sub-Saharan Africa
 Effective IPTp clears placental parasitemia and consequently modifies the exposure to 
malaria antigens. As a result, a significant reduction in placental malaria and maternal 
parasitemia has been extensively described in founding literature. Compared to case 
management or placebo in pregnant women, 2-dose IPTp with sulfadoxine-pyrimethamine 
(SP) reduced significantly placental malaria according to a review on 4 studies (relative risk 
(RR)=0.48). In a randomised, double blind, placebo-controlled trial with joint use of ITNs in 
Mozambique, SP-IPTp (1-2 doses) was not associated with placental malaria (p = 0.964), 
defined as the presence of parasites and/or pigment in the histological examination, and/or in 
the impression smear. Nevertheless, the SP group showed a 40% reduction (95% CI (7.40; 
61.20); p-value = 0.02) in the incidence of clinical malaria during pregnancy, and reductions 
in the prevalence of peripheral parasitemia (7.10% vs 15.15%) (p-value=0.001), and of 
actively infected placentas, defined as presence of parasites (7.04% vs 13.60%) (p-value= 
0.002), (Table1). 
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In Mali placental parasitemia was significantly reduced by SP-IPTp (aOR=0.69) when 
compared to weekly chloroquine (CQ) and confirmed higher SP efficacy compared to CQ 
already reported in Malawi. A recent meta-analysis has concluded to significant PM reduction 
for 3 doses of SP compared to 2 doses which approaches the current WHO recommendations. 
Problems related to reduced compliance with drug regimes and the increasing resistance to 
anti-malaria drugs bring up the complexity of IPTp management at present. A 2007 meta-
analysis confirmed that SP IPTp continued to benefit pregnant women in areas of up to 39% 
resistance to SP by day 14 in children, and similar results were found in Benin, where rates of 
in vivo resistance to SP were estimated to be 50% by day 28 of treatment in infants, and yet 
SP IPTp succeeded to prevent LBW. However, studies published more recently display 
contradictory results. A study in Malawi, where there is a strong fixation of the resistant 
quintuple mutant (mutations at dhfr codons 51, 59, and 108 and dhps codons 437 and 540), 
showed that the number of IPTp doses has a protective effect on birth outcomes but not on 
placental infection. More concretely, there were significantly less small for gestational age 
(SGA) rates in offspring of primigravid women having received ≥2 doses of SP compared to 
0-1 doses even if peripheral parasitemia was significantly higher among women having 
received ≥2 doses of SP. Indeed, the effects of resistance on malaria clinical outcomes 
become more frequent in more recent studies from East Africa. In a Tanzanian site with high 
SP resistance (14-day parasitologic SP treatment failure rate in children of 68%), IPTp was 
not associated with a reduction in the odds of PM, LBW or maternal anemia. Furthermore, it 
was associated with increased odds of fetal anemia and severe malaria among the offspring 
(AOR=2.31). IPTp in this setting was associated with an increased risk of severe malaria 
overall. Nevertheless, a recent longitudinal study showed no significant increase of malaria at 
delivery after IPTp treatment albeit the increasing prevalence and fixation of SP-resistant P. 
falciparum haplotypes in another area in Malawi. In conclusion, evidence on the present 
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efficacy of SP-IPTp regimes is inaccurate but resistance to SP is spreading. And close 
monitoring of its efficacy is necessary to determine if or when the treatment failure of SP-
IPTp detected by some recent studies is generalized at the population level and, in this case, a 
switch to other drug regimes would become necessary. 
Furthermore, effective IPTp diminishes PM and malaria associated morbidity like LBW, pre-
term delivery, IUGR and perinatal mortality in areas where resistance to SP is not highly 
significant. Even the Malaria Policy Advisory Committee (MPAC) concluded that there is 
currently insufficient data to determine at what level of resistance IPTp-SP should be 
interrupted in the absence of an established and effective alternative. Yet, the influence of 
different IPTp regimes on malaria morbidity in infants remains a question for further research. 
The concrete effect of resistance and the ongoing immune tolerance process in utero are 
neither elucidated so far. Further evidence lacks as well on the importance of the timing of 
infection during pregnancy and infant malaria morbidity for instance. There is some evidence 
that earlier administration of IPTp has a positive effect on birth outcomes like LBW, 
nevertheless, it seems that later dosing provides a better protection at delivery. This is one 
reason because of which the administration of 3 doses instead of 2 shows better clinical 
outcomes. In addition, the implementation of different IPTp regimes, in the context of 
different resistance patterns, entails novel stakes to the question regarding the adequate IPTp 
policy according to the transmission and resistance setting. For instance, intermittent 
screening and testing (IST) has been applied successfully in an area of moderately high 
malaria transmission in Ghana. IST consists in screening for malaria infection using a malaria 
rapid diagnostic test (RDT) at scheduled antenatal clinic visits and subsequently treating 
positive women with an effective anti-malarial drug. Currently, the DHA-PQ IST is a 
proposed alternative to IPTp in areas with substantial resistance against IPTp regimes. 
However, at present conclusive evidence on IST efficacy is lacking in African regions and 
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further efficacy studies should be conducted. 
The evaluation of its efficacy in other transmission settings is necessary to ascertain its utility 
as an effective tool for the control of PAM. 
II.1.2. Effect of iron levels on PAM
II.1.2.a. Iron markers
Before analyzing the effect of iron levels on PAM, it is useful to discern the specific 
information provided by the different iron markers. A joint summary is presented in table 2.
Table 2: Iron indicators selected by the WHO-CDC Technical Consultation for iron assessment  
Indicator Refers to Threshold values (venous blood of 
persons residing at sea level)
Other valuable information
Hemoglobin Anaemia For anaemia:
children aged 6 months to 6 years: 
11g/100ml
children aged 6–14 years: 12g/100ml
adult males: 13g/100ml
adult females, non-pregnant: 12g/100ml
adult females, pregnant: 11g/100ml
The assessment of hemoglobin alone can provide 
only a rough estimate of the likely prevalence of 
iron deficiency anaemia (IDA). The absence of a 
consistent standard for identifying iron 
deficiency contributes to confound the analyses 
on the relationship between anaemia and IDA 
prevalence rates
Zinc 
protoporphyrin 
(ZPP)
Iron deficient 
erythropoiesis
>70-80 µmol/mol for infants In the last step in hemoglobin synthesis, the 
enzyme ferrochetalase inserts iron. A lack of iron 
available to ferrochetalase during the early stages 
of iron deficient erythropoiesis results in a 
measurable increase in the concentration of zinc 
protoporphyrin, as trace amounts of zinc are 
incorporated into protoporphyrin instead. 
The normal ratio of iron to zinc in 
protoporphyrin is about 30 000:1.
Thresholds for ZPP vary between 40 and 70 
µmol/ mol haem depending on whether the cells 
have been washed before the assay or not
Mean cell volume 
(MCV)
Red blood cell size, 
anaemia 
characteristics.
Microcytic anaemia 
is a sign of iron 
deficiency anaemia, 
whereas macrocytic 
anaemia indicates 
deficiency of vitamin 
B12 or folate
<67-81fl Even if MCV is used widely for the evaluation of 
nutritional iron deficiency, low values are not 
specific to iron deficiency, but they are also 
found in thalassaemia and in about 50% of 
people with anaemia due to inflammation
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Transferrin 
receptor in serum 
(STR)
Inadequate delivery 
of iron to bone 
marrow and tissue
It is not possible to assign a single 
threshold value that would be accurate 
for all commercial kits. Approximately:
During severe beta thalassaemia the sTfR 
concentration is>100 mg/l
During severe iron deficiency anaemia it 
is >20–30 mg/l
sTfR is sensitive to erythropoiesis due to any 
cause. Hence, it cannot be interpreted as an 
indicator of solely iron deficiency erythropoiesis. 
Its concentration increases in individuals with 
stimulated erythropoiesis, such as haemolytic 
anaemia and sickle cell anaemia. Indeed, acute or 
chronic inflammation and the anaemia of chronic 
disease, malaria, malnutrition, age and pregnancy 
may modify significantly sTfR.
There is a lack of standardization between 
different commercial kits for measuring the 
concentration of transferrin receptor
Serum ferritin 
(SF)
Iron deficiency. 
SF is an iron storage 
protein that provides 
iron for haem 
synthesis when 
required.
Iron deficiency anameia:
SF concentration<12–15 µg/l.
Needs to be corrected upon inflammation. In 
clinical malaria a high SF values result from the 
destruction of red blood cells, an acute phase 
response, suppressed erythropoiesis, and ferritin 
released from damaged liver or spleen cells. 
However, in “holo-endemic” settings, the 
influence of parasite load on SF appears to be 
restrained and reliable after correction. 
The changes in SF concentration during 
development from birth to old age reflect 
changes in the amounts of iron stored in tissues
Source: Report of a technical consultation on the assessment of iron status at the population level. WHO-CDC, 2004
The joint WHO-CDC Technical Consultation for iron assessment selected 5 different 
indicators as good iron markers: hemoglobin, mean cell volume (MCV), (sTfR) 
concentration, serum ferritin concentration, and red cell protoporphyrin (measured by the zinc 
protoporphyrin/hemoglobin ratio (ZPP:H)). Hemoglobin is deeply useful in the monitoring of 
health status and its determination is easy to realize on the field. Although it is a basic 
fundamental haematological indicator, it is not specific as an iron marker because of the 
multiple causes of anaemia and the physiological variations with regard to sex, age or 
ethnicity. Therefore, it can be misleading for the extrapolation of conclusive results. Mean 
cell volume accuracy is limited in the context of thalassemia and malaria as inflammation 
serum transferrin receptor modifies significantly its values. Due to its physiopathological 
pathway, serum transferrin receptor is also influenced by the haemolysis of malaria, and its 
determination method is not always standardized nor cost-effective. 
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Serum ferritin is a precise indicator of iron storages in healthy individuals and it can be 
corrected according to other inflammation proteins. It provides further information as it also 
shows different patterns of behaviour depending on the aetiology of anaemia. In an iron 
supplementation study in children, Doherty et al. compared the erythrocyte incorporation of 
oral iron supplement in 37 Gambian children 8 to 36 months old with anaemia after malaria 
treatment, to supplemented control children with IDA but no recent malaria. The non-malaria 
control children showed progressively increased serum ferritin whereas the post-malarial 
children showed decreased serum ferritin levels. Serum ferritin levels became similar in both 
groups only by day 15 and 30. This is thought to be due to the normalization of the immune 
response and to the normalization of the acute phase proteins following the malaria treatment. 
Indeed serum ferritin is an acute phase protein. Hence, serum ferritin is either corrected upon 
inflammation (with correction factors according to C-reactive protein (CRP) or α-1-
glycoprotein (AGP) levels), or samples with high acute inflammation proteins are 
systematically excluded. Nevertheless the exclusion of samples with increased inflammation 
might entail a subsequent bias in the context of malaria, as samples with high ferritin would 
be systematically excluded as well. Despite its limited accuracy in case of inflammation, 
ferritin is a consistent extended iron marker. 
Along with ferritin, ZPP:H ratio is the most frequently used indicator for iron assessment. The 
chelation of ferrous iron by protoporphyrin is the final step for the heme synthesis. In iron 
deficiency zinc is chelated as iron is not available and ZPP formation is decreased. In the iron-
deficient parasitized RBC, the increased ZPP could bind to heme crystals, and inhibit the 
formation of hemozoin. Longstanding inflammation processes, thalassaemia, and 
asymptomatic P. falciparum parasitemia might also show elevated ZPP:H ratios, and 
consequently be erroneously associated to iron deficiency. In addition there is no standardized 
corrections applicable to ZPP:H ratios in the context of long-term inflammation processes.  
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Finally high lead levels interfere with ZPP:H, and polluted regions frequently overlap with 
malaria endemic settings. However, the impact of inflammation on ZPP:H is not as important 
as on serum ferritin. 
A novel marker has recently emerged as an alternative indicator: hepcidin. Hepcidin is a 
peptide hormone, which plays a crucial role in iron regulation and is determinant in the 
malaria infection process. Hepcidin binds ferroportin, it increases in response to inflammation 
and blocks iron entry into the plasma. It has been proposed as a good marker for iron levels, 
especially because it might be up-regulated after malaria episodes compared to other markers 
of iron-deficiency. Therefore, a priori, it might permit to distinguish between iron-deficiency 
and malaria related anaemia. However, hepcidin shows a non-linear association with anaemia 
in the context of malaria albeit its significant association with parasitemia in children. 
Furthermore, in Kenya it was increased on admission at hospital for P. falciparum malaria 
and was significantly associated with parasite density, but hepcidin levels were very low in 
severe malaria anaemia. In addition, its accuracy as an iron marker has been recently 
questioned as it has been shown that it is associated with the anti-inflammatory response but 
not with iron or anaemic status among malarial Nigerian children. Hence, further studies with 
more statistical power should be encouraged to ascertain its utility as an iron marker. 
In conclusion, complementary indicators are needed for the accurate assessment of iron status. 
In this respect, inflammation parameters are necessary to correct ferritin levels in the context 
of malaria, and further research is expected in order to determine precisely the utility of 
hepcidin in iron assessment in the context of malaria. It is also important to highlight the 
danger of categorising non-iron deficient individuals as "iron-replete", as limits for iron 
deficiency are not rigid and should be considered with caution and in relation to the clinical 
and environmental settings. 
II.2.2.b. Effect of iron levels on PAM: epidemiological evidence 
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To certainly ascertain the effect of iron on PAM, it is essential to consider both the effect of 
iron levels at baseline and with no intervention, and also the effect of iron supplements on 
PAM as both measures embody different information.
With regard to iron supplementation during pregnancy, its benefits for reducing iron related 
diseases are undeniable. A Cochrane review showed supplementation was associated to a 70% 
decreased risk of anaemia and to a 57% reduced risk of iron deficiency at delivery compared 
to controls. However, epidemiological studies have set into question the inviolability of the 
benefits of iron supplementation in the context of malaria-endemic countries. In a recent 
meta-analysis of the association between malaria and iron status or supplementation, data 
were reported to be insufficient for assessing the potential for an increased risk of P. 
falciparum infection. In addition, iron deficiency at baseline was associated with a decreased 
malarial risk in pregnancy when measured by ferritin, which is a robust indicator for iron 
levels. 
Although iron supplementation trials do not show augmented malaria morbidity associated 
with iron supplements, iron deficiency is correlated with lower odds of malarial episodes. Iron 
deficiency was statistically linked to reduced risk of placental malaria in Tanzania. Ferritin 
was also higher among placenta-infected mothers in Gabon and zinc protoporphyrin in 
Malawi, but these differences were not statistically significant. Similar results were found in 
clinical trials in The Gambia or Kenya. The recent meta-analysis on malarial risk and iron 
status suggested a possible but not significant difference in placental malaria associated with 
iron supplementation depending on sickle cell genotype. However, these studies report iron 
levels only at enrolment, at delivery, or both, and the limited sample sizes may be insufficient 
to show a statistically significant effect.
II.2.2.c. Effect of iron levels on PAM: physiopathology and further perspectives
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Possible explanations for the increased malarial risk associated with iron levels are related to 
malaria physiopathology in both the host and the parasite. At the host level, iron inhibits the 
synthesis of nitric oxide by inhibiting the expression of inducible nitric oxide synthase 
(iNOS), and thereby interferes with macrophage-mediated cytotoxicity against Plasmodium. 
Moreover, non-transferrine bound iron (NTBI) is involved in the severity of malaria. Indeed, 
Plasmodium has the capacity of acquiring iron in a transferrin-independent pathway.
In any case, the lack of complete follow-up of women through pregnancy is an important 
obstacle for the assessment of the influence of iron levels on P.falciparum malaria. In the 
majority of the studies included in the meta-analysis, iron was only determined either at 
enrolment, at delivery, or both, as already said. In the only prospective cohort malaria was 
analysed solely with regard to the first episode of the pregnancy. Furthermore, the authors 
themselves have underlined that the present evidence is inconclusive. Hence, the continuous 
monitoring of iron levels in the context of a PAM episode, might allow us to provide 
important supplementary evidence on the effect of iron levels on PAM.
II.2. Malaria risk factors in infants: Effect of PAM and iron levels on 
malaria episodes and Plasmodium falciparum parasitemia. 
II.2.1. Effect of PAM and IPTp on malaria in infants
II.2.1.a. Epidemiological evidence of PAM and IPTp 
As already described in the pregnancy section, the impact of PAM on the infants includes low 
birth weight (LBW) (mainly induced by intra-uterine growth retardation (IUGR) and to a 
lesser extent pre-term delivery), stillbirth, reduced anthropometric parameters, increased 
mother-to-child HIV transmission, congenital malaria and fetal anemia. Taking all these 
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effects into account, PAM would be responsible for 75,000 to 200,000 deaths in infants in 
Sub-Saharan Africa. 
But beyond this indirect effect on infant mortality and morbidity, the impact of the exposure 
to parasites in utero on the parasitemia of the infant arises in epidemiological studies as a risk 
factor for increased susceptibility to malaria among the offspring. In this respect, research on 
whether infants of primigravid women will be possibly at higher risk for subsequent malaria 
as a result of reduced antibody transfer is still ongoing. In parallel, a significant reduction in 
placental malaria and maternal parasitemia has been extensively described in founding 
literature following the implementation of IPTp programs. Finally, the timing of high 
parasitemia infections during pregnancy entails different effects on the infant. Therefore, the 
administration of IPTp at different moments determines different protection patterns for the 
infant. 
Placental malaria (presence of parasites in the placenta) is shown to be an important 
trademark for increased susceptibility to malaria during infancy, possibly due to its role as a 
surrogate of the maternal infection. It has been associated with congenital malaria, increased 
malaria episodes, anaemia, and non-malaria fever episodes in infants.  
Congenital malaria is defined as the presence of asexual parasites in the cord blood or in the 
peripheral blood during the first week of life. It is the result of transplacental transmission of 
parasites just before or during delivery. Congenital malaria rates range between 0,83-5,96% 
of total births in recent epidemiological studies. Nevertheless, the introduction of molecular 
techniques has increased the detection of cord blood parasitemia raising prevalence rates up to 
33%. Although it might entail clinical important consequences in some cases and should be 
considered in the differential diagnostic of neonatal fever in endemic countries, congenital 
malaria does not seem to constitute an epidemic emergency at present. Nevertheless, we 
should consider that symptomatic congenital malaria is more frequent in unstable malaria 
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transmission settings compared to high transmission settings. 
Placental malaria is consistently associated with susceptibility to malaria with regard to both 
first event and overall clinical episodes. In a landmark longitudinal cohort of infants in 
Cameroon placental P. falciparum infection was associated with infant malaria between 4 and 
6 months, and parasitemia rates were higher between 5 to 8 months in offspring of placenta-
infected mothers independently of congenital infection. A study in Tanzania found an 
interaction between gravidity and placental malaria. Albeit the lowest odds for offspring of 
primigravid placenta infected pairs, multigravid gestation among placenta positive pairs was 
the highest (Adjusted Odds Ratio (aOR=1.59)).  Nevertheless epidemiological studies show 
overall increased susceptibility to malaria among primigravidae (Table 1).
With regard to the early appearance of parasites in infants, the above mentioned study in 
Tanzania reported a 1.41 estimated hazard ratio (HR) of first parasitemia for offspring of 
mothers with P. falciparum placental infection, after adjustment for gravidity, transmission 
season at time of birth, area of residence, and bed net usage. In Gabon a significant correlation 
was also found (adjusted HR (aHR)=2.1) after adjustment for gravidity, season of birth, area 
of residence, IPTp versus placebo, and ITNs. In Tori Bossito (Benin) the consistent 
entomologic and environmental follow-up of infants confirmed the link between PM and 
malaria in infants controlling for transmission intensity (aHR=2.13) for infants sleeping in a 
house with an ITN, even after control for season, number of anopheles, antenatal care visits 
and maternal severe anaemia, compared with infants whose mothers did not have placental 
malaria at delivery. In addition, this cohort reports an increased susceptibility of infants to P. 
falciparum parasites with antigens to which they were previously exposed in utero, 
suggesting an immune tolerance process undergoing during pregnancy. PAM has also been 
correlated to reduced transfer of maternal antibodies to the foetus, and this would increase the 
infant susceptibility to parasites. Consistent with the idea that the type, the timing and the 
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duration of exposure to the parasite in utero determine susceptibility to malaria, infections 
occurring during the 3rd trimester are associated with increased risk of infection and clinical 
malaria during the first year of life in another study in Mono (Benin). In parallel, there is also 
a first scientific evidence on the fact that HLA-G polymorphisms could be associated with 
different malaria susceptibility.
But the effect of PAM may entail consequences for the morbidity and mortality of the infant 
also in a broad manner.  Indeed, both acute placental malaria and cord blood parasitemia have 
been found associated with increased mortality. Moreover, placental malaria was a significant 
risk factor for mortality in general during the first year of life in a study in Malawi. In 
Mozambique infant mortality was also significantly associated with malaria infection of the 
placenta (p-value<0.012) after adjustment for HIV status, LBW, maternal clinical malaria 
during pregnancy, fetal anemia and IPTp regime. And mortality risk was significantly higher 
(odds ratio (OR)=5.08) for infants issued of acute infection of the placenta at delivery. 
Placental malaria was also correlated with non-malaria infections in the Tori Bossito cohort 
infants during the first 18 months of life, suggesting that immune tolerance could also imply 
immunity in a more general manner besides malaria specific immunity.
Even if complete explanation of the physiopathology of PAM has not been found so far to our 
knowledge, in utero exposure to malaria might be correlated with placental sequestration of 
erythrocytes, and the immune tolerance process might depend on the type of malaria antigen 
in contact with the foetus, the amount and the duration of the exposure, and the moment of 
exposure during pregnancy. However these parameters are modified by the introduction of 
intermittent preventive treatment in pregnancy (IPTp). Indeed, intermittent preventive 
treatment in pregnancy modifies parasite exposure to the fetus. Hence, IPTp may introduce 
substantial changes in the epidemiologic pattern of malaria in infants, possibly as the result of 
an ongoing process of immune tolerance to antigens in utero. However, little evidence exists 
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on the subject at present. 
II.2.2. Effect of iron on malaria in infants
II.2.2.a. Effect of iron levels on malaria in infants: epidemiological evidence 
Observational studies display information reflecting the association between iron and malaria 
based on the real circumstances of the field, but accurate iron monitoring is not commonly 
realized on a systematic basis in this context. Clinical trials focus rather on the effect of 
supplements and investigate the possible consequences for malaria outcomes of the iron 
supplementation policy, but their methodological protective constraints do not reflect the 
epidemiological reality of malaria endemic settings. Indeed, both approaches assemble 
different but important information and, therefore, both should be considered for the analysis 
of the iron-malaria link. The results of the main studies on the malaria-iron relationship in 
infants are presented in table 3.
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Clinical malaria is the consequence of the asexual cycle of Plasmodia parasites in the RBC. It 
constitutes the main outcome of the majority of the observational studies and it is currently 
defined as temperature>37.5º or 38º C within the previous 48 hours and a blood film positive 
for blood-stage asexual parasites. In this respect, a study gathering evidence from two cross-
sectional observational surveys from 2001 to 2003 in Kenya among children aged 8 months to 
8 years reported significant protection among iron deficient children (Adjusted incidence rate-
ratio (IRR)= 0.7, 95%CI (0.51; 0.99) with ferritin<12μg/ml and transferrin saturation<10%). 
Furthermore, iron status was inversely correlated with malaria-specific immunoglobulins. 
Similar results were found in an observational cohort study in Tanzania among children 
between birth and 3 years. Iron deficiency (defined by ferritin concentration corrected on 
CRP) was also associated with a significant protection with regard to lower odds of malaria 
parasitemia (OR=0.15, 95%CI (0.12; 0.19)), lower odds of hyperparasitemia 
(parasites>2500/200 white blood cells (OR=0.04, 95%CI (0.02; 0.07)), and lower odds of 
severe malaria (OR=0.25, 95%CI (0.14; 0.46)) after adjustment for possible confounders.
In a pioneer randomized placebo controlled trial in Tanzania in 1995 in infants between 8 and 
24 weeks of age, no increased susceptibility to malaria was observed among iron 
supplemented children with regard to first or only malaria episode compared to placebo 
(protective efficacy (PE)= 12.8%, 95%CI (-12.8; 32.5)). Albeit this first reassuring result, 
supplementation effects on children health status were re-evaluated after the Pemba trial. In 
2002-2003 a randomised, double blind, placebo-controlled trial, gathered medical evidence on 
all-cause morbidity and mortality among over 24,000 children up to 35 months daily 
supplemented with folic acid and iron, iron, folic acid, zinc or placebo in Pemba, Tanzania. In 
the same cohort, a sub-study among 2413 children addressed the impact of supplements on 
haematological status, zinc, malaria prevalence, and infectious disease morbidity. Combined 
groups of supplemented children had significant higher risk for serious clinical events 
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resulting from malaria compared to placebo (RR=1.16, 95%CI (1.02; 1.32)). Malaria related 
hospital admissions were also significantly higher (RR=1.18, 95%CI (1.02; 1.36)) among 
supplemented children. In the case of cerebral malaria, the RR of the iron and folic acid 
group, was also significant compared to placebo (RR=1.22, 95%CI (1.02; 1.46)). In addition, 
another deeply relevant aspect of the malaria-iron association was first raised up: the 
importance of the iron levels at baseline. Iron-deficient children at baseline, defined by zinc 
protoporphyrin>80 µmol/molhaeme, had a reduced risk of malaria-related adverse events 
when supplemented compared to placebo (RR=0.56, 95%CI (0.32; 0.97)). Due to the 
increased morbidity found in this trial, the WHO recommendations restrained supplements to 
iron deficient children in malaria endemic regions. 
Nevertheless, more recent studies report different results. A study in Tanzania in 2008-2009 
investigated the consequences of micronutrient supplementation in 612 children between 6 
and 60 months. While there was no significant increase in overall malaria episodes among 
supplemented children compared to placebo, multi-nutrient supplementation was associated to 
a 41% increase in the overall number of malaria episodes in children with iron deficiency 
(HR=1.41, 95%CI (1.09; 1.82)), whereas there was no significant impact among the iron-
replete children (p-value for difference in effect=0.01). 
In 2010 in Ghana, in a double blind, cluster randomized trial providing a micronutrient 
powder (MNP) with or without iron, 1958 infants of 6 to 35 months of age were followed for 
6 months and no significant increase in malaria risk was observed compared to placebo 
(RR=1, 95%CI (0.81; 1.23)). No significant association with increased malaria was described 
among iron-replete children, with or without concomitant anaemia (RR=0.83, 95%CI (0.64; 
1.08) and RR=1.04, 95%CI (0.82; 1.32), respectively). However, supplemented children with 
both iron deficiency and anaemia showed significantly reduced risk of malaria (RR=0.67, 
95%CI (0.5; 0.88)) compared to placebo. 
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Because of these a priori contradictory results of the studies, a Cochrane review of 2011 
analysed 71 trials collecting evidence on 45,353 children. For the 13 trials selected, the 
Cochrane review concluded to an absence of significant differences in clinical malaria rates 
between iron and placebo (RR=0.99, 95%CI (0.9; 1.09)). No statistical differences were 
found neither among supplemented infants (children<2years) (RR=0.94, 95%CI (0.82; 1.09)) 
nor for severe malaria (RR=0.91, 95%CI (0.76; 1.08)) compared to placebo. Furthermore, no 
statistical difference was found among non-anemic children at baseline (RR=0.97, 95%CI 
(0.86; 1.09)). However, analyses on iron deficiency defined by ferritin were not realized. 
Even if it is difficult to screen children for iron status at the population level, information on 
the effect of iron deficiency is relevant to develop useful supplement strategies based on 
scientific accurate evidence. Finally, this Cochrane meta-analysis describes increased risk for 
clinical malaria among iron or iron plus folic acid supplemented children in the absence of 
malaria surveillance and treatment.
Beyond clinical malaria, it is necessary to consider also malaria mortality to capture broader 
aspects of the iron-malaria association. In the context of the clinical trial with iron 
supplements in Pemba, mortality due to malaria was higher (although not significantly higher) 
among supplemented children compared to placebo (RR=1.08, 95%CI (0.84; 1.40)). Among 
children supplemented with iron and folic acid, there was a significant increased risk for 
cerebral malaria as a cause of death compared to placebo (RR=1.70, 95%CI (1.08; 2.68)). The 
iron and folic acid supplemented children were 12% more likely to suffer an adverse event 
resulting in hospitalisation or death (95%CI (2; 23)) compared to placebo and all-cause 
mortality was also significantly higher (OR= 1.61, 95%CI (1.03; 2.52)). Iron deficiency and 
moderate anaemia at baseline were significantly associated to lower rate of adverse events 
(death or severe morbidity leading to admission) among supplemented children compared to 
placebo. Further extensive studies on the impact of iron supplements on malaria attributable 
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mortality are scarce due to the difficulty of attributing correctly the cause of death in endemic 
settings and, hence, it is difficult to accurately assess the interaction between malaria and 
infection with regard to mortality. In addition more statistical power is needed as iron 
measures are rare and death is also a rare event. 
In a good attempt to clarify finally the conundrum, the Cochrane meta-analysis on the impact 
on iron supplements addressed certainly this question but did not provide a definite answer. In 
this review, the relative risk for all-cause mortality was not estimable. However, it was 
capable of displaying useful information with regard to transmission settings. Mortality was 
not significantly different between hyper- and holo-endemic areas (Risk difference= 1.93 per 
1000 children, 95% CI (-1.78; 5.64)). 
In summary, the risk for clinical malaria differs according to iron status between 
observational studies and clinical trials on iron supplementation. Overall, observational 
studies describe a certain protection for malaria risk among iron deficient children. In parallel, 
meaningful ancient studies report increased susceptibility to clinical malaria among iron 
supplemented children, and so does the Pemba trial, which has a considerable statistical 
power. However, other recent clinical trials with important malaria monitoring and protective 
measures, show no significant increase for malaria risk among iron supplemented children 
and neither does the Cochrane review. Albeit the absence of overall significance, the cross-
sectional studies in Tanzania report also significant earlier malaria among supplemented 
children.
II.2.2.b. Effect of iron levels on malaria in infants: physiopathology and further 
perspectives
As in the case of PAM, the physiopathology of malaria infection involves a direct interaction 
between Plasmodia and iron. This aspect has already been detailed for PAM, but briefly, only 
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within the infected RBC, P. falciparum, the parasite responsible for most malaria cases, 
consumes up to 80% of the hemoglobin. In addition, the parasite sequestration in the intestinal 
blood vessels impairs the optimal nutritional absorption.  Furthermore, non-transferrine bound 
iron (NTBI) is associated to increased severity of the malaria episode and to reduced 
performance of the immune function. Beyond these direct interactions, further clinical 
conditions, such as certain genetic variants, interfere to determine the association between 
malaria and iron levels. Indeed, genetic variants are estimated to be responsible for over 25% 
of the variation in susceptibility to malaria. In this respect sickle hemoglobin is a significant 
example, but evidence on the possible interaction between sickle cell hemoglobin and iron 
availability to Plasmodium is lacking. In any case, genetic protection against malaria is 
thought to be rather multigenic. As in the case of the pregnant women, other co-morbidities, 
such as HIV, bacterial and helminthic infections are also correlated with both iron and 
malaria. 
Evidence on the effect of iron levels on malaria risk is subject to certain limitations, such as 
methodological study constraints, homogenous measurement of iron and haematological 
indicators, the effect of different transmission patterns, and further possible confounders.
In effect, statistical limitations are inherent to ethical research studies. Clinical trials display 
results based on intensively monitored parameters. In most of them prophylactic protection by 
ITNs or preventive treatment for malaria is more frequent among enrolled patients than in 
observational studies, and treatment is also given as soon as a case is confirmed. As a 
consequence, it is difficult to disentangle the possible protective effect of IDA from the 
protection given by protective measures, especially in the case of severe malaria or 
hyperparasitemia in clinical trials. Preventive measures reduce the number and the severity of 
malaria episodes and, hence, statistical power decreases, as does the force of the association. 
The dimension of the association, or its absence, should be ideally assessed in the conditions 
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in which population undergo the malaria burden and the nutritional interventions. 
Nevertheless, accurate iron monitoring is not realized systematically and malaria episodes are 
not always captured by demographic or surveillance data. In addition, observational studies 
that do not provide treatment are unethical in malaria endemic countries with limited access to 
health care. However, surveillance data or data issue of demographic surveys may be useful to 
get a basic idea on malaria risk and haematological indicators. 
With regard to the epidemiological indicators, malaria infection outcomes (clinical malaria 
and parasitemia) reflect more specifically the malaria-iron relationship, and mortality reflects 
rather a broad association between iron and pathogens. In addition, its assessment is difficult 
because of diagnostic reasons, and evidence lacks with regard to specific malaria deaths 
related to iron supplements. 
The transmission setting constitutes an additional important stake of the question. Disease 
burden in children after iron supplementation does certainly differ in the absence of malaria 
compared to malaria endemic settings. The existence of a possible malaria prevalence 
threshold at which iron supplements start to have a deleterious effect on infant health requires 
as well further research.
Other methodological obstacles contribute to the inconclusive results of the analyses of the 
association between iron and malaria risk. Analyses in the clinical trials are seldom adjusted 
on other significant co-variables and odds ratios (OR) and relative risks originate often from 
univariate analyses. In addition, the exclusion of the children with inflammation in some 
studies might have introduced a bias in the interpretation of results concerning the children 
with the most severe disease, as inflammation is predominantly present in these more severe 
cases.
Finally, the haematological indicators at baseline show contradictory results in literature at 
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present. Indeed, a clinical trial describes a significant protection against malaria among 
supplemented children with both anaemia and iron deficiency. However, a study in Tanzania 
observed an increase in malaria risk among iron-deficient infants. Similar results are found in 
pregnant women.  Indeed, there might be a possible protective role of anaemia or iron 
deficiency in the context of iron supplementation.  In case of anaemia the incorporated iron 
might be used for hemoglobin synthesis whereas in the context of iron deficiency with no 
anaemia at baseline the incorporated iron might entail an increase in NTBI, enhancing 
parasite growth. More extensive research including different iron deficiency indicators is 
needed to advance in the knowledge in this aspect. Yes it is essential to ascertain the meaning 
of the information provided by the different iron markers used in the research studies to better 
unravel the iron-malaria conundrum.
II.3. Complementary factors associated with malaria risk in infants: 
the case of lead 
Simultaneously to our study in the same cohort another epidemiological project was 
evaluating the effect of lead on the neurocognitive development in children. Our colleagues 
found out lead levels were particularly high in the infants of our cohort. Nriagu had found in 
Nigeria that malaria had a significant effect on lead levels in univariate analysis. In addition, 
elevated blood lead levels (BLL) carry a significant burden of disease in Western Africa and 
malaria is the first cause of infant mortality in Benin. Therefore, we aimed at assessing the 
possible association of lead levels with malaria risk considering other major malarial risk 
factors.
II.3.1. Lead levels and malaria: clinical and epidemiological background
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II. State of the art     
Elevated lead levels have severe harmful effects on infant health. They are associated with 
impaired neurocognitive development, anemia (due to either disruption of heme synthesis or 
hemolysis), and renal and gastro-intestinal effects. Although high blood lead levels (BLL) 
(BLL >100 µg/dl) can entail acute neurologic symptoms, such as ataxia, hyperirritability, 
convulsions, coma, and death, BLL as low as 10 µg/dl have been also correlated with poor 
neurocognitive outcomes and behavioral disorders. Indeed, the Center for Disease Control 
(CDC) reduced the reference level of blood lead from 10 µg/dl to 5 µg/dl  in 2012. This is of 
special concern in young children as neuro-cognitive impairment has been found to be 
associated with the degree of exposure to lead between the ages of 12 and 36 months. Albeit 
the severe impact of elevated lead levels on infant health, epidemiological studies of lead 
levels in Sub-Saharan Africa are limited. Data from the few existing studies, published in a 
systematic review on BLL among Sub-Saharan children, suggest an alarming burden of 
disease. This review reported a BLL weighted mean of 13.1 µg/dl which increases up to 16.2 
µg/dl considering solely studies with robust quality BLL analyses. In addition, the prevalence 
of BLL >10 µg/dl ranged from 7.0% to 70.9% in six of the studies reviewed. Recent mass 
level intoxications reported in Senegal and Nigeria further raise the public health concern 
about lead levels in West Africa. Notwithstanding these concerns, infectious diseases, mainly 
malaria, lead the disease burden in West Africa. In Benin, malaria is the main cause of 
mortality among children less than 5 years and there were over 1.5 million cases in 2012. 
Both malaria and lead poisoning can have severe hematologic and neurologic symptoms on 
children and development disruptions. Because of the recent evidence on the role of the 
complement system in the regulation of neurodevelopment, it has been proposed that 
excessive complement activation induced by placental malaria may disrupt normal 
neurodevelopment resulting in neurocognitive impairment of infants exposed to Plasmodia in  
utero. 
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II. State of the art     
Epidemiologically, malaria and lead poisoning may not only overlap geographically, but they 
have major impact on the health of children, especially those under 5 years. Consequently, 
their possible association may have an effect on one of the most vulnerable age groups in the 
population, and it could have severe long-term implications for the development of the 
children. Furthermore, Nriagu found a significant effect of malaria on the children lead levels 
in different areas of Nigeria.  Concern has been repeatedly raised up on the importance of 
alarmingly high anemia rates in West Africa, and both malaria and EBLL are associated with 
increased anemia rates. However, no evidence exists at present on the possible joint effect of 
lead and P.falciparum. To our knowledge, no published study exists on lead levels in Benin, 
and in particular, on the effects of lead levels on malaria risk in infants. 
83
254
255
256
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
257
  
III. Objectives
84
258
1641
1642
1643
1644
1645
259
III. Objectives
In Benin, the prevalence of anemia during pregnancy is over 60%. The main causes of anemia 
in pregnancy are malaria and helminth infections. To fight nutritional deficiencies during 
pregnancy, the Beninese Ministry of Health prioritized the prevention of anemia (defined by 
WHO as hemoglobin (Hb) <11g/l). Therefore, it recommends supplements of 200 mg of 
ferrous sulphate and 5 mg of folate given daily until 45 days after delivery.
Indeed, anemia, including iron-deficiency anemia, constitute a public health concern not only 
during pregnancy but also during infancy. As said, albeit the lack of official 
recommendations, in case of iron defiency anemia, Beninese paediatricians give daily 
supplements of iron of 10 mg/kg/day and 0.5 mg/kg/day of folic acid during 2 months, every 
6 months, starting at 6 months of age until 5 years. This is similar to WHO guidelines, which 
recommend 12.5 mg iron and 50µg folic acid to prevent anaemia in children 6-24 months. In 
case of low birth-weight (LBW), defined by birth weight<2500g, supplements start at 2 
months. 
Nevertheless, some epidemiological evidence suggests that iron supplements could influence 
malaria episodes and severity. In addition, a recent meta-analysis declares that the present 
epidemiological evidence is inconclusive to ascertain a possible increased risk of PAM 
associated with iron supplements during pregnancy.  Indeed, the lack of prospective follow-up 
cohorts is a considerable obstacle to come to a conclusion on the issue. Considering that iron 
supplements are given systematically during pregnancy in Benin, and that malaria is endemic 
in the region, our first objective was to analyse the possible effect of iron levels on PAM in 
the context of a prospective follow-up of pregnant women. Furthermore, we wanted to 
investigate the effect of the infant iron levels on malaria in infants as malaria is the first 
cause of infant mortality, and there are no national guidelines on the iron supplementation 
policy in infants.
In parallel, PAM appearance and severity seems to be associated with increased malaria risk 
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III. Objectives
in infants, and IPTp has an impact on secondary malaria outcomes (such as LBW and 
anaemia). Hence, our second objective was to investigate the possible impact of IPTp on 
malaria in infants during the first year of life.
Finally, a research group working on the same cohort found very high rates of elevated blood 
lead levels in the infants. Both malaria and elevated lead levels have a severe impact on the 
infant health. In addition Nriagu had found a significant effect of malaria on the children lead 
levels in different areas of Nigeria.  Therefore, our third objective was to assess the possible 
effect of elevated lead levels on malaria in infants, as their possible association may have 
severe long-term implications for the development of the children. Indeed, no published study 
exists on lead levels in Benin, and in particular, on the effects of lead levels on malaria risk in 
infants.
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IV. Methods
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To investigate our objectives, we conducted our research in the context of the clinical trial 
MiPPAD and a nested study APEC. 
The clinical trial MiPPAD (Malaria in pregnancy preventive alternative drugs, 
http://clinicaltrials.gov/ct2/show/NCT00811421) was conceived to compare the efficacy and 
safety of IPTp with SP (1500/75 mg per dose) and mefloquine (15 mg/kg taken either in 
simple or split intake).
The study APEC (Anemia in pregnancy: etiology and consequences) was a nested study to 
MiPPAD that analysed parameters relevant to the anemia status of both the pregnant women 
and infants. 
More precisely, in the context of both studies in Benin, 1005 pregnant women and 400 of 
their offspring (200 born to mothers with anemia at delivery, and 200 born to mothers without 
anemia at delivery) were followed through pregnancy and the first year of life, respectively.
The APEC study was conducted in three maternity clinics in the district of Allada, between 
January 2010 and May 2012. Allada is a semi-rural area of 91,778 inhabitants located 50 km 
North of Cotonou (Benin). Malaria has a perennial transmission pattern with two transmission 
peaks corresponding to the rainy seasons in April-July and October-November. Plasmodium 
falciparum is the species responsible for the majority of infections.
The eligibility criteria included no intake of IPTp, iron, folic acid, vitamin B12, or anti-
helminthic treatment. All women were offered confidential pre-test HIV counselling and 
thereafter informed consent was obtained.
IV. 1. Cohort follow-up methods
Clinical and biological follow-up: 
During follow-up, socio-demographic, economic, clinical and biological data were collected 
in mothers at 1st antenatal clinical visit (ANC), 2nd ANC and delivery. The same data were 
also recorded in infants at birth, 6, 9 and 12 months of life. In case of sickness, both pregnant 
89
272
273
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
274
women and infants came to the clinics for clinical examination. In these unscheduled visits, 
haemoglobin concentration and blood smear were performed when malaria signs were 
present. Concrete clinical and biological exams are summarized in Figure 6.
Figure 6: Clinical and biological exams during the follow-up through pregnancy and 
infancy. (Figure realized by M. Accrombessi)
After obtaining informed consent, sociodemographic and socioeconomic characteristics of the 
women  were  collected  at  enrolment.  At  the  1st  ANC visit,  women  were  examined  and 
gestational age, middle upper arm circumference (MUAC), weight and height were recorded. 
This information, except for height, was also collected at 2nd ANC and delivery. Gestational 
age was determined from fundal height measurement by bimanual palpation and following 
McDonald's rules. Weight and height in pregnant women were respectively measured to the 
nearest 0.1 kg using an electronic scale (Seca corp., Hanover, MD) and to the nearest 0.1 cm 
by using  a  bodymeter  device  (Seca  206 Bodymeter;  Seca  corp.).  These  parameters  were 
measured twice by nurses, and the mean of both measurements was calculated.
At birth, newborn’s sex, weight, length, head circumference and axillary temperature were 
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collected.  Weight  was measured  using  an  electronic  baby scale  (SECA type  354)  with  a 
precision of 10 g and length was measured to the nearest 1 mm with a locally manufactured 
wooden measuring scale according to the criteria recommended by WHO. At the 6, 9 and 12 
months systematic visits, the possible history of fever within the previous 24 hours, malaria 
treatment  or  hospitalization  since  the  last  visit  and  use  of  insecticide-treated  nets  were 
investigated and recorded.
Concerning  the  blood  and  stool  sample  collection,  8  ml  of  mother’s  venous  blood  were 
collected at 1st ANC, 2nd ANC visit and at delivery. The same volume was also collected on 
cord blood at birth and on infant's venous blood at 6, 9 and 12 months of life. All the samples 
were  used  to  look  for  malaria  parasitaemia,  to  determine  C-reactive  protein  (CRP), 
micronutrient  (serum  ferritin,  folic  acid  and  vitamin  B12)  and  Hb  concentration  and  to 
genotype Hb. At delivery,  samples (biopsy and impression smear) were collected from the 
placenta for parasitological evaluation. A container was also given to the woman to collect 
infant’s stools in search of intestinal helminths.
On unscheduled visits, Hb dosages and thick blood smears were performed in infants with 
clinical signs of malaria (history of fever in the last 24 hours or temperature   37.5°C and 
pallor).
Laboratory methods. The Hb level  was measured with a  Hemo-Control  photometer  (EKF 
Diagnostics, Magdeburg, Germany) device. A daily calibration of the Hemo-Control device 
was performed by the laboratory technicians.  In  addition,  an external  quality  control  was 
made by sending one of 10 consecutive samples to the Allada Central Hospital laboratory, 
where dosages were assessed using a hematology analyser (Erma Laboratory, Tokyo, Japan). 
Hb  genotypes  were  determined  by  alkaline  electrophoresis  on  cellulose  acetate  (Helena 
laboratories, Beaumont, TX).
Serum  ferritin,  folic  acid,  and  vitamin  B12  concentrations  were  measured  using  a 
microparticle  enzyme and fluorescence polarization immunoassay (AxSym Immuno-Assay 
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Analyser, Abbott Laboratories). CRP concentration was determined by rapid slide test (CRP 
Latex; Cypress Diagnostics Inc.) to correct the effect of inflammatory syndromes on ferritin 
concentrations.
The Determine  (HIV1 and 2 kit;  Abbott  Laboratories)  and Bioline  (HIV1 and 2 3.0 kit; 
Bioline, Taunton,MA) rapid tests were used to detect HIV infections using a serial testing 
algorithm.
The Lambaréné technique was used to analyse peripheral malaria infection in blood smears.
It consists of spreading a calibrated 10 μl amount of blood on a slide’s rectangular area of 1.8 
cm² (1.8 x 1 cm). The slide was stained with Giemsa and read at a magnification of 1,000 ×  
with an oil immersion lens. A multiplication factor was applied to the average parasitemia/ 
field to determine the number of parasites/μl. The Lambaréné method detection threshold has 
been estimated to be 5 parasites/μL.
Placental  biopsies  (2.5  x  2.5  cm3),  collected  at  delivery  for  histology  assessment,  were 
immediately put in 50 ml of 10% buffered formalin. It was then stored at 4°C in a refrigerator 
until the placental  tissue was processed at the pathology department. The maximum delay 
before fixation was of 5 days.  Placental  malaria  infection was defined as the presence of 
parasites with /without pigment or pigment confined to fibrin in the histological examination. 
Placental histology was examined without knowledge of the peripheral blood smears results. 
In  addition,  an external  quality  control  was made on 100% of positive  slide and 10% of 
negative slide in reference laboratory to Barcelona Centre for International Health Research 
(CRESIB), Hospital Clínic-Universitat de Barcelona. Infestations by helminths were assessed 
by using the Kato-Katz concentration method (Vestergaard Frandsen, Lausanne, Switzerland).
Environmental data: As no entomological data was available, we used rain quantity instead as 
a  surrogate  for  the  anopheline  presence.  Because  of  the  anopheline  timeliness,  rain  was 
calculated as the mean rainfall of the 7 days prior to the two weeks before the consultation. 
Ethics statement
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These studies  were approved by the Ethics  Committee  of  the Health Sciences  Faculty of 
Cotonou in Benin. Before each inclusion, all participants involved in our study provided their 
written informed consent to participate in this study. The study was also explained in the local 
language to the participant, and her voluntary consent was obtained. In case the woman could 
not read,an impartial witness was involved in the process. Mothers were free to interrupt their 
participation at any time in the study.
IV. 2. Cohort follow-up
The  follow-up  of  pregnant  women  and  infants  are  described  in  Figure  7  and  Figure  8, 
respectively. 
In the case of pregnant women, the lost to follow-up were below 10%. Therefore, no data 
treatment was applied.  In the case of infants, multiple imputation technique was used and 
results did not differ significantly.
The sample size of the presented tables are below the sample size presented in these diagrams, 
as often measures were not always available for each sample of every participant during the 
follow-up.
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Figure 7: Follow-up of pregnant women 
1623 pregnant women screened
(MiPPAD trial)
1008 pregnant women included
1005 pregnant women for follow-up (ANV1)
615 pregnant women not included
108 refusals
262 gestational age >28 weeks
14 HIV positive
195 non resident in the study area
34 allergy to SP or MQ
2 Halofantrine intake
978 pregnant women at IPTp intake 
941women at delivery 
3 pregnant women excluded 
(protocol violation)
1 fibroma
1 gestational age >28 weeks
1 HIV positive
Between ANV1 and ANV2
16 refusals
7 lost to follow-up
4 migrations
Between ANV2 and delivery
17 refusals
4 lost to follow-up
16 migrations
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 Figure 8: Follow-up of infants
IV. 3. Definitions
PAM was defined as peripheral or placental infection by Plasmodium while PM was defined 
as presence of Plasmodium in the placenta. 
LBW corresponds to newborn weights<2500g, and prematurity refers to offspring born prior 
to 37 weeks of gestation. 
Anemia was defined by Hb levels below 11g/l for both pregnant women and infants. Between 
birth and 6 months anemia was defined by Hb below 140 g/l.
Severe, moderate and mild anemia were defined as Hb concentrations<80 g/l, 80-99 g/l, and 
100-109 g/l, respectively, following WHO criteria. 
Inflammation was determined by C-reactive protein (CRP) levels ≥5 mg / ml. We corrected 
serum ferritin in the context of inflammation following the procedure inspired by the meta-
analysis by Thurnham before conducting the analyses, so we multiplied serum ferritin by 0.76 
in the presence of Plasmodia without inflammation, and we multiplied serum ferritin by 0.53 
400 newborns 
353 until 6 months
47 way-out before 6 months
18 refusals
13 deaths
12 migrations
4 lost to follow-up
12 way-out between 6 and 9 months
6 refusals
2 deaths
4 migrations
341 until 9 months
17 way-out between 9 and 12 months
8 refusals
1 deaths
7 migrations
1 lost to follow-up324 until 12 months
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in case of concurrent Plasmodia infection and inflammation. 
ID was then defined as corrected serum ferritin <15 µg/l in pregnant women and corrected 
serum ferritin concentration <12 µg/l in infants. Iron deficiency anemia (IDA) was defined as 
Hb<110 g/l with ID. 
Folic acid deficiency was defined as a serum concentration<6 ng/ml. Vitamin B12 deficiency 
was  defined  as  a  serum  concentration<150  pg/ml.  Intestinal  helminth  infestations  were 
diagnosed by the presence of intestinal helminth eggs in the stool sample. 
To estimate pre-pregnancy body mass index (BMI), all pregnant women included in the study 
had a gestational age less than 28 weeks. From the end of the first trimester of gestation, it 
was estimated that pregnant women gained on average 1 kg per month until delivery.
We used the gestational age at inclusion to estimate approximately the weight that women 
were supposed to have gained since the beginning of the pregnancy. This amount was then 
subtracted from the weight on the day of inclusion to obtain a rough estimate of the weight 
before pregnancy. BMI was calculated as the weight in kilograms divided by the square of the 
height in meters (kg/m²).
IV. 4. Statistical analyses 
Data  were  double  entered  and  analysed  with  ACCESS2003 and  STATA12.0 (Stata  Corp, 
College Station, USA). 
Continuous variables were analysed as follows: polynomes were considered and the number 
of monomes was held depending on the adequacy of the polynome to the variable.  More 
concretely, only maternal age squared was retained as a squared variable.
Then, all continuos variables were also split into categories, and depending on the adequacy 
of the case, their were either kept as a continuous variable or as categories in the final model.
Kruskal-Wallis test was used to analyse continuous variables. Chi-square test was used for 
comparing categorical variables by gravidity status or infant age, respectively. 
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Socio-economic items (home possession of latrines, electricity, a refrigerator, a television, a 
vehicle with at least two wheels, being married, and working outside the home) were plotted 
into  a  multiple  correspondence  analysis.  Then,  a  predictor  was  created  to  synthesize  the 
information, and was kept as the final socio-economic index.
In the pregnant women follow-up, univariate analysis was conducted to assess the association 
of all  variables  with positive smear  and maternal  peripheral  parasitaemia  using multilevel 
models with a random intercept at the individual level. More precisely, we used the following
co-variables:  age  (years),  age  squared,  ethnic  group,  socio-economic  index,  gravidity, 
gestational  age  (weeks),  number  of  antenatal  visits,  BMI,  maternal  hemoglobin,  maternal 
anaemia, iron levels, folic acid, vitaminB12, folic acid and vitaminB12 deficiencies, socio-
economic index, IPTp regime, IPTp interval length (number of days between IPTp doses), 
IPTp timing, and Kato-Katz positivity. 
Thereafter,  two different  multilevel  models  regressions were built:  the first  on the risk of 
having a positive blood smear during the follow-up period and the second on  P.falciparum 
parasite density.  Both models included the smears and blood films of both systematic and 
unscheduled visits. The variables with p-values<0.2 in univariate analysis were included in 
the multilevel models. Maternal age squared was used due to the quadratic relationship of age 
with the malarial risk. Preliminary fixed effects analyses were realized using the maximum 
likelihood method, and variance components were estimated using the restricted maximum 
likelihood method. However, for both the analysis of the possibility of a positive blood smear 
and for the analysis of parasite density, random coefficient models were used as they were 
statistically  better  than  fixed  effects  according  to  AIC  and  BIC  criteria.  The  Akaike 
information criterion (AIC) and the Bayesian information criterion (BIC) compare maximum 
likelihood  models.  More  precisely,  random  intercept  was  applied  in  both  cases  at  the 
individual level as the effect of the variables is correlated within the women. Random slope 
was applied to gestational age as the effect of gestational age might vary differently according 
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to the timing of the measure. Multivariable linear regression was used in the analysis of birth 
weight, and logistic regression was used for PM and LBW assessment. Certain variables were 
forced into the model because of their meaning in the analyses according to the literature: 
socio-economic status and rainfall in the case of malarial indicators, and BMI in the case of 
LBW. Manual backward selection procedure was performed and statistical significance was 
set at P < 0.05. The presented p-values and the significance threshold were two-sided.
In the infant follow-up, univariate  analysis  was conducted to assess the association of all 
variables with positive smear and the infant peripheral parasitaemia using multilevel models 
with a random intercept at the individual level. More precisely, we used the following
co-variables: sex, low birthweight ((LBW), weight < 2500 g), preterm birth (gestational age < 
37 weeks), fever (temperature  37.5°C), inflammation syndrome, placental malaria status, age 
(months),  ethnic  group,  socio-economic  index,  gestational  age  at  birth  (weeks),  maternal 
hemoglobin at  delivery,  maternal  anaemia at  delivery,  hemoglobin,  iron levels,  folic acid, 
vitaminB12,  folic  acid  and  vitaminB12  deficiencies,  IPTp  regime,  IPTp  interval  length 
(number of days between IPTp doses), IPTp timing, and Kato-Katz positivity. 
Thereafter,  two different  multilevel  models  regressions were built:  the first  on the risk of 
having a positive blood smear during the follow-up period and the second on  P.falciparum 
parasite density.  Both models included the smears and blood films of both systematic and 
unscheduled visits. The variables with p-values<0.2 in univariate analysis were included in 
the multilevel models. Preliminary fixed effects analyses were realized using the maximum 
likelihood method, and variance components were estimated using the restricted maximum 
likelihood method. However, for both the analysis of the possibility of a positive blood smear 
and for the analysis of parasite density, random coefficient models were used as they were 
statistically  better  than  fixed  effects  according  to  AIC and  BIC criteria.  More  precisely, 
random intercept was applied in both cases at the individual level as the effect of the variables 
is correlated within the infant. Random slope was applied to age as the effect of age might  
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vary differently according to the timing of the measure. Finally, iron levels were also analysed 
as a variable with categories corresponding to the 4 quartiles. 
In any case, to take into account the fact that parasites are absent at birth, we excluded the 
malaria measurements at birth from the hierarchical mixed model.
Certain  variables  were  forced  into  the  model  because  of  their  meaning  in  the  analyses 
according  to  the  literature:  socio-economic  status  and  rainfall  in  the  case  of  malarial 
indicators. Manual backward selection procedure was performed and statistical significance 
was set at P < 0.05. The presented p-values and the significance threshold were two-sided.
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V. Results     
V.I. LITERATURE REVIEW
To better analyse the data of the study in Benin, and to better understand the relationships 
between gestational malaria, iron levels, and malaria in infants, we conducted a consistent 
literature review of the epidemiologic evidence regarding these issues. In this first part of the 
section, I will present the result of the work on reviewing 1.The influence of gestational 
malaria on malaria in infants; and 2. The association of iron levels with malaria.
The number of articles presented in the “references” section of the articles is limited by the 
journal requirements. Moreover, we have not kept in our reviews all articles read related to 
the subject. The articles kept for review are presented in the “references” section of the 
articles below. The complete list of all articles considered for the reviews can be accessed 
online in my Mendeley webpage. More precisely, the articles considered for the article on the 
influence of gestational malaria on malaria in infants can be found in the files “mother”, 
“placenta”, “child”, “PAM”, and “parasitemia”. The complete list of the articles that were first 
selected for the article reviewing the evidence on the association of iron levels with malaria 
can be found in the same Mendeley webpage in the file “iron”. References, figures and tables 
in this section are independent of those in the whole dissertation as they are presented at the 
end of each article.
Both articles have no date restriction, meaning that articles were considered irrespective of the 
date of appearance. However, the time period during which we conducted our research is 
limited to certain months, which is described in each article. 
Even if both review articles are not meta-analyses, we wanted to mention that publication 
biais was not adessed to give complementary information to the reader.
Finally, to give a more accurate idea of what our articles add to the previous state of art, we 
have added a little paragraphe at the end of the article summary.  
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V. Results     
V.I.1. Pregnancy associated malaria and malaria in infants: an old 
problem with present consequences.
Summary of the article: We wanted to analyse the impact of PAM and IPTp on malaria 
outcomes during pregnancy, and during the first year of life in infants. Consequently, it was 
necessary to imbalance the present knowledge on pregnancy-related factors that influence 
malaria in infants, including the effect of control interventions and novel research 
perspectives. We realized a review on the subject that was published in June 2014 in the 
Malaria Journal.
Therefore, we analysed between the 10th January 2012 and the 9th June 2014 1,136 articles 
published in PubMed, the Cochrane Library, Global Health and WHO databases. The search 
terms used were the Medical Subjects Headings (MeSH) “Parasitemia” OR “Malaria” OR 
“Anaemia”. Complementary articles, reports, and studies were identified through review and 
citations. Finally, 355 articles were selected for final review. 
PAM, defined as peripheral or placental infection by Plasmodium, constitutes a major public 
health concern due to its significant adverse health effects on both the mother and the foetus. 
Epidemiological studies estimate 32 million women become pregnant every year in malaria 
endemic sub- Saharan Africa countries. Pregnant women are increasingly susceptible to 
malaria infection since Plasmodium falciparum, the most common parasite responsible for 
malaria in Africa, avoids spleen clearance through expression of proteins that bind to the 
chondroitin sulphate A (CSA) in the placental intervillous space. Thus, PAM determines 
foetal exposure to P. falciparum in utero and it is consistently associated with an increased 
malaria risk during infancy. PAM has been associated with congenital malaria, increased 
malaria episodes, anaemia, and non-malaria fever episodes. Although a complete explanation 
of the physiopathology of PAM has not yet been elucidated, in utero exposure to malaria is 
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probably nonetheless correlated with placental sequestration of erythrocytes. The immune 
tolerance process would plausibly depend on the type of malaria antigen in contact with the 
foetus, the amount and the duration of the exposure, and the timing of exposure during 
pregnancy. Indeed, the interaction between gestation and infection timing during pregnancy 
has been previously shown to influence the pathologic consequences for the offspring. A 
specific immunity develops during the first pregnancy and, hence, primigravidae and their 
infants are at higher risk of PAM compared to multigravidae, the infants mainly as a result of 
reduced antibody transfer. Finally, the timing of PAM results in different effects on both the 
mother and the foetus with regard to LBW and anaemia rates. 
With regard to control strategies, effective IPTp diminishes PM and malaria associated 
morbidity such as LBW, pre-term delivery, IUGR, and perinatal mortality in areas where 
resistance to SP is not highly significant. Still, the influence of different IPTp regimes on 
malaria morbidity in infants remains a question for further research. 
Further evidence is also needed on the importance of the timing of infection during pregnancy 
and infant malaria morbidity. In addition, the implementation of different IPTp regimes 
should be adapted according to transmission and the SP-resistance pattern. Furthermore, 
preventive strategies should start during the pre-conceptual period or as soon as possible, as 
there is evidence of increased infant susceptibility to parasites carrying antigens to which they 
were exposed while in utero. Moreover, the role of protective maternal antibodies has to be 
clarified yet. Operational research on different preventive IPT regimes and cost effectiveness 
analysis for community-level IST interventions should be also encouraged. 
Ultimately, the long-term neuro-cognitive consequences of placental malaria, as well as the 
influence of HLA-G polymorphisms on subsequent malaria symptoms would significantly 
contribute to better identify malaria risk factors in infants.
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What the article adds to the previous state of art: Albeit the important prevalence of PAM, 
no review gathering the epidemiologic evidence on the effect of PAM on malaria in infants 
had been conducted. In addition, we include consistent information on the possible 
physiopathological hypothesis undergoing in this interaction. Furthermore, we describe in 
which manner malaria control strategies might also have an effect and the increasing 
importance of resistance agains SP in Africa. Finally, we present research gaps, such as the 
influence of HLA-G on symptoms, the neuro-cognitive effect of malaria, and the lack of 
consistent evidence regarding IST.
NB: The following article summarizes the state of the art of the topic. Consequently, 
substantial information has already been explained in the “State of the art” section.
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V.I.2. Malaria and iron levels: where do we stand?
Summary of the article: We wanted to analyse the state of art concerning the impact of iron 
levels on malaria risk during infancy. Consequently, we realized a systematic literature search 
on iron deficiency, anaemia, and malaria risk factors in infants between the January 2012 and 
April 2014. We used PubMed, the Cochrane Library, Global Health and the World Health 
Organization regional databases. In total, 398 articles in English, French, and Spanish were 
considered for review according to the specificity of the subject. No date restrictions were 
applied. We used Standardised terms and subsequent related citations and links as search 
criteria. In the case of PubMed, the search terms were the Medical Subjects Headings 
(MeSH) "Parasitemia" OR "Malaria" OR "Anemia, Iron deficiency". Two hundred and 
ninety-four articles were selected for final review. With regard to clinical trials, all study 
designs were accepted with the sole restriction of precedence from a malaria endemic country. 
No restriction with regard to the type of iron supplement intervention was applied (food 
based, ferrous sulphate, NaFeEDTA etc.). 
Observational studies describe a certain protection for malaria risk among iron deficient 
children, and ancient clinical trials report increased susceptibility to clinical malaria among 
iron-supplemented children. Nevertheless neither recent clinical trials with important malaria 
monitoring and protective measures, nor the Cochrane review show significant increase for 
malaria risk among iron-supplemented children. Evidence on the effect of iron levels on 
malaria risk is subject to limitations, such as the interference of protective measures, and the 
lack of homogenous iron markers and haematological indicators. The effect of the previous 
haematological and infectious health status, including the chronicity of iron deficiency and the 
possible threshold effect of iron levels, needs to be investigated in the context of a gold 
standard combination of iron markers taking into account both parasitological and clinical 
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malaria outcomes. Further epidemiological elements, such as age of the children, immunity 
status, hemoglobinopathies, or the transmission setting should be considered as well. Finally, 
it is essential to ponder the possible benefits of iron supplementation for anaemia and child 
neurocognitive development beyond its possible deleterious effect. 
What the article adds to the previous state of art: Albeit the important meta-analyses on 
the association of malaria risk with iron, a qualitative review summarizing the complexity of 
this relationship was yet to be conducted. Indeed, we do not analyse the power of each study. 
However, we identify the fact that studies, which do not report increased malaria risk 
associated to iron supplements, have strong protective measures. Furthermore, we bring up 
the lack of prospective cohorts analyzing the association. Finally, we describe the important 
obstacle of not having a gold standard indicator of iron levels and we suggest some proposals 
for further research. 
NB: The following article summarizes the state of the art of the topic. Consequently, 
substantial information has already been explained in the “State of the art” section.
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Article under review in Nutrition reviews:
Malaria and iron levels: the dangerous liaisons?
Violeta Moya-Alvarez, Florence Bodeau-Livinec, Michel Cot.
Abstract: Malaria is the disease with the highest infant morbidity and mortality (WHO 
estimates 207 million cases and 627,000 deaths in 2012), and it raises the burden of anaemia 
in low-income countries, where 40% of children are anaemic according to WHO estimates. 
Anaemia compromises immunity, and iron deficiency anaemia (IDA) has long-term 
permanent neuro-cognitive consequences. However iron has been pointed out as an important 
co-factor for Plasmodium falciparum, the main parasite responsible for malaria, raising fears 
that current iron supplementation policies might be harmful. Albeit the complexity of the 
effect of iron levels on malaria risk, an accurate review clarifying their epidemiological 
association and assessing the different novelties on iron markers has yet to be conducted. 
Observational studies describe a certain protection for malaria risk among iron deficient 
children, and ancient clinical trials report increased susceptibility to clinical malaria among 
iron supplemented children. Nevertheless neither recent clinical trials with important malaria 
monitoring and protective measures, nor the Cochrane review show significant increase for 
malaria risk among iron supplemented children. Evidence on the effect of iron levels on 
malaria risk is subject to limitations, such as the interference of protective measures, and the 
lack of homogenous iron markers and haematological indicators. The effect of the previous 
haematological and infectious health status, including the chronicity of iron deficiency and the 
possible threshold effect of iron levels, needs to be investigated in the context of a gold 
standard combination of iron markers taking into account both parasitological and clinical 
malaria outcomes. Further epidemiological elements, such as age of the children, immunity 
status, hemoglobinopathies, or the transmission setting should be considered as well. Finally, 
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it is essential to ponder the possible benefits of iron supplementation for anaemia and child 
neurocognitive development beyond its possible deleterious effect. 
 Title. Iron and malaria: the dangerous liaisons?
 Abstract. 
Malaria raises the burden of anaemia in low-income countries, where 40% of children are 
anaemic (WHO,2012). Moreover, iron is an important co-factor for Plasmodium falciparum, 
raising fears that iron supplementation might be harmful. We realized a systematic literature 
search to review the present knowledge on the malaria-iron association considering recent 
novelties and substantial qualitative information. Observational studies describe a certain 
protection among iron deficient children, and ancient clinical trials report increased 
susceptibility among iron supplemented children. Nevertheless, neither recent clinical trials, 
nor the 2011 Cochrane review show significant increased malaria risk associated with iron 
supplements. Evidence on the effect of iron on malaria is subject to limitations, such as the 
interference of protective measures, the limited follow-up of the children, and the lack of 
homogenous iron indicators. The effect of the previous haematological and infectious health 
status and the possible threshold effect of iron levels need to be investigated in the context of 
a gold standard combination of iron markers. Finally, it is necessary to ponder the benefits of 
iron supplementation.
 Key words. Iron, malaria, iron supplements, iron indicators, anaemia. 
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Introduction
Malaria is the disease with the highest infant morbidity and mortality worldwide. In 2012 there 
were over 207 million cases and 627,000 deaths according to WHO estimates [1]. The burden of 
disease involves major constraints for public health and also for development in low-income 
countries, where infants constitute the most numerous age-group in society. Malaria entails the 
haemolysis of red blood cells (RBC) and the suppression of erythropoiesis resulting in important 
anaemia. Iron deficiency, defined by WHO by serum ferritin levels<15μg/l [2], remains the main 
cause of anaemia, affecting over 2 billion people globally and it is indeed the most common 
nutritional deficiency. Iron deficiency anaemia (IDA) hinders the correct psychomotor 
development and has important long-term permanent consequences for the neuro-cognitive 
performance of the children [3]. According to WHO, 40% of children in low-income countries are 
estimated to be anaemic. Both malaria and iron deficiency affect mainly infants, pre-school 
children and pregnant women. Furthermore both diseases overlap geographically. Anaemia is not 
only a consequence of malaria, but anaemia compromises immunity and predisposes to infections. 
As a consequence, iron supplements have been recommended by WHO guidelines to fight the 
impaired health status of anaemic children [4]. More precisely, daily supplements of 12.5 mg iron 
and 50µg folic acid are encouraged to prevent anaemia in children 6-24 months where anaemia 
prevalence >40% or from 6 to 12 months in settings with low prevalence of anaemia. In case of 
low birth-weight supplements should start at 2 months. However iron has also been pointed out as 
an important co-factor for infective agents. Since Kochan first described the term “nutritional 
immunity” to describe the importance of iron deficiency as a defensive mechanism against 
bacteria in 1973 [5], controversy on the role of iron in infections in general, and specially in 
malaria, has been always present.  Iron repletion was described as a risk factor for malaria in 1975 
[6] and for infection in general in 1978 [7]. While other articles had reported a deleterious effect 
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of high iron levels regarding the risk of malaria [8,9], the study realized in Pemba [10], Tanzania, 
where malaria was highly prevalent, found a 12% increased mortality among iron supplemented 
children in 2002-2003. Hence, substantial changes in iron supplementation guidelines ensued and 
iron supplementation was restricted to iron deficient children [11]. Nevertheless universal and 
systematic iron levels screening is highly difficult on the field. And the epidemiology of malaria 
infections is substantially variable among transmission settings. Indeed, evidence should be 
applied according to epidemiological infective settings and the effective control interventions 
available.  Therefore, we aim at reviewing the present knowledge on malaria-iron associations 
taking into account the endemic setting, the recent novelties on markers of iron repletion, and the 
forthcoming epidemiological challenges to elaborate a balanced analysis of the malaria risk 
associated to iron. The main objectives are first, to clarify the association between iron and 
malaria and to analyse the nature and the extent of their possible interactions; and second, to 
identify the most adequate iron marker for both research and clinical purposes in order to optimize 
the interventions tackling these complex but extended diseases.
Methods: Search strategy and selection criteria
A systematic literature search on iron deficiency, anaemia, and malaria risk factors in infants was 
realized between the January 2012 and April 2014 using PubMed, the Cochrane Library, Global 
Health and the World Health Organization regional databases. In total, 398 articles in English, 
French, and Spanish were considered for review according to the specificity of the subject. No 
date restrictions were applied. Standardised terms and subsequent related citations and links were 
used as search criteria. In the case of PubMed, the search terms were the Medical Subjects 
Headings (MeSH) "Parasitemia" OR "Malaria" OR "Anemia, Iron deficiency". Two-hundred and 
ninety-four articles were selected for final review. With regard to clinical trials, all study designs 
were accepted with the sole restriction of precedence from a malaria endemic country. No 
restriction with regard to the type of iron supplement intervention was applied (food based, ferrous 
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sulphate, NaFeEDTA etc.). Even if all studies on the iron-malaria association were considered, 
only the studies concerning infants are included in the article. In addition, special attention was 
given to epidemiological studies focused specifically on the iron-malaria association reporting 
concrete haematologic and parasitological indicators (haemoglobin, ferritin, blood smear, 
parasitaemia). Publication bias is not addressed.
Malaria and iron levels: evidence from epidemiological studies
Because of its importance for public health, the attempt to unravel the complexity of malaria in 
infants has brought up new aspects that influence parasitemia beyond entomological or 
immunological factors and preventive interventions. Malaria endemic countries carry a significant 
burden of nutritional deficiencies that a priori predispose to diseases. Numerous studies have been 
carried out in these malaria endemic regions in order to observe the consequences of iron repletion 
and supplementation policies on the appearance and severity of malaria. Effects are however 
difficult to quantify and results should be interpreted according to their outcomes and their 
measure indicators. To address the effect of iron levels on malaria risk, it is necessary to identify 
the most significant outcomes illustrating the interaction between iron and malaria, and to analyse 
the adequacy of the biological parameters used for measurement.
Therefore, certain methodological elements need to be taken into account. Iron deficiency is 
defined according to different biological parameters across the studies. The demographic 
characteristics of the population, the methodology of the study (clinical trial or observational 
study), and the duration of the follow-up period need to be considered as well. Only the answers to 
these questions can give further light on the question to prioritize public health policies.
Malaria indicators and iron: epidemiological evidence
The physiopathology of malaria infection involves a direct interaction between Plasmodia and 
iron. Only within the infected RBC, P. falciparum, the parasite responsible for most malaria cases, 
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consumes up to 80% of the haemoglobin [12]. In addition, the parasite sequestration in the 
intestinal blood vessels impairs the optimal nutritional absorption [13].  Furthermore, non-
transferrine bound iron (NTBI) is associated to increased severity of the malaria episode and to 
reduced performance of the immune function [14–16]. Beyond these direct interactions, further 
clinical conditions, such as certain genetic variants, interfere to determine the association between 
malaria and iron levels. Indeed, genetic variants are estimated to be responsible for over 25% of 
the variation in susceptibility to malaria [17]. In this respect sickle haemoglobin is a significant 
example, but protection is thought to be rather multigenic [18].Other co-morbidities, such as HIV, 
bacterial and helminthic infections are also correlated with both iron and malaria [19–21]. 
There are certainly numerous pathways in which iron and malaria interact. Consequently, it is 
necessary to analyse their association with a holistic approach that arises from the epidemiological 
pattern of infections on the field. Table 1 summarizes the landmark studies on iron levels and 
malaria in different malaria endemic regions.
Observational studies display information reflecting the association between iron and malaria 
based on the real circumstances of the field, but accurate iron monitoring is not commonly 
realized on a systematic basis in this context. Clinical trials focus rather on the effect of 
supplements and investigate the possible consequences for malaria outcomes of the iron 
supplementation policy, but their methodological protective constraints do not reflect the 
epidemiological reality of malaria endemic settings. Indeed, both approaches assemble different 
but important information and, therefore, both should be considered for the analysis of the iron-
malaria link.
Clinical malaria is the consequence of the asexual cycle of Plasmodia parasites in the RBC. It 
constitutes the main outcome of the majority of the observational studies and it is currently 
defined as temperature>37.5º or 38º C within the previous 48 hours and a blood film positive for 
blood-stage asexual parasites. In this respect, two cross-sectional observational surveys from 2001 
to 2003 in Kenya among children aged 8 months to 8 years reported significant protection among 
123
396
397
398
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
399
V. Results     
iron deficient children (Adjusted incidence rate-ratio (IRR)= 0.7 (95%CI 0.51;0.99) with 
ferritin<12μg/ml and transferrin saturation<10%) [22]. Furthermore, iron status was inversely 
correlated with malaria-specific immunoglobulins. Similar results were found in an observational 
cohort study in Tanzania [23] among children between birth and 3 years. Iron deficiency (defined 
by ferritin concentration corrected on CRP) was also associated with a significant protection with 
regard to lower odds of malaria parasitemia (OR=0.15 (95%CI 0.12;0.19)), lower odds of 
hyperparasitemia (parasites>2500/200 white blood cells (OR=0.04 (95%CI 0.02;0.07)), and lower 
odds of severe malaria (OR=0.25 (95%CI 0.14;0.46)) after adjustment for possible confounders.
In a pioneer randomized placebo controlled trial in Tanzania in 1995 in infants between 8 and 24 
weeks of age, no increased susceptibility to malaria was observed among iron supplemented 
children with regard to first or only malaria episode compared to placebo (protective efficacy 
(PE)= 12.8% (CI -12.8;32.5) [24]. Albeit this first reassuring result, supplementation effects on 
children health status had to be re-evaluated after the Pemba trial. In 2002-2003 a randomised, 
double blind, placebo-controlled trial, gathered medical evidence on all-cause morbidity and 
mortality among over 24,000 children up to 35 months daily supplemented with folic acid and 
iron, iron, folic acid, zinc or placebo10 in Pemba, Tanzania. In the same cohort, a sub-study 
among 2413 children addressed the impact of supplements on haematological status, zinc, malaria 
prevalence, and infectious disease morbidity. Combined groups of supplemented children had 
significant higher risk for serious clinical events resulting from malaria compared to placebo 
(RR=1.16, CI 1.02; 1.32). Malaria related hospital admissions were also significantly higher 
(RR=1.18, (95%CI 1.02; 1.36)) among supplemented children. In the case of cerebral malaria, the 
RR of the iron and folic acid group, was also significant compared to placebo (RR=1.22 (CI 1.02; 
1.46). In addition another deeply relevant aspect of the malaria-iron association was first raised 
up: the importance of the iron levels at baseline. Iron-deficient children at baseline, defined by 
zinc protoporphyrin>80 µmol/molhaeme, had a reduced risk of malaria-related adverse events 
when supplemented compared to placebo (RR=0.56, 95%CI 0.32; 0.97). Due to the increased 
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morbidity found in this trial, the WHO recommendations restrained supplements to iron deficient 
children in malaria endemic regions [25]. 
Nevertheless, as previously said, more recent studies report different results. A study in Tanzania 
in 2008-2009 investigated the consequences of micronutrient supplementation in 612 children 
between 6 and 60 months [26]. While there was no significant increase in overall malaria episodes 
among supplemented children compared to placebo, multi-nutrient supplementation was 
associated to a 41% increase in the overall number of malaria episodes in children with iron 
deficiency (HR=1.41 (95%CI 1.09; 1.82)), whereas there was no significant impact among the 
iron-replete children (p-value for difference in effect=0.01). 
In 2010 in Ghana, in a double blind, cluster randomized trial providing a micronutrient powder 
(MNP) with or without iron, 1958 infants of 6 to 35 months of age were followed for 6 months 
and no significant increase in malaria risk was observed compared to placebo (Risk ratio (RR)=1 
(95%CI 0.81;1.23)) [27]. No significant association with increased malaria was described among 
iron replete children, with or without concomitant anaemia (RR=0.83 (95%CI 0.64;1.08) and 
RR=1.04 (95%CI 0.82;1.32), respectively). However, supplemented children with both iron 
deficiency and anaemia showed significantly reduced risk of malaria RR=0.67 (95%CI 0.5;0.88) 
compared to placebo. 
Because of these a priori contradictory results of the studies, a Cochrane review of 2011 analysed 
71 trials collecting evidence on 45,353 children [28]. For the 13 trials selected, the Cochrane 
review concluded to an absence of significant differences in clinical malaria rates between iron 
and placebo (RR=0.99, 95%CI 0.9; 1.09). No statistical differences were found neither among 
supplemented infants (children<2years) (RR=0.94 (95%CI 0.82; 1.09) nor for severe malaria 
(RR=0.91 (95%CI 0.76; 1.08)) compared to placebo. Furthermore, no statistical difference was 
found among non-anaemic children at baseline (RR=0.97 (95%CI 0.86; 1.09). However, analyses 
on iron deficiency defined by ferritin were not realized. Even if it is difficult to screen children for 
iron status at the population level, information on the effect of iron deficiency is relevant to 
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develop useful supplement strategies based on scientific accurate evidence. Finally, this Cochrane 
meta-analysis describes increased risk for clinical malaria among iron or iron plus folic acid 
supplemented children in the absence of malaria surveillance and treatment.
Beyond clinical malaria, it is necessary to consider also malaria mortality to capture broader 
aspects of the iron-malaria association. In the context of the clinical trial with iron supplements in 
Pemba, mortality due to malaria was higher (although not significantly) among supplemented 
children compared to placebo (RR=1.08, (95%CI 0.84; 1.40)). Among children supplemented with 
iron and folic acid, there was also a significant increased risk for cerebral malaria as a cause of 
death compared to placebo (RR=1.70, 95%CI 1.08; 2.68). The iron and folic acid supplemented 
children were 12% more likely to suffer an adverse event resulting in hospitalisation or death 
(95%CI 2;23) compared to placebo and all-cause mortality was also significantly higher: OR= 
1.61 (95%CI 1.03; 2.52). Iron deficiency and moderate anaemia at baseline were significantly 
associated to lower rate of adverse events (death or severe morbidity leading to admission) among 
supplemented children compared to placebo. Further extensive studies on the impact of iron 
supplements on mortality to malaria are scarce due to the difficulty of attributing correctly the 
cause of death in endemic settings and, hence, it is difficult to accurately assess the interaction 
between malaria and infection with regard to mortality. In addition more statistical power is 
needed as iron measures are rare and death is also a rare event. 
In a good attempt to clarify finally the conundrum, the Cochrane meta-analysis28 on the impact on 
iron supplements addressed certainly this question but did not provide a definite answer. In this 
review, the relative risk for all-cause mortality was not estimable. However, it was capable of 
displaying useful information with regard to transmission settings. Mortality was not significantly 
different between hyper- and holo-endemic areas (Risk difference= 1.93 per 1000 children (95% 
CI -1.78; 5.64). 
In summary, the risk for clinical malaria differs according to iron status between observational 
studies and clinical trials on iron supplementation. Overall, observational studies describe a certain 
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protection for malaria risk among iron deficient children. In parallel, meaningful ancient studies 
report increased susceptibility to clinical malaria among iron supplemented children7,8, and so 
does the Pemba trial, which has a considerable statistical power. However, other recent clinical 
trials with important malaria monitoring and protective measures, show no significant increase for 
malaria risk among iron supplemented children26,27 and neither does the Cochrane review28. 
Albeit the absence of overall significance, the cross-sectional studies in Tanzania report also 
significant earlier malaria among supplemented children26.
Evidence on the effect of iron levels on malaria risk is subject to certain limitations, such as 
methodological study constraints, homogenous measurement of iron and haematological 
indicators, the effect of different transmission patterns, and further possible confounders.
In effect, statistical limitations are inherent to ethical research studies. Clinical trials display 
results based on intensively monitored parameters. In most of them prophylactic protection by 
ITNs or preventive treatment for malaria is more frequent among enrolled patients than in 
observational studies, and treatment is also given as soon as a case is confirmed. As a 
consequence, it is difficult to disentangle the possible protective effect of IDA from the protection 
given by protective measures, especially in the case of severe malaria or hyperparasitemia in 
clinical trials. Preventive measures reduce the number and the severity of malaria episodes and, 
hence, statistical power decreases as does the force of the association. The dimension of the 
association, or its absence, should be ideally assessed in the conditions in which population 
undergo the malaria burden and the nutritional interventions. Nevertheless, accurate iron 
monitoring is not realized systematically and malaria episodes are not always captured by 
demographic or surveillance data. In addition, observational studies that do not provide treatment 
are unethical in malaria endemic countries with limited access to health care. However, 
surveillance data or data issue of demographic surveys may be useful to get a basic idea on 
malaria risk and haematological indicators. 
With regard to the epidemiological indicators, malaria infection outcomes (clinical malaria and 
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parasitaemia) reflect more specifically the malaria-iron relationship, and mortality reflects rather a 
broad association between iron and pathogens. In addition its assessment is difficult because of 
diagnostic reasons, and evidence lacks with regard to specific malaria deaths related to iron 
supplements. 
The transmission setting constitutes an additional important stake of the question. Disease burden 
in children after iron supplementation does certainly differ in the absence of malaria compared to 
malaria endemic settings [29]. The existence of a possible malaria prevalence threshold at which 
iron supplements start to have a deleterious effect on infant health requires as well further 
research.
Other methodological obstacles contribute to the inconclusive results of the analyses of the 
association between iron and malaria risk. Analyses in the clinical trials are seldom adjusted on 
other significant co-variables and odds ratios (OR) and relative risks (RR) originate often from 
univariate analyses. In addition, the exclusion of the children with inflammation in some studies 
might have introduced a bias in the interpretation of results concerning the children with the most 
severe disease, as inflammation is predominantly present in these more severe cases.
Finally, the haematological indicators at baseline show contradictory results in literature at 
present. Indeed, a clinical trial describes a significant protection against malaria among 
supplemented children with both anaemia and iron deficiency [27]. However a study in Tanzania 
observed an increase in malaria risk among iron-deficient infants26. Similar results are found in 
pregnant women [30].  Indeed, there might be a possible protective role of anaemia or iron 
deficiency in the context of iron supplementation.  In case of anaemia the incorporated iron might 
be used for haemoglobin synthesis whereas in the context of iron deficiency with no anaemia at 
baseline the incorporated iron might entail an increase in NTBI, enhancing parasite growth. More 
extensive research including different iron deficiency indicators is needed to advance in the 
knowledge in this aspect. Yes it is essential to ascertain the meaning of the information provided 
by the different iron markers used in the research studies to better unravel the iron-malaria 
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conundrum.  
Iron status assessment and iron markers: the Rosetta stone to understanding 
In order to better discern the importance of iron levels for malaria morbidity and mortality, the 
determination of iron levels requires precision and consensus among researchers. The 
understanding of the nature and the meaning of the different iron and haematological markers is 
necessary as the definition of common indicators might enable the extrapolation of results and 
improve their interpretation. Therefore, it becomes a prerequisite to remind briefly the 
physiopathology of iron involved in the P. falciparum infection process.
Iron has multiple effects on malaria physiopathology: it interacts with the host’s immunity but also 
with the parasite. With regard to the host immunity, iron interferes with zinc and with the 
inducible nitric oxide synthase (iNOS). In parallel, the host inflammation process increases 
hepcidin, a hormone regulating iron disposal in plasma, in order to block iron absorption. Thus it 
was first reported that by inhibiting the absorption of zinc, iron would alter the immune response 
to infection [31], but recent studies describe no improvement in infection outcomes in zinc 
supplemented children [26]. In addition, iron inhibits the synthesis of nitric oxide, an anti-
infectious agent [32], even if the subsequent consequences for malaria are not fully understood.
At the host level the interaction of iron and P. falciparum is also significantly determined by the 
NTBI, involved in parasite metabolism. Hepatocytes take up faster NTBI than transferrin-bound 
iron [33] and, in animal models, the supply of iron contributes to the penetration of hepatocytes by 
Plasmodium and stimulates their growth to merozoites [34]. Furthermore NTBI is involved in 
parasite sequestration of malaria-infected erythrocytes in the capillaries of the brain and intestine 
through up-regulation of ICAM-1 and is thus linked to severe malaria [14–16].
The biological indicators reflect the different pathways in which iron interferes with malaria 
infection, and their choice as iron markers in research studies are crucial to determine the meaning 
of the results.  The joint WHO-CDC Technical Consultation for iron assessment selected 5 
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different indicators as good iron markers: haemoglobin, mean cell volume (MCV), (sTfR) 
concentration, serum ferritin concentration, and red cell protoporphyrin (measured by the zinc 
protoporphyrin/haemoglobin ratio (ZPP:H) [35,36]). Table 2 summarizes the main characteristics 
of these markers. Haemoglobin is deeply useful in the monitoring of health status and its 
determination is easy to realize on the field. Although it is a basic fundamental haematological 
indicator, it is not specific as an iron marker because of the multiple causes of anaemia and the 
physiological variations with regard to sex, age or ethnicity. Therefore, it can be misleading for 
the extrapolation of conclusive results. Mean cell volume accuracy is limited in the context of 
thalassemia and malaria as inflammation serum transferrin receptor modifies significantly its 
values. Due to its physiopathological pathway, serum transferrin receptor is also influenced by the 
haemolysis of malaria, and its determination method is not always standardized nor cost-effective 
[37]. 
Serum ferritin is a precise indicator of iron storages in healthy individuals and it can be corrected 
according to other inflammation proteins. It provides further information as it also shows different 
patterns of behaviour depending on the aetiology of anaemia [16]. In an iron supplementation 
study, Doherty et al. compared the erythrocyte incorporation of oral iron supplement in 37 
Gambian children 8 to 36 months old with anaemia after malaria treatment, to supplemented 
control children with IDA but no recent malaria [38]. The non-malaria control children showed 
progressively increased serum ferritin whereas the post-malarial children showed decreased serum 
ferritin levels. Serum ferritin levels became similar in both groups only by day 15 and 30. This is 
thought to be due to the normalization of the immune response following the malaria treatment 
[16]. Indeed, serum ferritin is an acute phase protein. Hence, serum ferritin is either corrected 
upon inflammation (with correction factors according to C-reactive protein (CRP) or α-1-
glycoprotein (AGP) levels), or samples with high acute inflammation proteins are systematically 
excluded. Nevertheless the exclusion of samples with increased inflammation might entail a 
subsequent bias in the context of malaria, as samples with high ferritin would be systematically 
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excluded as well. Despite its limited accuracy in case of inflammation, ferritin is a consistent 
extended iron marker. 
Along with ferritin, ZPP:H ratio is the most frequently used indicator for iron assessment. The 
chelation of ferrous iron by protoporphyrin is the final step for the heme synthesis. In iron 
deficiency zinc is chelated as iron is not available and ZPP formation is decreased. In the iron-
deficient parasitized RBC, the increased ZPP could bind to heme crystals, and inhibit the 
formation of hemozoin [12]. Longstanding inflammation processes, thalassaemia, and 
asymptomatic P. falciparum parasitemia might also show elevated ZPP:H ratios, and consequently 
be erroneously associated to iron deficiency [26]. For this reason Oppenheimer suggested that the 
benefit of iron supplementation in the Pemba sub-study might be due to the selection of 
individuals who were thalassemic or sickle cell carriers (WHO/UNICEF/IVACG Innocenti 
Conference on Micronutrients and Health: Emerging Issues Related to Supplementation, 2005). In 
addition there is no standardized corrections applicable to ZPP:H ratios in the context of long-term 
inflammation processes.  Finally high lead levels interfere with ZPP:H, and polluted regions 
frequently overlap with malaria endemic settings. However the impact of inflammation on ZPP:H 
is not as important as on serum ferritin. 
A novel marker has recently emerged as an alternative indicator: hepcidin. Hepcidin is a peptide 
hormone which plays a crucial role in iron regulation and is determinant in the malaria infection 
process. Hepcidin binds ferroportin [39], it increases in response to inflammation and blocks iron 
entry into the plasma. It has been proposed as a good marker for iron levels, especially because it 
might be up-regulated after malaria episodes compared to other markers of iron-deficiency [16]. 
Therefore, a priori, it might permit to distinguish between iron-deficiency and malaria related 
anaemia. However, hepcidin shows a non-linear association with anaemia in the context of malaria 
albeit its significant association with parasitemia [40,41]. Furthermore, in Kenya it was increased 
on admission at hospital for P. falciparum malaria and was significantly associated with parasite 
density, but hepcidin levels were very low in severe malaria anaemia [41]. In addition, its 
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accuracy as an iron marker has been recently questioned as it has been shown that it is associated 
with the anti-inflammatory response but not with iron or anaemic status among malarial Nigerian 
children [42]. Hence, further studies with more statistical power should be encouraged to ascertain 
its utility as an iron marker. 
In conclusion, complementary indicators are needed for the accurate assessment of iron status. In 
this respect, inflammation parameters are necessary to correct ferritin levels in the context of 
malaria, and further research is expected in order to determine precisely the utility of hepcidin in 
iron assessment in the context of malaria. It is also important to highlight the danger of 
categorising non-iron deficient infants as "iron-replete", as limits for iron deficiency are not rigid 
and should be considered with caution and in relation to the clinical and environmental settings. 
Conclusion
Iron physiopathology interacts with P. falciparum at different levels. Therefore, the iron balance 
influences the appearance and the evolution of the infection with regard to both the immune 
system and the parasite. As a consequence, it is important to analyse in which manner providing 
supplementary iron has an effect on immunity and on invading pathogens taking into account the 
previous haematological and infectious health status of the infants.  
With regard to epidemiological studies, malaria risk should be assessed with regard to both 
clinical episodes and P.falciparum density to monitor accurate measures of the impact of iron. 
Further epidemiological elements should be taken into account to analyse the effect of iron on P. 
falciparum parasitemia: age of the children, immunity status, or hemoglobinopathies should be 
considered as well to give further light on the subject. Indeed, Sazawal et al. have already 
underlined that reviews do not always assess separately studies from malaria-endemic areas with 
different transmission or studies in different age groups [10]. In addition, meta-analyses should 
differentiate studies in which iron was given as treatment for anaemia and studies for prevention 
of iron deficiency. Adjustment on other causes of iron deficiency and anaemia, such as nutritional 
deficiencies, helminthic infections or haemoglobinopathies should be compulsory as well.
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In general, observational studies display a certain protection against malaria among iron-deficient 
children. However, iron assessment including multiple markers must be introduced yet on a 
systematic basis among all study designs to guarantee a solid accuracy of the iron-malaria 
association, especially in relation to haematological indicators at baseline. Corollary to this 
question is the necessity to find a gold standard or a best iron marker combination. Ferritin and 
haemoglobin are still at the core of the haematological assessment, but the role of hepcidine must 
be further investigated in the context of large epidemiological studies in parallel to other best 
known iron indicators like ferritin, haemoglobin or ZPP:H.
In any case, the budget and technology constraints will determine the implementation of this 
screening strategy, and blood test to determine iron levels should become more affordable. For 
these reasons, targeting low-birth weight infants for iron supplements has been proposed since 
they are at higher risk for iron deficiency and anaemia [4]. Still, low birth weight is associated to 
increased mortality, and the effect of iron on infection can further contribute to the deterioration of 
the infant health status when malaria treatment is not available.
Another aspect, which should be further investigated, is the link between the chronicity of iron 
deficiency and the response to iron supplementation and infection, especially as chronic effects of 
inflammation might modify the malaria-iron association. Furthermore, the existence of 
P.falciparum strains requiring more or less iron should be investigated, as well as the possible 
selection of P.falciparum drug-resistant strains in the context of increased iron availability.
With regard to transmission, the existence of a possible malaria prevalence threshold at which iron 
supplements start to have a deleterious effect on infant health requires as well further 
investigation.
Finally, when analyzing the effect of iron on infant health, it is essential to take into account the 
possible benefits of iron supplementation for anaemia and child neurocognitive development 
beyond its deleterious effect. According to the Cochrane review [28], iron supplements given as 
part of the treatment for anaemia resulted in higher increases in haemoglobin than iron given as 
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prophylaxis for anaemia in both malaria hyper- and holo-endemic areas. Indeed, joint malaria 
treatment and iron supplements reduce malaria rates significantly compared to no prophylaxis. 
Nevertheless, it is important for both preventive and treatment iron supplementation policies to 
consider the poor utilization of the iron intake by the body until one week after the malaria 
episode.  In conclusion, the joint treatment for malaria along with oral iron supplements seems to 
improve anaemia without increased risk for malaria. 
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Table 1. Effect of iron supplements on malaria incidence 
     
Study site Country Year 
Type of 
study 
Malaria 
transmission 
Number of 
individuals 
included 
Follow-up 
period 
Age at 
supplements 
Iron deficiency or 
anaemia indicator Relationship with malaria Effects on anaemia and iron indicators 
Aware Somalia 1975 
placebo 
controlled 
trial perennial 137 30 days 
 
Hemoglobin<11g/dl 
Serum iron 
concentration<4.48µmol/l 
Transferrin 
saturation<15% 
Peripheral blood smear 
with microcytic 
hypochromasia 
In univariate analysis: Placebo group 2/66; Iron 
supplemented group: 21/71 
Mean hemoglobin (g/dl) 
Before treatment: Placebo 8.1±0.7 Iron 8.3±0.6 
After treatment: Placebo 8.7±0.9 Iron 12.3±1.1 
Mean serum Fe (µmol/l) 
Before treatment: Placebo 3.4±0.57 Iron 
3.6±0.52 
After treatment: Placebo 3.9±0.7 Iron 13.1±0.93 
Mean % saturation transferrin 
Before treatment: Placebo 7±1.4 Iron 7±1.8 
After treatment: Placebo 8±0.7 Iron 31±1.4 
Madang 
Papua 
New-
Guinea 
1980-
1981 
matched 
randomized 
prospective 
trial 
perennial with 
seasonal peaks 486 12 months 2 months 
Hemoglobin, transferrin 
saturation, serum ferritin 
(log) 
At 6 months: OR=1.78 (CI 1.02; 3.1) 
At 12 months: OR=1.95 (CI 1.21; 3.13) 
Mean hemoglobin at 6 months (g/dl): Placebo 
9.82 (1.39) Iron 9.14 (1.09) (p<0.001)  
Mean hemoglobin at 12 months (g/dl): Placebo 
9.78 (1.36) Iron 9.32 (1.34) (p<0.002)  
Ifakara Tanzania 
1995-
1996 
randomised 
placebo-
controlled 
trial 
perennial and 
intense 832 
minum of 
52 up to a 
maximum 
of 153 
weeks 8 to 24 weeks Hemoglobin 
PE with regard to the 1st malaria episode compared to 
placebo 
Daily iron and weekly placebo: 11% (CI ; 21.8;  35) 
Daily placebo +weekly Deltaprim 59.4% (CI 41.1;  72) 
Daily iron + weekly Deltaprim 65.9% (CI 49.6;   77) 
PE with regard to the severe anaemia 
(PCV<25%) compared to placebo 
Daily iron and weekly placebo: 32.1% (CI  4.9 ;  
51.6) 
Daily placebo +weekly Deltaprim 59.8% (CI 
41.1;  72.6) 
Daily iron + weekly Deltaprim 68.5% (CI 52.3;  
79.2) 
Ngerenya Kenya 
2001-
2003 
observational 
study 
perennial with 
seasonal peaks 240 
2 cross-
sectional 
surveys at 6 
and 12 
months 
after 
enrolement  
no 
supplements 
ID: plasma 
ferritin<12µg/ml in 
association with TFS<10% 
Adjusted IRR in iron-deficient children=0.7 (CI 0.51 ;  
0.99) No supplements 
Pemba Tanzania 
2002-
2003 
randomised 
placebo-
controlled 
trial 
holoendemic 
with year-
round 
transmission 
and seasonal 
peaks 24076 
until 
discharge 
or death 20 weeks 
ID: zinc protoporphyrin 
>80µmol/mol haeme 
Anaemia: hemoglobin 70–
100 g/L 
Overall adverse events, deaths, and admissions to 
hospital caused by malaria compared to placebo 
Iron and folic acid: RR= 1.16 (CI 1 ;  1.34) 
Iron, folic acid, and zinc: RR=1.16 (CI 1.01 ;  1.34) 
Non significative trend for smaller proportion of 
children with anaemia among all admissions 
compared to placebo 
Muheza Tanzania 
2002-
2005 
observational 
study intense 785 
at birth 
until 3 
years 
no 
supplements 
ID:ferritin concentration 
<30 ng/mL when CRP 
<8.2 µg/mL or ferritin 
concentration <70 ng/mL 
when CRP >8.2 µg/mL 
Children with ID OR=0.15 (CI 0.12;  0.19) and 3.9 fold 
lower parasite count (P<.001) compared with iron replete 
children 
Children with ID, for Hyperparasitemia (= 
parasitemia>2500/200 WBC) OR=0.04 (CI 0.02; .07) 
and for severe malaria OR=0.25 (CI 0.14;  0.46) 
compared to iron-replete No supplements 
Handeni Tanzania 
2008-
2009 
randomised 
placebo-
controlled 
trial intense 612 
median 
follow-up 
331 days 
6-60 months 
ID: plasma ferritin 
concentration <12 µg/L 
Compared to placebo: 
All malaria episodes: 
Zinc group: AHR= 0.99 (CI 0.82; 1.18) 
Multinutriments without zinc: AHR=1.04 (CI 0.87; 1.23) 
Multinutriments with zinc: AHR=1.14 (CI 0.96; 1.35)  
First malaria episodes: 
Zinc group: AHR= 1.12 (CI 0.86; 1.44) 
Multinutriments without zinc: AHR=1.35 (CI 1.05; 1.73) 
Multinutriments with zinc: AHR=1.38 (CI 1.07; 1.77) 
 
Number of episodes with versus without multinutriments 
Iron deficient: HR=1.41 (1.09; 1.82) 
Iron replete: HR=0.93 (0.77; 1.13) 
*Difference relative to placebo (95%CI), 
Hemoglobin concentration (g/l)  
Micronutrients without zinc: 106.6 (10.7) *2.6 
(0.0; 5.2) 
Micronutrients with zinc: 107.5 (11.4) *3.5 (0.8 ; 
6.1) 
Geometric mean ferritin concentration (µg/l) 
All children  
Micronutrients without zinc: 57.1 (0.03) *24.5 
(14.8; 36.2) 
Micronutrients with zinc: 57.2 (0.03) *24.6 
(14.8; 36.3) 
without inflammation: 
Micronutrients without zinc: 43.9 (0.03) *19.5 
(11.3; 28.6) 
Micronutrients with zinc: 51.1 (0.03) *26.7 
(17.5; 38.1) 
Brong-
Ahafo Ghana 2010 
double blind, 
cluster-
randomized 
trial 
perennial with 
seasonal peaks 1958 6 months 
6 to 35 
months 
ID: $plasma ferritin 
concentration <12 µg/L 
Malaria risk for iron supplemented group compared to 
placebo: 
Malaria risk for all children RR=1 (CI 0.81; 1.23) 
RR for malaria with ID and without inflammation=0.81 
(CI 0.63; 1.03) 
RR for iron replete children without inflammation=0.92 
(CI 0.81; 1.06) 
Iron replete children: 
Plus anaemia: RR=0.83 (CI 0.64; 1.08) 
No anaemia: RR=1.04 (CI 0.82; 1.32) 
Iron deficient children: 
Plus anaemia: RR=0.67 (CI 0.5; 0.88) 
No anaemia: RR=0.84 (CI 0.63; 1.12) 
Iron supplemented group compared to placebo for 
malaria with parasitemia>5000/µl: 
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V.II. ARTICLES REPORTING ORIGINAL RESULTS 
In this second part of the section, I will present the results of the study that we conducted in 
Benin. They respond to the objectives and they are structuctured as follows: 1.The influence 
of iron levels on malaria risk during pregnancy; 2. The association of iron levels and IPTp 
with malaria in infants; and 3. The association of elevated blood lead level with malaria in 
infants.
As in the previous sub-section, references, figures and tables in this section are independent of 
those in the whole dissertation as they are presented at the end of each article.
Finally, to give a more accurate idea of what our articles add to the previous state of art, we 
have added a little paragraphe at the end of the article summary.  
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V.II.1. Iron levels and pregnancy associated malaria
Summary of the article: As explained in the introduction, cross-sectional studies report that 
iron might be associated with increased malaria morbidity, raising fears that current iron 
supplementation policies will cause harm in the present context of increasing resistance 
against intermittent preventive treatment in pregnancy (IPTp). Therefore, we wanted to assess 
the relation of iron levels with malaria risk during the entire pregnancy.
To investigate the association of maternal iron levels on malaria risk in the context of an IPTp 
clinical trial, 1005 human immunodeficiency virus-negative, pregnant Beninese women were 
monitored throughout their pregnancy between January 2010 and May 2011 in three 
maternities of the district of Allada. Allada is a semi-rural area of 91,778 inhabitants located 
50 km North of Cotonou (Benin). Malaria has a perennial transmission pattern with two 
transmission peaks corresponding to the rainy seasons in April-July and October-November. 
Plasmodium falciparum is the species responsible for the majority of infections.  
This study is a sub-study of the MiPPAD clinical trial, where 4,749 pregnant women were 
enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, 
and Tanzania comparing 2-dose MQ or SP for IPTp and MQ tolerability of two different 
regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose 
MQ in the context of long lasting insecticide treated nets. In the MiPPAD trial there was no 
difference on low birth weight prevalence (primary study outcome) between groups 
(360/2,778 (13.0%)) for MQ group and 177/1,398 (12.7%) for SP group (RR= 1.02, 95% CI 
(0.86; 1.22), p-value = 0.80 in the ITT analysis). Women receiving MQ had reduced risks of 
parasitemia (63/1,372 (4.6%) in the SP group and 88/2,737 (3.2%) in the MQ group (RR= 
0.70, 95% CI (0.51; 0.96), p-value = 0.03) and anemia at delivery (609/1,380 (44.1%) in the 
SP group and 1,110/2743 (40.5%) in the MQ group (RR= 0.92, 95% CI (0.85; 0.99), p-value 
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= 0.03), and reduced incidence of clinical malaria (96/ 551.8 malaria episodes person/year 
(PYAR) in the SP group and 130/1,103.2 episodes PYAR in the MQ group (RR= 0.67, 95% 
CI (0.52; 0.88), p-value = 0.004) and all-cause outpatient attendances during pregnancy 
(850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the 
MQ group (RR= 0.86, 95%CI (0.78; 0.95), p-value =0.003). In the MiPPAD study there were 
no differences in the prevalence of placental infection and adverse pregnancy outcomes 
between groups. In conclusion women taking MQ IPTp (15 mg/kg) in the context of long 
lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking 
SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy 
outcomes and safety profile were similar. The conclusions of the MiPPAD trial do not support 
a change in the current IPTp policy. 
On the contrary to the MiPPAD trial, in our sub-study in Benin, named “Anaemia in 
pregnancy: etiology and consequences (APEC)”, women were followed prospectively until 
delivery through a close monitoring of their haematologic parameters as well, including 
hemoglobin, serum ferritin and CRP in addition to the blood smear, blood film and Kato-Katz 
exam. During the follow-up of the Beninese cohort, 29% of the women had at least 1 episode 
of malaria. On average, women had 0.52 positive smears (95% CI (0.44; 0.60)). 
Multilevel models with random intercept at the individual levels and random slope for 
gestational age were used to analyse the factors associated with increased risk of a positive 
blood smear and increased Plasmodium falciparum density. Indeed, high iron levels 
(measured by the log10 of ferritin corrected on inflammation) were significantly associated 
with increased risk of a positive blood smear (aOR = 1.75, 95% CI (1.46; 2.11), p-value 
<0.001) and high P. falciparum density (beta estimate = 0.22, 95% CI (0.18; 0.27); p-value 
<0.001) during the follow-up period adjusted on pregnancy parameters, comorbidities, 
environmental and socioeconomic indicators, and IPTp regime. Furthermore, iron-deficient 
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women were significantly less likely to have a positive blood smear and high P. falciparum 
density (p-value < 0.001 in both cases). Supplementary interventional studies are needed to 
determine the benefits and risks of differently dosed iron and folate supplements in malaria-
endemic regions.
What’s known on this subject: The prevalence of anemia in Sub-Sahran Africa is high. 
Malaria, helminth infection and iron deficiency are the main causes of gestational anemia. 
WHO recommends iron supplements and IPTp during pregnancy. However, the benefits of 
iron supplements are set into question in settings with high malaria incidence. Indeed, 
evidence is inconclusive, and prospective longitudinal data is lacking. 
What this study adds:  We show that elevated iron levels are associated with increased risk 
of malaria and P.falciparum density in a longitudinal prospective cohort during pregnancy in 
the context of ITN use, considering environmental, clinical and obstetric risk factors. Women 
with iron deficiency are significantly protected against malaria.
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V.II.2 Association of iron levels and interval length between IPTp 
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doses on malaria in infants during the first year of life
Summary of the article: As already explained in the « State of art » section, epidemiological 
studies have reported an increased malarial risk in infancy associated with high iron levels. 
This aspect is of special concern in Benin, because malaria is the first cause of mortality of 
infants under 5 years, and no national guidelines exist at present regarding iron supplements 
in infancy. 
To investigate the effect of iron on malaria risk during the first year of life, we used the data 
of 400 infants (200 born of the anemic and 200 born of non anemic mothers) included in the 
APEC (Anaemia in Pregnancy: Etiology and Consequences) study. In addition to the 
mother’s follow-up, clinical data of the infants were collected during systematic visits at 6, 9, 
and 12 months in three clinics in the district of Allada (Allada, Attogon, Sékou). In case of 
sickness infants were accurately examined in unscheduled visits and, if necessary, treated 
according to the Beninese Ministry Health guidelines. In the unscheduled visits clinical and 
biological exams were realized following the same protocol as systematic visits, i.e., 
anthropometric measures, and an extensive clinical examination were realized. In addition, 8 
ml of venous blood (4ml in a dry tube and 4ml in an edta tube) were collected at each visit. 
Haemoglobin, serum ferritin, CRP, vitamin B12, and folate levels were assessed. A container 
was also given to the women to collect stools to examine the presence of intestinal helminths 
in the infants. These containers were collected the following day by the study nurses within 
the first 6 hours after emission. 
During the first year of life, 40% of the infants had at least one malarial episode, with a range 
of 0-4 positive smears. Offspring of mothers with longer IPTp protection (number of days 
between IPTp doses) were significantly less likely to both have a positive smear (adjusted 
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odds ratio (aOR)=0.87, p-value=0.04) and high P. falciparum parasite density (beta 
estimate=-0.06, p-value<0.001) during the entire follow-up period. Iron levels (measured by 
the log of ferritin corrected on inflammation) were significantly associated with the risk of a 
positive blood smear (aOR=2.77, p-value<0.001) and P. falciparum parasitaemia (beta 
estimate=0.38, p-value<0.001). In multilevel model analysis, infants with iron levels in the 
lowest quartile were significantly less likely to have a positive blood smear during the first 
year of life (p-value<0.001), and the risk increases with higher iron levels. 
We were surprised that the interval length between IPTp doses (i. e. the number of days 
between doses) was associated with malarial risk and not with PAM. However, PAM might 
not be symptomatic enough in the women of our cohort to make them go consult to the 
clinics. Therefore, we might have lost valuable information during the mother’s follow-up 
and, hence, our data might not have enough power to show an effect. Nevertheless, it is 
coherent that, knowing that the interval length between IPTp doses modifies the time of 
exposure of the foetus to Plasmodium, it might have an effect of malaria in infants due to a 
possible immune tolerance process. 
Similarly to the mother’s case, iron levels in infants were significantly associated with 
increased malaria risk during the first year of life. Furthermore, our results suggest the 
existence of dose effect of iron levels on malaria risk. Because of these results and the 
previous literature on the topic, we think that additional epidemiological studies are required 
to evaluate the effect of different doses of iron supplements on the infant health outcomes. In 
addition, the comparison of cohorts in which iron is given with preventive purpose versus iron 
given for the treatment or anaemia or iron deficiency (ID) is also interesting. Finally, public 
policies should be encouraged to increase the observance of IPTp as it has a protective effect 
not only in mothers but also in their offspring. 
What’s known on this subject: Malaria and iron deficiency are the main causes of anemia in 
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infants. The benefits of iron supplements are questioned in malaria settings, but no 
longitudinal data exist. Moreover, the influence of IPTp on malaria in infants has seldom been 
analysed.
What this study adds:  We show that elevated iron levels and short interval between IPTp 
doses are associated with increased risk of malaria and P.falciparum density in a longitudinal 
prospective cohort during infancy in the context of ITN use, considering environmental, 
clinical and obstetric risk factors.
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Article under review in “Pediatrics”
The effect of iron levels and IPTp on malaria risk in infants: a 
prospective cohort study in Benin
Violeta Moya-Alvarez, Gilles Cottrell, Smaila Ouédraogo, Manfred Accrombessi, Achille 
Massougbodgi, Michel Cot
Abstract:
Background: In areas with high malaria and anaemia rates, intermittent preventive treatment 
in pregnancy (IPTp) and iron supplements are recommended by WHO. However, studies have 
set into question the inviolability of the benefits of iron supplementation in the context of 
malaria. In addition, pregnancy-associated malaria (PAM) has been found to be associated to 
malaria in infants, but epidemiological studies do seldom analyse the influence of IPTp. We 
investigated the effect of IPTp and iron levels during the first year of life on malarial risk.
Methods: We followed 400 women and their offspring between January 2010 and May 2012 
in Allada (Benin). Environmental, obstetric and numerous clinical maternal and infant risk 
factors were considered.
Results: In multilevel models, offspring of mothers with longer IPTp protection were 
significantly less likely to both have a positive smear (adjusted odds ratio (aOR)=0.87,p-
value=0.04) and high P.falciparum parasitaemia (beta-estimate=-0.06,p-value<0.001). Iron 
levels were significantly associated with the risk of a positive blood smear (aOR=2.77,p-
value<0.001) and P.falciparum parasitaemia (beta-estimate=0.38,p-value<0.001). Infants with 
iron levels in the lowest quartile were less likely to have a positive blood smear (p-
value<0.001), and the risk increased with higher iron levels. 
Conclusion: Our results appeal for additional evaluation of different doses of iron 
supplements on the infant health outcomes. Thus, the comparison of cohorts in which iron is 
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given with preventive purpose versus iron given for treatment is also required. Finally, the 
observance of IPTp should be encouraged as it has a protective effect not only in mothers but 
also in their offspring. 
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Body of the article:
Introduction
Infant health morbidity in Sub-Saharan Africa is mainly driven by infectious diseases and 
nutritional deficiencies [1]. Indeed, malaria and anaemia (mainly due to iron deficiency) are 
two leading pathologies contributing to enhance the disease burden among African infants 
[2]. In 2013, malaria was responsible for an estimated 198 million cases and an estimated 584 
000 deaths [3]. In addition, malaria causes anaemia, which is the second leading cause of 
disability [4] and entails severe consequences for the development of the children [5]. 
Moreover, both diseases harm mainly children under 5 years of age. For these reasons, public 
health strategies have been developed to tackle both diseases simultaneously. 
To tackle anaemia WHO recommends the administration of 12.5 mg iron and 50µg folic acid 
daily between 6 and 12 months [6]. However, in Benin this policy has not been implemented 
so far, and, in general, Beninese paediatricians give a preventive treatment consisting in 10 
mg/kg and day during 2 months every 6 months starting at 6 months of age until 5 years of 
age. With regard to malaria, the present WHO recommendations for the control of malaria are 
the use of insecticide treated nets (ITNs) and/or indoor residual spraying (IRS) for vector 
control, and prompt access to diagnostic testing of suspected malaria and treatment of 
confirmed cases. 
Albeit the large implementation of these interventions, epidemiological studies have set into 
question the inviolability of the benefits of iron supplementation in the context of malaria-
endemic countries [7], and iron deficiency has been associated to reduced malaria odds 
among pregnant women and infants [8,9]. However, in a recent meta-analysis of the 
association between malaria and iron status or supplementation in children, data were reported 
to be insufficient for assessing the potential of an increased risk of P.falciparum infection [9]. 
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Indeed, evidence on the iron-malaria association lacks from prospective cohorts during 
infancy. 
In parallel, PAM is significantly associated to malaria in infants [10], but epidemiological 
studies do seldom analyse its influence. Therefore, we investigated the effect of iron levels 
during the first year of life on malarial risk in infants taking into account complementary 
information on PAM, IPTp, environmental, socio-economic, and clinical indicators and co-
morbidities to better understand malaria risk factors in the context of the present malaria 
control strategies.
Materials and methods
A prospective cohort of 400 infants was followed from birth to 12 months of age in the 
context of the APEC study (Anaemia in Pregnancy: Etiology and Consequences). APEC 
study is an ancillary survey nested within the MiPPAD trial in Benin (Malaria in Pregnancy 
Preventive Alternative Drugs “http://clinicaltrials.gov/ct2/show/NCT00811421”). This study 
was conducted in three clinics in the district of Allada, between January 2010 and May 2012. 
Allada is a semi-rural area of 91,778 inhabitants located 50 km North of Cotonou (Benin). 
Malaria has a perennial transmission pattern with two transmission peaks corresponding to the 
rainy seasons in April-July and October-November. Plasmodium falciparum is the species 
responsible for the majority of infections. 
Complete details of MiPPAD are presented elsewhere [11], but, briefly, MiPPAD was a 
randomized trial comparing the efficacy and safety of IPTp with SP (1,500/75 mg per dose) 
and mefloquine (15 mg/kg per dose). At delivery placenta was examined in order to analyse 
P. falciparum parasite infestation. Clinical data of the infants were collected during 
systematic visits at 6, 9, and 12 months. In case of sickness infants were accurately examined 
in unscheduled visits and, if necessary, treated according to Beninese guidelines. In the 
unscheduled visits clinical and biological exams were realized following the same protocol as 
systematic visits. All drugs prescribed to the infants during the follow-up were free of charge. 
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For the purpose of the APEC sub-study, anthropometric measures, and an extensive clinical 
examination were realized during the visits. In addition, 8 mL of venous blood were collected 
at each visit. Haemoglobin, serum ferritin, CRP, vitamin B12, and folate levels were assessed. 
A container was also given to the women to collect stools that were collected the following 
day by the study nurses within the first 6 hours after emission. Microbiological exams were 
realized as follows: Lambaréné technique was used to assess malaria infection [12]. 
Helminthic infestations were assessed using the Kato-Katz concentration method 
(VestergaardFrandsen kit®). In case of inflammation (CRP>5mg/l) serum ferritin was 
adjusted following the corrections recommended by Thurnham et al. in their meta-analysis 
[13] to avoid the extrinsic effect of inflammation on serum ferritin levels.
We used rain quantity as a surrogate for the risk of exposure to anopheline bites. Because of 
the anopheline timeliness, rainfall quantity was calculated as the mean rain volume of the 7 
days prior to the two weeks before the consultation. It was independently assessed for each 
visit and each health centre of the study.
Socio-economic status was assessed using a socio-economic index. The socio-economic index 
was created in a two-step process. First a multiple correspondence analysis of socio-economic 
items was performed. Then the first principal axis was used as an overall socio-economic 
index in the further regression analysis. 
Data were double entered and analysed with ACCESS 2003, and STATA 12.0 Software 
(Stata Corp, College Station, TX, USA). Then exploratory and univariate analyses were 
realized to assess the association of all variables with both infant positive smear and 
peripheral P.falciparum density at each visit (systematic or unscheduled visit). Chi-square and 
Kruskal-Wallis tests were used in the univariate analyses. For time-dependent variables, 
univariate analyses were realized using a random intercept model at the infant level. 
Thereafter, all variables with P values<0.2 were included in either a logistic or a linear 
multivariate multilevel model with a random intercept and slope at the infant level including 
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all visits for each infant, to explore the determinant of the probability of having a positive 
smear or peripheral P.falciparum parasitaemia, respectively. More precisely, a random slope 
was applied to the infant age, as the effect of the variables might differ between the infants. 
The statistical significance in the final multivariate models was set to P<0.05 (two-sided 
tests). To evaluate the possible diverse effect of different iron levels on malaria risk, we run 
the same multilevel model considering the different quartiles of corrected ferritin. 
This study was approved by the Ethics Committee of the Faculty of Medicine of Cotonou. It 
was explained in the local language to the mothers and their voluntary consent was obtained 
before enrolment. 
Results
Between January 2010 and 2012, 400 mother-infant pairs were included in the cohort. Three-
hundred and twenty-seven infants continued to be followed-up until the first systematic visit 
at 6 months, 325 until the second visit at 9 months, and 324 completed the 12 month follow-
up. At birth 10.9% of the infants were born from a malaria infected placenta, but no cord 
blood infection by Plasmodium was detected at the microscopy exam. The main 
characteristics of the infants at birth are presented in Table 1. 
During the first year of life 40% of the infants had at least one malarial episode, with a range 
of 0-4 positive smears taking into account both systematic and unscheduled visits. More 
precisely, 60.25% of infants had no positive blood smear during the entire follow-up, 22% of 
infants had 1, 12.50% had 2, 4.5% had 3, and 0.75% had 4 positive blood smears during 
follow-up. The clinical and biological characteristics of the infants at the systematic visits are 
summarized in Table 2. The proportion of infants with a positive smear at the systematic 
visits remained constant along the follow-up (around 12% of the infants were infected at each 
visit). However, P.falciparum parasitaemia did change significantly during the first year of 
life. Among infants with a positive smear, the median P.falciparum density was 7597.5 
parasites/mm3 (95% confidence interval (CI)= 17584.92; 97814.82) at 6 months, 14839 
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parasites/mm3 (95% CI= 45882.41; 263310.7) at 9 months, and 7919.5 parasites/mm3 (95% 
CI= 26019.96; 136360.9) at 12 months.
In parallel, the mean haemoglobin values increased slightly, though not significantly, through 
the follow-up (102.1 g/l, 102.9 g/l, and 103.6 g/l at the 6, 9, and 12 month systematic visits, 
respectively). 
Iron indicators decreased through the follow-up. The mean ferritin levels decreased after the 6 
month visit from 605 µg/l (95% CI= 508; 702) to 455 µg/l (95% CI= 384; 526) at 9 months, 
and then decreased again until 436 µg/l (95% CI= 350; 522) at 12 months. Iron deficiency 
increased in parallel from 16% at 6 months, to 29% at 9 months, and up to 34% at 12 months. 
During the first year of life malaria rates and P. falciparum parasitaemia were determined by 
clinical, environmental and socio-economic factors, but pregnancy related aspects did also 
influence significantly the malarial outcomes of the infant during the entire follow-up. The 
risk factors for malaria and P.falciparum parasite density are presented in Table 3 and Table 
4, respectively.  
There were no statistical differences in the number of positive smears or P. falciparum 
density during the first year of life depending neither on the placental malarial status nor on 
the intermittent preventive treatment in pregnancy (IPTp) regime of the mothers (either 
sulphadoxine-pyrimethamine (SP) IPTp or mefloquine (MQ)). Nevertheless, the time interval 
between IPTp doses of the mothers (number of days between IPTp doses), i.e. the period 
during which the mothers were protected against malaria, was significantly associated with 
the risk of malarial infection of the infant during the first year of life. Infants born to mothers 
who had longer IPTp protection were significantly less likely to both have a positive smear 
(adjusted odds ratio (aOR)=0.87, 95% CI= 0.76; 0.99, p-value=0.04) and high P. falciparum 
parasite density (beta-estimate=-0.06, 95% CI= -0.10; -0.01, p-value<0.001) during the entire 
follow-up. Higher maternal folate levels and helminth infection at delivery were also 
significantly linked to increased parasite density during the first year of life (beta-
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estimate=0.34, 95% CI=0.01; 0.66, p-value=0.04, and beta-estimate=0.88, 95% CI= 0.20; 
1.57, p-value=0.03, respectively).
The clinical and nutritional status of the infant was also correlated with malarial risk. Iron 
levels (log of ferritin corrected on inflammation) were significantly associated with the risk of 
a positive blood smear (aOR=2.77, 95% CI= 1.95; 3.96, p-value<0.001) and P. falciparum 
parasite density (beta-estimate=0.38, 95% CI= 0.29; 0.47, p-value<0.001) during the first year 
of life. Infants with iron deficiency were significantly less likely to have a positive blood 
smear and a high P. falciparum density (p-value=0.01 in both cases). In parallel, ongoing 
inflammatory status of the infant (CRP>5mg/l) was significantly associated to an increased 
risk of positive blood smear (aOR=4.37, 95% CI= 2.20; 8.65, p-value<0.001) and to a higher 
P. falciparum parasite density (beta-estimate=0.77, 95% CI= 0.53; 1.01, p-value<0.001). The 
presence of other parasites such as intestinal helminths was not significantly associated with 
increased malaria risk. There were no statistical differences in malaria risk between the 
different age periods of the follow-up. 
The rain volume (representing the anopheline risk) was marginally associated to increased 
malaria risk with regard to both increased risk of a positive smear (aOR=1.06, p-value=0.06), 
and to increased P.falciparum parasitaemia (beta-estimate=0.03, p-value=0.06). 
Finally, we investigated further the differences in malarial risk factors considering the 
different quartiles of iron levels in infants to evaluate the possible different effects of iron on 
malaria risk depending on the different levels of iron. Indeed, infants with iron levels in the 
three upper quartiles had significantly higher risk of having malaria during the first year of 
life (table 5). Infants with iron levels in the upper quartiles had significantly higher P. 
falciparum parasite density. 
Discussion
In this study, we evidenced the influence of two important factors related with malaria 
infection during the first year of life, time duration between two IPTp doses and iron levels. 
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More precisely, we found that the time period between IPTp doses (number of days) is 
inversely correlated to malaria risk. When the period of time between IPTp doses is longer, 
infants have significantly reduced risk of malaria during the first year of life. High iron levels 
also have a significant effect on malaria severity in infants during the first year of life 
considering both the possibility of having a positive blood smear and P.falciparum parasite 
density.
PAM has been frequently correlated to an impaired health status of the offspring [10]. In a 
recent follow-up of a mother-child cohort in Benin, Borgella et al. showed that infants born to 
a mother with PAM during the third trimester of pregnancy had a significantly increased risk 
of infection (OR=4.2 95% CI (1.6; 10.5), p-value=0.003) or of malaria episode (OR=4.6 95% 
CI (1.7; 12.5), p-value=0.003), assuming the period covered by IPTp (2nd trimester of 
pregnancy) was at low risk for malaria infection [14]. In addition, Huynh found IPTp calendar 
was associated with consequences of malaria such as LBW and anaemia [15]. Considering 
that PAM has a significant effect on malaria in infants and that IPTp, by preventing new 
infections, has an impact on secondary malaria outcomes, such as LBW and anaemia, we 
think that albeit their novelty our results are coherent with the existing literature. A single 
discordant study in Tanzania found that IPTp could be associated with an overall increase of 
severe malaria and earlier first malaria episodes in the offspring [16]. Such paradoxical results 
could be explained by the high level of resistance to SP in this area of Tanzania [17,18]. 
Indeed, Dechavanne found increased susceptibility of infants to P. falciparum parasites with 
antigens to which they were previously exposed in utero [19], suggesting the existence of an 
in utero ongoing immune tolerance process. However, no evidence exists at present on its 
concrete physiopathological pathways. 
At present an adjustment of IPTp calendar to enhance protection is already ongoing in Benin. 
In effect, Benin is setting a 3rd dose in the IPTp regime to implement the WHO new 
recommendations. 
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Another important result of our study is the significant association of iron levels with malaria 
risk. We have assessed the influence of iron levels on malarial risk with regard to the 
possibility of having a positive blood smear and P.falciparum parasite density throughout the 
first year of life in a prospective longitudinal cohort, considering environmental, socio-
economic, and PAM factors. Iron levels, measured by ferritin corrected for inflammation, a 
consistent indicator of iron [20,21], were significantly associated with malarial episodes and 
P.falciparum parasitaemia. Furthermore, this association was significant even after 
adjustment on inflammatory status. Iron deficiency was associated to a significant protection 
through the entire follow-up. More precisely, infants with iron levels in the first quartile 
seemed to be significantly protected against malaria. Indeed, iron deficiency has frequently 
been linked to a certain protection against malaria [9]. Nevertheless, results on the effect of 
iron levels on malaria differ in the context of clinical trials with iron supplements. In a 
specific Cochrane review [9] no significant difference in clinical malaria episodes was 
detected between children supplemented with iron alone and those receiving a placebo (risk 
ratio (RR)=0.99, 95% CI (0.90; 1.09). However, the effect of iron deficiency was not 
assessed, and solid preventive measures against malaria were implemented in the clinical 
trials. Indeed, an increased risk of malaria with high iron levels was observed in trials that did 
not provide malaria surveillance and treatment, and the risk of malaria and parasitaemia was 
higher with high iron levels (RR=1.13, 95% CI (1.01; 1.26) [9]. Furthermore, in numerous 
studies included in the meta-analysis, iron was seldom determined longitudinally. 
Malaria physiopathology could explain the increased malarial risk associated with elevated 
iron levels. In effect, iron inhibits the synthesis of nitric oxide by inhibiting the expression of 
inducible nitric oxide synthase (iNOS) at the host level, and thereby interferes with 
macrophage-mediated cytotoxicity against Plasmodium [22]. Furthermore, non-transferrine 
bound iron (NTBI) is associated with the severity of malaria [23–25], and Plasmodium has 
the capacity of acquiring iron in a transferrin-independent pathway [26].
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Albeit the hereby reported results, iron supplements have undeniable benefits for infants. A 
2013 meta-analysis showed supplementation was associated to a reduced risk of anaemia, of 
iron deficiency, and of iron deficiency anaemia [27]. As pondering the advantages and risk of 
iron supplements is daunting because they are not epidemiologically quantifiable, the 
implementation of malaria protective strategies should be seriously encouraged. 
Complementary findings of our study are the significant impact of maternal folate levels and 
helminths at delivery on P. falciparum parasite density of the infant. Indeed, folate is an 
important cofactor used by P.falciparum in DNA synthesis and methylation, and mRNA 
translation. Therefore, high folate levels could enhance the immune tolerance process 
undergoing PAM. With regard to the significant association between maternal helminths and 
increased P. falciparum parasite density, this was already described In Uganda, where 
Ndibazza et al. suggested this could be due to hyporesponsiveness of T-cells of the of the 
infants previously exposed in utero to parasites [28]. Therefore, further epidemiological 
evidence could be useful to analyse the extent of the immune tolerance process undergoing in 
utero. 
Conclusion 
The impact of PAM on malaria in infants does not only involve placental malaria, prematurity 
or LBW. PAM entails increased risk of malaria in infants and PAM preventive interventions 
have a significant influence on malaria in infants as well. In our study, long IPTp interval is 
associated to reduced malaria risk in infants during the first year of life. Public policies should 
be encouraged to increase the observance of IPTp as it has a protective effect not only in 
mothers but also in their offspring, as it has been recently recommended by the WHO [29].
Malaria risk during the first year of life is also associated with high ferritin levels in a 
prospective longitudinal cohort considering complementary risk factors. Our data also suggest 
that malaria risk increases with higher ferritin levels. Indeed, the interaction between iron and 
malaria is complex because of the iron requirements during infancy and the fact that iron 
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contributes to the parasite growth. These results appeal for additional epidemiological studies 
to evaluate the effect of different doses of iron supplements on the infant infectious and 
haematological outcomes. Complementary interventional data are needed to determine the 
benefits and risks of differently dosed iron supplements, in order to ascertain their impact on 
infant health in malaria-endemic regions. Finally, the epidemiological comparison of cohorts 
in which iron is given as preventive intervention and cohorts in which iron is given solely on 
the purpose of treatment for anaemia or ID should also be analysed.
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Tables:
Table 1. Clinical and biologic indicators of the infants at birth
 Mean or Proportion(95% CI)
Sex of the infants Male: 183 (46.9%)Female: 207 (53.1%)
Gestational age at birth (weeks)
(Ballard score)
38.1
(37.8; 38.4)
Weight (g) 3033.5(2992; 3075)
Low birthweight (%)
(birthweight<2500g)
9
(6.2; 11.9)
P. falciparum infected placenta (%)  10.9(7.8; 13.9)
Haemoglobine (g/l) 139(136.9; 141)
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Serum ferritin (µg/l) 182.6(165.5; 199.7)
Folate (ng/l) 16.5(12.6; 20.4)
95% CI= 95% Confindence interval  
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Table 2. Clinical and biologic indicators of the infants during the follow up period (6, 9, 12 months)  
Characteristics 6 months (n=327)  9 months (n=325)  12 months (n=324)  
 
Mean or 
Proportion
(95% CI)
Mean or 
Proportion
(95% CI)
Mean or Proportion
(95% CI)
P. falciparum infection (%)  12.06 (8.45; 15.68)
12.00
(8.28; 15.52)
12.34
(8.70; 15.99)
Parasite density (nb/mm3)   6960.862(1869.05; 12052.19)
18392.52
(4791.55; 31993.49)
9794.40
(2764.46; 16824.35)
Haemoglobine (g/l) 102.22(100.55; 103.88)
102.91
(101.32; 104.50)
103.80
(102.14; 105.47)
Anaemia (%)
(Hb<110g/l) 
66.99
(61.74; 72.23)
69.81
(64.65; 74.96)
64.86
(59.54; 70.17)
Mild anaemia (%)
(Hb 100-109 g/l)
31.41
(26.23; 36.59)
34.09
(28.77; 39.41)
36.42
(31.06; 41.78)
Moderate anaemia (%)
(Hb 80-109 g/l)
28.53
(23.48; 33.56)
30.52
(25.34; 35.69)
21.73
(17.13; 26.32)
Severe anaemia (%)
(Hb<80 g/l)
7.05
(4.19; 9.90)
5.19
(2.70; 7.69)
6.70
(3.92; 9.50)
Corrected serum ferritin 
(µg/l)
604.58
(507.64; 701.52)
455.37
(384.27; 526.48)
436.16
(350.42; 521.90)
Iron deficiency (%)
(corrected SF<15µg/l)
16.09
(8.21; 23.97)
29.63
(20.88; 38.38)
34.28
(25.06; 43.52)
    
95% CI= 95% Confindence interval; Hb: Haemoglobin; SF: Serum ferritin
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Table 3.  Multilevel model on factors associated with having positive blood smears during the first year of life
Factor  aOR (95% CI) p-value
Infant factors
Ferritin corrected on inflammation (logarithm of µg/l) 2.77 (1.95; 3.96) <0.01
Inflammatory process (CRP>5mg/l) 4.37 (2.20; 8.65) <0.01
Kato-katz test positivity 0.89 (0.33; 2.40) 0.82
Age 1-4 months (reference)
Age 4-8 months 2.95 (0.41; 21.23) 0.28
Age 8-12 months 2.07 (0.25; 16.99) 0.50
Pregnancy associated factors
IPTp extent (days between IPTp doses) 0.87 (0.76; 0.99) 0.04
Demographic and environmental factors
Low socio-economic index 1.22 (0.89; 1.66) 0.20
Rain volume (mm) 1.06 (0.99; 1.11) 0.06
Random intercept at the infant level. Random slope for the age of the infants. Analysis on 746 blood smears from 329 
infants. 
174
600
601
602
3012
3013
603
V. Results     
Table 4.  Multilevel model on factors associated with P.falciparum parasitemia (in logarithm) during the first year of life 
Factor
 
Beta estimate 
(95% CI) p-value
Infant factors
Ferritin corrected on inflammation (logarithm of µg/l)  0.38 (0.29; 0.47) <0.01
Inflammatory process  0.77 (0.53; 1.01) <0.01
Kato-katz test positivity -0.20 (-0.58; 0.18) 0.30
Age of the infant (1-4 months (reference))
Age of the infant 4-8 months  0.20 (-0.14; 0.54) 0.24
Age of the infant 8-12 months -0.06 (-0.39; 0.26) 0.71
Pregnancy associated factors
IPTp extent (days between IPTp doses) -0.06 (-0.10; -0.01) <0.01
Kato-katz test positivity of the mother at delivery  0.88 (0.20; 1.57) 0.03
Folate of the mother at delivery (Logarithm of ng/ml)  0.34 (0.01; 0.66) 0.04
Demographic and environmental factors
Low socio-economic index  0.12 (0.01; 0.23) 0.03
Rain volume (mm)  0.03 (-0.00; 0.06) 0.06
Random intercept at the infant level. Random slope for age of the infant. Analysis on 542 blood smears of 236 infants. 
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Table 5.  Multilevel model on factors associated with malaria risk during the first year of life depending on the different iron levels  
  
Multilevel model on the positive 
blood smear   
Multilevel model on P.falciparum 
parasitaemia  
Factor aOR  (95% CI) p-value   
Beta estimate  
(95% CI) p-value 
 Infant factors 
      Ferritin corrected on inflammation (logarithm of µg/L) 1st quartile reference 
  
reference  
 Ferritin corrected on inflammation 2nd quartile 3.28  (1.20; 8.96) 0.02 
 
 0.06  
(-0.26; 0.38) 0.73 
 Ferritin corrected on inflammation 3rd quartile 4.53  (1.75; 11.77) <0.01 
 
 0.35  
(0.03; 0.66) 0.03 
 Ferritin corrected on inflammation 4th quartile 6.16  (2.40; 15.81) <0.01 
 
 0.55  
(0.24; 0.87) <0.01 
 Inflammatory process 4.37  (2.44; 7.80) <0.01 
 
 0.76  
(0.51; 1.01) <0.01 
 Kato-katz test positivity 0.92  (0.36; 2.36) 0.86 
 
-0.16  
(-0.55; 0.24) 0.44 
 Age of the infant (1-4 months (reference)) 
      Age of the infant 4-8 months 3.39  (0.58; 19:71) 0.18  
 0.26  
(-0.08; 0.61) 0.14 
 Age of the infant 8-12 months 2.95  (0.30; 29.24) 0.36  
 0.03  
(-0.31; 0.36) 0.88 
                                           Pregnancy associated factors       IPTp extent (days between IPTp doses) 0.88  (0.78; 0.99) 0.04 
 
-0.06  
(-0.10; -0.01) 0.01 
 Kato-katz test positivity of the mother at delivery 
   
 0.96  
(0.24; 1.68) <0.01 
 Folate of the mother at delivery (Logarithm of ng/mL)  
   
 0.32  
(-0.02; 0.65) 0.06 
                                  Demographic and environmental factors 
      Low socio-economic index 1.16  (0.87; 1.55) 0.32 
 
 0.12  
(0.004; 0.23)                 0.04 
 Rain volume (mm) 
 
1.06  
(0.99; 1.12) 0.06 
 
 0.03  
(-0.004; 0.07)                 0.08 
 
R
andom
 intercept at the infant level. R
andom
 slope for age of the infant. A
nalysis on 542 blood sm
ears of 236 infants. 
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V.II.3 Other factors associated with malaria risk during infancy: 
the case of lead
Summary of the article: As said in the “State of art” section, simultaneously to our study in 
the same cohort another epidemiological project was evaluating the effect of lead on the 
neurocognitive development in children. Our colleagues found out lead levels were 
particularly high in the infants of our cohort. Nriagu had found in Nigeria that malaria had a 
significant effect on lead levels in univariate analysis. In addition, elevated blood lead levels 
(BLL) carry a significant burden of disease in Western Africa and malaria is the first cause of 
infant mortality in Benin. Therefore, we aimed at assessing the possible association of lead 
levels with malaria risk considering other major malarial risk factors.
Elevated lead levels have severe harmful effects on infant health. They are associated with 
impaired neurocognitive development, anemia (due to either disruption of heme synthesis or 
hemolysis), and renal and gastro-intestinal effects. Although high blood lead levels (BLL) 
(BLL >100 µg/dl) can entail acute neurologic symptoms, such as ataxia, hyperirritability, 
convulsions, coma, and death, BLL as low as 10 µg/dl have been also correlated with poor 
neurocognitive outcomes and behavioral disorders. Indeed, the Center for Disease Control 
(CDC) reduced the reference level of blood lead from 10 µg/dl to 5 µg/dl  in 2012. This is of 
special concern in young children as neuro-cognitive impairment has been found to be 
associated with the degree of exposure to lead between the ages of 12 and 36 months. Albeit 
the severe impact of elevated lead levels on infant health, epidemiological studies of lead 
levels in Sub-Saharan Africa are limited. Data from the few existing studies, published in a 
systematic review on BLL among Sub-Saharan children, suggest an alarming burden of 
disease. This review reported a BLL weighted mean of 13.1 µg/dl which increases up to 16.2 
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µg/dl considering solely studies with robust quality BLL analyses. In addition, the prevalence 
of BLL >10 µg/dl ranged from 7.0% to 70.9% in six of the studies reviewed. Recent mass 
level intoxications reported in Senegal and Nigeria further raise the public health concern 
about lead levels in West Africa. Notwithstanding these concerns, infectious diseases, mainly 
malaria, lead the disease burden in West Africa. In Benin, malaria is the main cause of 
mortality among children less than 5 years and there were over 1.5 million cases in 2012. 
Both malaria and lead poisoning can have severe hematologic and neurologic symptoms on 
children and development disruptions. Because of the recent evidence on the role of the 
complement system in the regulation of neurodevelopment, it has been proposed that 
excessive complement activation induced by placental malaria may disrupt normal 
neurodevelopment resulting in neurocognitive impairment of infants exposed to Plasmodia in  
utero. 
Epidemiologically, malaria and lead poisoning may not only overlap geographically, but they 
have major impact on the health of children, especially those under 5 years. Consequently, 
their possible association may have an effect on one of the most vulnerable age groups in the 
population, and it could have severe long-term implications for the development of the 
children. Furthermore, Nriagu found a significant effect of malaria on the children lead levels 
in different areas of Nigeria.  Concern has been repeatedly raised up on the importance of 
alarmingly high anemia rates in West Africa, and both malaria and EBLL are associated with 
increased anemia rates. However, no evidence exists at present on the possible joint effect of 
lead and P.falciparum. To our knowledge, no published study exists on lead levels in Benin, 
and in particular, on the effects of lead levels on malaria risk in infants. 
What’s known on this subject: Malaria and elevated lead levels overlap geographically in 
West Africa. Both entail anemia and impaired neuro-cognitive development and their effect is 
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particularly severe in infants. Albeit the effect of malaria on lead levels found by Nriagu in 
Nigeria, no evidence exists at present on the effect of lead levels on malaria risk. 
What this study adds:  We show that the rate of elevated blood lead levels is very high in 
Benin. In addition, we show that elevated lead levels give a certain protection to infants with 
regard to the malaria risk, possibly due to a toxic effect of lead on Plasmodium. Furthermore, 
we show that even in the context of high lead levels, iron levels are still significantly 
associated to increased malaria risk. 
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Article under review in Plos One:
Elevated blood lead levels are associated with reduced risk of malaria in Beninese infants
Violeta Moya-Alvarez, Michael Osei Mireku, Pierre Ayotte, Michel Cot, and Florence Bodeau-
Livinec.
Abstract 
Introduction: Elevated blood lead levels (BLL) and malaria carry an important burden of 
disease in West Africa. Both diseases might cause anemia and they might entail long-term 
consequences for the development and the health status of the child. Albeit the significant 
impact of malaria on lead levels described in Nigeria, no evaluation of the effect of elevated 
BLL on malaria risk has been investigated so far.
Materials and methods: Between 2010 and 2012, 203 Beninese infants were followed 
during the first year of life through three systematic visits at 6, 9, and 12 months, and 
emergency unscheduled visits to evaluate their health status and gather clinical, 
microbiological and hematological data. Blood lead levels were assessed at 12 months. 
Results: At 12 months, the mean BLL of infants was 7.41 µg/dl (CI: 65.2; 83), and 128 
infants (63%) had elevated blood lead levels, defined by the CDC as BLL>5 µg/dl. Lead 
poisoning, defined as BLL>10 µg/dl, was found in 39 infants (19%). Twenty-five infants 
(12.5%) had a positive blood smear at 12 months and 144 infants were anemic (71%, Hb<110 
g/l). Elevated blood lead levels were significantly associated with reduced risk of a positive 
blood smear (aOR=0.98, p-value=0.02) and P. falciparum parasite density (beta-estimate=-
0.003, Pvalue=0.048) in logistic and linear regression multivariate models, respectively 
adjusted on clinical and environmental indicators.
Conclusion: Our study shows for the first time that BLL are negatively associated with 
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malarial risk considering other risk factors. Malaria is the main cause of mortality for infants 
under 5 years worldwide, and lead poisoning is the 6th most important contributor to the 
global burden of diseases measured in disability adjusted life years (DALYs) according to the 
Institute of Health Metrics. In conclusion, environmental factors, such as lead levels, need to 
be considered in the debate about iron supplements in malaria endemic countries.  
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Body of the article
Introduction
Elevated lead levels have severe harmful effects on infant health. Symptoms related to 
toxicity occur from mid to high levels of exposure and they depend on the amount of lead in 
the blood and tissues. High lead levels are associated with impaired neurocognitive 
development, anemia (due to either disruption of heme synthesis or hemolysis [1]), and renal 
and gastro-intestinal effects [2]. Although high blood lead levels (BLL) (BLL >100 µg/dl) can 
entail acute neurologic symptoms, such as ataxia, hyperirritability, convulsions, coma, and 
death, BLL as low as 10 µg/dl have been also correlated with poor neurocognitive outcomes 
and behavioral disorders [3,4]. This is of special concern in young children as neuro-cognitive 
impairment has been found to be associated with the degree of exposure to lead between the 
ages of 12 and 36 months [5]. Indeed, the Center for Disease Control (CDC) reduced the 
reference level of blood lead from 10 µg/dl to 5 µg/dl [6] in 2012. 
Albeit the severe impact of elevated lead levels on infant health, epidemiological studies of 
lead levels in Sub-Saharan Africa are limited. Data from the few existing studies, published in 
a systematic review on BLL among Sub-Saharan children, suggest an alarming burden of 
elevated BLL. This review reported a BLL weighted mean of 13.1 µg/dl, which increased up 
to 16.2 µg/dl considering solely studies with robust quality BLL analyses [7]. In addition, the 
prevalence of BLL >10 µg/dl exceeded 44% in all cases reviewed, with a maximum of 70.9% 
in Nigeria. Only one study in Kenya reported a relatively low prevalence (7%). Recent mass 
level intoxications reported in Senegal and Nigeria [8] further raise the public health concern 
about lead exposure in West Africa. 
In addition, malaria and lead poisoning overlap geographically. Indeed, infectious diseases, 
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mainly malaria, dominate the disease burden in West Africa [9]. In Benin, malaria is the main 
cause of mortality among children less than 5 years and there were over 1.5 million cases in 
2012 [10]. As already explained, both malaria and lead poisoning can have severe 
hematologic and neurologic symptoms on children and their development.  Malaria and lead 
poisoning may not only overlap, but they have major impact on the health of children, 
especially those under 5 years. Consequently, their possible association may have an effect on 
one of the most vulnerable age groups in the population, and it could have severe long-term 
implications for the development of the children. Furthermore, Nriagu found a significant 
effect in univariate analysis of malaria on the children lead levels in different areas of Nigeria 
[11].  However, no evidence exists at present on the possible joint effect of lead and 
P.falciparum. To our knowledge, no published study exists on lead levels in Benin, and in 
particular, on the effects of lead levels on malaria risk in infants. Therefore we aim at 
analyzing the effect of lead levels on malaria risk with regard to both the possibility of having 
a positive smear and their effect on P.falciparum parasite density taking into account 
hematological and parasitological factors.
Materials and methods
Data used in this study were obtained from two-hundred and three infants who were followed 
from birth until 12 months of age in two embedded studies: the APEC study (Anemia in 
Pregnancy: Etiology and Consequences) and the TOVI study.  More precisely, a prospective 
cohort of 400 infants was followed from birth to 12 months of age in the context of the APEC 
study (Anaemia in Pregnancy: Etiology and Consequences). APEC study is an ancillary 
survey nested within the MiPPAD study in Benin (Malaria in Pregnancy Preventive 
Alternative Drugs “http://clinicaltrials.gov/ct2/show/NCT00811421”). This study was 
conducted in three clinics in the district of Allada (Allada, Attogon, Sékou), between January 
2010 and May 2012. Allada is a semi-rural area of 91,778 inhabitants located 50 km North of 
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Cotonou (Benin). Malaria has a perennial transmission pattern with two transmission peaks 
corresponding to the rainy seasons in April-July and October-November. Plasmodium 
falciparum is the species responsible for the majority of infections.  Complete details of 
MiPPAD are presented elsewhere [12], but, briefly, MiPPAD was a randomized trial 
comparing the efficacy and safety of intermittent preventive treatment in pregnancy (IPTp) 
with sulphadoxine pyrimethamine (SP) (1,500/75 mg per dose) and mefloquine (15 mg/kg per 
dose). At delivery placenta was examined in order to analyse P. falciparum parasite 
infestation. All live born children of recruited pregnant women who survived to 12 months 
were invited for neurocognitive assessment in the TOVI study, which evaluated the children 
for cognitive and motor functions using the Mullen Scales of Early Learning as well as their 
lead levels at 12 months [13]. The 203 infants of the sample correspond to the infants for 
whom data at 12 months include a complete follow-up of lead and malaria indicators. 
Clinical data of the infants were collected at systematic visits at 6, 9, and 12 months. After 
delivery, in any case of sickness, infants were accurately examined and when necessary, 
treated in unscheduled visits. All drugs prescribed to the infants during the follow-up were 
free of charge. During the visits, anthropometric measures and clinical examination were 
realized. Eight milliliters of venous blood were collected at each visit. Hemoglobin, serum 
ferritin, CRP, vitamin B12, and folate levels were thereby assessed. At 12 months, lead levels 
were also determined. A container was also given to the women to collect stools to examine 
the presence of intestinal helminths in the infants. Microbiological exams were realized as 
follows: Lambaréné technique was used to assess malaria infection on thick blood smears 
[14]. To assess parasite density (in parasites/µL), a multiplication factor was applied to the 
average parasitaemia/field. Helminthic infestations were assessed using the Kato-Katz 
concentration method (VestergaardFrandsen kit®). Iron deficiency is defined according to 
WHO standards by serum ferritin levels<15μg/l [15].
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With regard to BLL, eight milliliters (ml) of venous blood were obtained from each 
participant, of which 4 ml were collected into a tube containing dipotassium EDTA and 4 ml 
into an iron-free dry tube. Blood samples were analysed at the Centre de Toxicologie, Institut 
National de Santé Publique du Québec (Québec, Canada), by inductively coupled plasma 
mass spectrometry (ICP-MS; Perkin Elmer Sciex Elan DRC II ICP-MS instrument) prior to 
20 fold dilution in amonia 0.5% v/v and 0.1 % v/v surfactant Triton-X. The limit of detection 
for blood sample analysis was 0.2 µg/l.
 Because of the anopheline breeding cycle, the mean rainfall of the 7 days prior to the two 
weeks before the consultation was calculated. It was independently assessed for each health 
centre of the district of Allada.
Socio-economic status was assessed using a socio-economic index created in a two-step 
process. First all socio-economic items (home possession of latrines, electricity, a refrigerator, 
a television, a vehicle with at least two wheels, being married, and working outside the home) 
were plotted into a multiple correspondence analysis. Then, two predictors were created to 
synthesize the information, and as the first captured the large majority of the information, it 
was withheld as the socio-economic index.
Statistical analysis
Data were double entered and analysed with ACCESS2003 and STATA12.0 softwares for 
Windows (Stata Corp, College Station, TX, USA). Univariate analysis was realized to assess 
the association of all variables with either the infant positive smear or peripheral P.falciparum 
density at the moment of lead assessment (at 12 months of age). Thereafter, all variables with 
P values<0.2 were included in a multivariate model regression. Logistic regression was used 
to evaluate the determinants associated with a positive blood smear. Linear regression was 
used for the multivariate analysis of P.falciparum parasite density. Socio-economic status was 
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forced into the model because of its known association with lead levels according to the 
literature [11]. The statistical significance in the final multivariate models was set to P<0.05.
Ethical considerations
This study and the consent procedure regarding the women and their offspring were approved 
by the Ethics Committee of the Faculty of Medicine of Cotonou, Benin. It was explained in 
local language to the participant and her voluntary written consent was obtained and recorded 
in the clinic files before enrolment. In case the woman could not read, an impartial witness 
was included in the process. In the case of the inclusion of minor women, both their consent 
and the consent from the parents or legal guardians were obtained. Women were free to 
interrupt their participation at any time of the study.
Results
The BLL of 203 infants included in the APEC-cohort were obtained at the 12-month visit 
between April 2011 and May 2012. During the 12-month follow-up 84 infants (42%) had at 
least one malarial episode. More precisely, 60.25% of infants had no positive blood smear 
during the entire follow-up period, 22% of infants had 1, 12.50% had 2, 4.5% had 3, and 
0.75% had 4 positive blood smears during follow-up. The main malarial and hematological 
indicators as well as lead levels are presented in table 1. At the moment of lead assessment, 25 
out of 200 (12.5%) of the infants had a positive blood smear, with a mean parasite density of 
13460 (CI:2775; 24145). Lead levels were high overall. The mean BLL of infants was 7.41 
µg/dl (CI: 65.2;83), and 128 infants (63%) had elevated blood lead levels, defined by the 
CDC as BLL>5 µg/dl. Lead poisoning, defined as BLL>10 µg/dl, was found in 39 infants 
(19%). With regard to the hematological indicators, 144 infants were anaemic (71%, Hb<110 
g/l), and 85 were iron deficient (42%, CRP-corrected serum ferritin (SF) <15 µg/l). The mean 
and median hemoglobin and ferritin values were 101.69 g/l and 104 g/l (CI: 99.51; 103.86), 
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and 571 mg/l and 201.5 mg/l (CI: 429.67; 712.34), respectively. 
At 12 months, ferritine, folate, and CRP levels as well as rain quantity and low socio-
economic status were associated in univariate analysis with increased malaria risk with regard 
to both the risk of having a positive smear and P. falciparum parasite density. In parallel, 
hemoglobin and lead levels were inversely correlated with malaria risk in univariate analysis. 
In univariate and multivariate analyses, girls were significantly less likely to have high P. 
falciparum parasitemia but there were no statistical differences in malaria risk between boys 
and girls with regard to the probability of having a positive smear. There were no statistical 
significant differences in malarial, lead, or hematologic indicators depending on the health 
care centre.  Table 2 and table 3 describe risk factors associated with the possibility of having 
a positive blood smear and high P.falciparum parasitaemia with lead levels as a continuous 
variable, whereas table 4 and table 5 include the possibility of having elevated BLL.
In multivariate analysis, high lead levels were significantly associated with reduced risk of a 
positive blood smear (p-value=0.02) and P. falciparum parasite density (p-value=0.048) in 
logistic and linear regression models, respectively. More precisely, no positive blood smear 
was found among infants with lead poisoning, and infants with elevated BLL (table 4) were 
significantly less likely to have a positive blood smear and a high P. falciparum density 
(aOR=0.38 95% CI (0.15; 0.99), and Coefficient=-0.44, p-value=0.03, respectively). Factors 
associated with increased malaria risk include high iron and folate levels and ongoing 
inflammatory process. In effect, elevated ferritin levels (log of ferritin corrected on 
inflammation) were associated with increased risk of a positive blood smear (aOR=2.46 (1.01; 
6.05), p-value=0.05). In addition, high folate levels were statistically associated to an 
increased P. falciparum parasite density (coefficient=0.0003, p-value=0.04).
Discussion
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The high proportion of infants with elevated BLL (63%) and lead poisoning (19%) plead for 
the necessity of considering the possible influence of lead levels on the infant infectious 
morbidity, especially with regard to malaria, the main cause of mortality in children<5 years. 
In effect, high BLL were significantly associated with reduced malaria risk with regard to 
both the possibility of having a positive blood smear and P. falciparum density. Concern has 
been repeatedly raised up on the importance of alarmingly high anemia rates in West Africa 
[16], and both malaria and elevated BLL are associated with increased anemia rates.
Similar prevalence of elevated BLL has been found in other West-African regions. The mean 
BLL value for this study (7.4 µg/dl) is slightly lower than the mean BLL found by Nriagu et 
al in Nigeria in 2008[11] (8.9 µg/dl). In Jos, Nigeria, another study reported an average BLL 
of 11.2 µg/dl (range: 9.1–13.3 µg/dl), and that 55% had BLLs above 10 µg/dl [17]. Indeed, 
the existing epidemiological evidence reveals the high prevalence of elevated BLL among 
African infants. However, there is very limited evidence on their effect on malaria. Nriagu et 
al described the inverse association of BLL and malaria in univariate analysis 
(pvalue=<0.001). Our results not only confirm this association in univariate analysis, but they 
are the first to evidence the significant effect of BLL on malarial risk. Furthermore, these 
results show that elevated BLL are also associated with reduced probability of a positive 
blood smear as well as reduced P.falciparum parasite density. As a consequence, 
epidemiological evidence in our study rejects the possible synergistic effect of lead on 
P.falciparum infection, but rather suggests a protective effect. Moreover, the high BLL 
present in our sample raise concern on their possible harmful consequences for the infant 
health. 
The mechanism by which lead might influence malaria infection has not been elucidated so 
far. However, Nriagu postulated that there are multiple levels at which lead can modulate the 
specific host response to Plasmodium infection including alterations in heme synthesis, 
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immunoregulation, and iron metabolism.
Lead concentrates in red blood cells (RBC) in the context of lead poisoning [18]. The 
accumulation of lead in the RBC, the main nutrition source of Plasmodium, may inhibit the 
development of the parasite. Elevated intra-erythrocytic concentration of lead may interfere 
with the development from the ring form to the schizont stage and, consequently, lead 
exposure may be associated to reduced parasitemia in malaria-infected infants.
In addition, elevated BLL can exert a general effect on the immune regulatory 
function[19,20]. In this respect, both lead poisoning and malaria favor the cytokine response 
which, in turn, has an influence on the Th1/Th2 balance [21,22]. Indeed, a certain protection 
against severe malaria has been described as a consequence of the Th2 response following the 
alteration of the immune system induced by lead poisoning [23]. 
Alternatively, iron deficiency and hemoglobinopathies can foster the anti-parasite effect of 
lead in the context of the blood stages of P. falciparum. Indeed, iron deficiency may interfere 
with the proper use of iron by the parasite [24]. However, iron deficiency was not 
significantly correlated with malaria risk in our analyses. Finally, high intra-erythrocyte lead 
concentration can inhibit protein synthesis [25], and thereby interfere with the correct iron 
utilization by Plasmodia [24]. 
With regard to iron levels, high iron levels have already been associated with increased 
malaria morbidity [26]. This raises the concern on the iron supplements recommended by the 
WHO when anemia prevalence >40%, which is the case of Benin. Furthermore, published 
literature reports both iron and lead have a significant effect not only on malaria, but also on 
anemia. Indeed, strategies to tackle anemia should consider not only iron supplementation but 
public health policies should also imply the sources of elevated BLL. 
Low folate levels are also associated to anemia. Nevertheless, high folate levels are associated 
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with high P.falciparum parasitemia as well. The significant role of high folate levels for 
increased risk of P. falciparum parasite density is coherent with the literature. Indeed, anti-
folates are one of the most anti-malarial drugs used worldwide. Finally, boys displaying 
higher P. falciparum parasite density than girls has already been described[27], may be due to 
their higher exposure because of socio-behavioural habits. 
Conclusion
Malaria is the main cause of mortality for infants under 5 years worldwide[10], and high iron 
levels have been associated to increased malaria risk[26]. Therefore, in the context of limited 
protection against malaria, iron supplements to fight anemia might entail some deleterious 
effect for P. falciparum infections. As a consequence, giving supplements to infants that do 
not need them might be harmful for their health status. 
However, iron supplements are crucial to fight anemia especially in the context of elevated 
BLL[28]. This is of special relevance, as iron deficiency is associated to increased lead 
absorption[29]. Lead poisoning is the 6th most important contributor to the global burden of 
diseases measured in disability adjusted life years (DALYs) according to the Institute of 
Health Metrics, with Sub-Saharan African countries being predominantly responsible for the 
global DALYs[30]. Lead poisoning entails severe consequences for the development of the 
children and is associated with major health problems highly prevalent in West Africa, such 
as anemia, having an important impact on the infants and their communities. In addition, iron 
is essential for the neurocognitive development of the child brain.
In conclusion, environmental factors, such as lead levels, need to be considered in the debate 
about iron supplements in malaria endemic countries.  
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Tables:
Table 1. Clinical characteristics of the infants: malaria indicators and blood lead levels 
Parameters Mean or number of people affected
Malaria infection (%) 25 (12.5%) 
P.falciparum density (parasites/µL) 13460 (CI:2775; 24145) 
Blood lead levels (µg/l) 74.1 (CI: 65.2;83)
Elevated blood lead levels (BLL>5 µg/dl) 128 (63.05%) 
Lead poisoning levels (BLL>10 µg/dl) 39 (19.21%) 
Haemoglobin (g/l) 101.69 (CI: 99.51; 103.86) 
Anaemia (Hb <110 g/l) 144 ( 70.94%) 
Ferritin (mg/l)  571 (CI: 429.67;  712.34) 
Iron deficiency (corrected SF <15 µg/l) 85 (42.93%) 
Table 2. Logistic regression on the possibility of having a positive blood smear at 12 months 
Factor aOR (95% CI) p-value 
Blood lead levels (µg/l)  0.98 (0.96; 0.99) 0.02 
Ferritin levels   2.46 (1.01; 6.05) 0.05 
(logartihm of the ferritin (mg/l) corrected on inflammation)  
Low socio-economic index   1.52 (0.95; 2.45) 0.08 
   
Prob>chi2=0.0002  Number of observations=197  
Table 3. Linear regression on factors associated with P.falciparum parasitemia 
(logarithm of parasite density at lead assessment) 
Factor Coefficient (95% CI) p-value 
Blood lead levels   -0.003 (-0.006; -0.0001) 0.04
Ongoing inflammatory process (CRP levels ≥5 mg / ml)  0.72 (0.31; 1.14) 0.01 
Ferritin levels 
(logartihm of the ferritin corrected on inflammation)   0.25 (-0.12; 0.61) 0.19
Folate levels (ng/ml)  0.0003 (0.0001; 0.006) 0.04 
Sex of the infant (female)  -0.44 (-0.81; -0.06) 0.02
Low socio-economic index   0.04 (-0.14; 0.22) 0.64 
Prob>F=0.00  Number of observations=196 
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Table 4. Logistic regression on the possibility of having a positive blood smear at 12 months with elevated BLL  
Factor aOR (95% CI) p-value 
Elevated blood lead levels (µg/l)  0.38 (0.15; 0.99) 0.048
Ferritin levels   2.86 (1.13; 7.27) 0.03
(logartihm of the ferritin (mg/l) corrected on inflammation)  
Low socio-economic index   1.42 (0.87; 2.32) 0.16 
Inflammatory process (CRP levels ≥5 mg / ml)  3.09 (1.2; 7.93) 0.02 
   
Prob>chi2=0.0005  Number of observations=197  
Linear regression on factors associated with P.falciparum parasitemia at 12 months with elevated BLL  
(logarithm of parasite density at lead assessment) 
Factor Coefficient (95% CI) p-value 
Elevated blood lead levels   -0.44 (-0.84; -0.04) 0.03
Inflammatory process (CRP levels ≥5 mg / ml)  0.65 (0.23; 1.06) <0.01 
Ferritin levels 
(logartihm of the ferritin corrected on inflammation)   0.22 (-0.15; 0.59) 0.24
Folate levels (ng/ml)  0.0004 (0.0001; 0.006) 0.02
Low socio-economic index   0.06 (-0.13; 0.24) 0.56
Prob>F=0.00  Number of observations=196 
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VI. Discussion     
VI.1. Effect of preventive public health interventions during 
pregnancy on pregnancy associated malaria
IV.1.1. Effect of IPTp on PAM outcomes
PAM has not a single dimension. It entails different clinical manifestations that depend, as 
said  in  the second section,  on transmission,  immunity,  and preventive  strategies.  Clinical 
malaria,  high parasite density,  LBW, and placental  malaria are the main symptoms of the 
infection by Plasmodium. Therefore, a holistic analysis that includes every outcome issue of 
PAM, should lead us to contemplate the multiple different dimensions of the protective effect 
of IPTp. 
IV.1.1.a. Effect of transmission and previous immunity
An initial approach of the results requires acknowledging the differences among women with 
regard to transmission and immunity.  Differences in transmission have been estimated by 
rainfall,  which is a useful tool to account for  anopheline risk. Rainfall varies significantly 
throughout the follow-up period. Nevertheless, it is not associated with malaria risk during 
pregnancy nor with placental malaria or LBW. The possible effect of rain might be mitigated 
by the  effect  of  previous  immunity.  Indeed,  there  is  some  evidence  suggesting  a  certain 
protection for multiparous women because of the immunity due to previous gestations.  In 
effect, in univariate analysis, gravidity was associated with the age of the mother, BMI, socio-
economic status, number of positive blood smears, PM and LBW. In this respect, infants of 
primigravid  women  will  be  possibly  at  higher  risk  for  subsequent  malaria  as  a  result  of 
reduced antibody transfer, even if one study has shown the opposite results in women with no 
infected placenta. As shown in the results section, the mean of positive blood smears during 
pregnancy was significantly higher for primi- and secundigravidae than for multigravidae. In 
addition, the percentage of women with placental malaria decreased significantly as gravidity 
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increased and the proportion of LBW babies was also inversely correlated with gravidity. 
However, gravidity was not significant in the multivariable analysis of positive blood smears 
and parasite density when considering maternal age. Furthermore, some studies suggest that 
age has an independent effect on immunity regardless of gestation. Therefore, the analyses 
include maternal age, as we estimated it was a better estimator for malaria risk in our study 
than gravidity.
IV.1.1.a. Effect of IPTp: absolute reduced risk, IPTp regime, and IPTp calendar
As there was no placebo group in our study, it is not possible to evaluate the absolute efficacy 
of  IPTp.  However,  we  can  comment  on  the  evolution  of  malarial  risk  after  IPTp 
implementation. The proportion of women with a positive smear decreased after IPTp (from 
15.3%  at  ANV1  to  3.9%  at  ANV2),  and  then  increased  again  up  to  9.6%  at  delivery. 
Nevertheless,  the  trend  was  slightly  different  concerning  parasite  density.  P.falciparum 
parasite  density  was  higher  at  ANV1  than  at  ANV2  (382.4,  SD=3709.2  and  214.1, 
SD=2728.5 parasites/µL, respectively) but then rose up to 3098.8, SD=31120.7 parasites/µL 
at delivery. Indeed, 2-dose IPTp seems to be effective after the first dose but its protection is 
not long enough to control parasitemia at delivery.
Concerning  parasitemia  at  delivery,  in  our  Beninese  sample  there  were  no  statistical 
differences between women who had received SP and women who had received MQ IPTp 
(RR=0.73, 95% CI (0.51; 1.06), p-value=0.14). Furthermore, neither there were significant 
differences among women with SP and MQ IPTp regimes with regard to LBW, nor with 
regard to placental malaria. More precisely, the adjusted RR for LBW was =1.06, 95% CI 
(0.7; 1.54), p-value=0.77) and RR for placental malaria was= 0.74, (95% CI (0.52; 1.06), p-
value  =0.10).   Our  study was  a  sub-study of  the  MiPPAD clinical  trial,  in  which  4,749 
pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, 
Gabon,  Mozambique,  and  Tanzania  comparing  2-dose  MQ  or  SP  for  IPTp  and  MQ 
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tolerability of two different regimens. The multi-centre analyses show women receiving MQ 
had reduced risk of parasitemia (63/1,372 (4.6%) in the SP group and 88/2,737 (3.2%) in the 
MQ group (RR=0.70, 95% CI (0.51; 0.96), p-value = 0.03), and reduced incidence of clinical 
malaria  (96/551.8 malaria  episodes person/year  (PYAR) in the SP group and 130/1,103.2 
episodes PYAR in the MQ group (RR=0.67, 95% CI (0.52; 0.88), p-value   = 0.004). In our 
sub-study in Benin women receiving the SP-IPTp regime had on average 0.5 positive blood 
smears whereas women receiving MQ had on average 0.54. Nevertheless, this difference is 
not statistically significant and MQ has been already found to be more effective against PAM 
than SP in other studies in Benin. 
IPTp timeframe also seems to influence PAM outcomes. According to Huynh et al. an early 
intake of the first SP dose (up to 4 months of gestation) was associated with a lower risk of  
LBW compared to a late intake (6-7 months of gestation) (aOR= 0.5, p-value = 0.01) in an 
observational  cohort  of  pregnant  women.  Even  if  our  results  show similar  trends  in  the 
association  of  early  IPTp  and  LBW  in  univariate  analysis,  we  do  not  obtain  the  same 
significant results in multivariate analysis, when considering other risk factors, such as other 
important clinical outcomes, environmental indicators and obstetric parameters. Furthermore, 
we do not  see  a  significant  association  of  IPTp timing  with positive  blood smear  during 
pregnancy, P. falciparum parasitemia or placental malaria. 
In conclusion, we do not see differences in malarial risk, parasite density, LBW or placental 
malaria  between  IPTp  regimes  and  IPTp  timing.  Additional  epidemiological  evidence 
concerning  the  effect  of  IPTp  timing  in  PAM  is  required  to  conclude  to  consistent 
recommendations.  Consequently,  IPTp clinical  trials  should analyse the effect of different 
timing of IPTp on PAM outcomes beyond LBW and anemia at delivery.
VI.1.2. Effect of iron levels on PAM outcomes
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As presented in the state of art section, iron levels are of crucial interest for public health 
strategies during pregnancy. Indeed, iron supplements alleviate anemia, but they might also 
trigger infectious agents to develop. Hence, the analysis of iron levels and the simultaneous 
co-infections need to be analysed in a prospective, longitudinal manner in order to capture the 
dynamics of the process and to be able to evaluate iron levels at the precise moment when 
infection takes place.
VI.1.2.a. Complementary aspects of the analysis of iron I: a foreword on ferritin and 
inflammation
As stated in the second section, ferritin is a consistent marker of iron levels. However, ferritin 
is also an acute phase protein and it is associated with the inflammatory response, which, in 
turn, increases in the context of malaria. Indeed, infections entail the activation of the 
inflammatory response and CRP levels increase as a consequence. To attenuate the 
interference of inflammation on ferritin values, we corrected ferritin upon inflammation (with 
correction factors according to CRP) following the correction suggested by Thurham meta-
analysis. Conversely, there is substantial scientific evidence that significant differences in the 
inflammatory response of the individual will determine the development and severity of 
malaria. Kabyemela et al. showed that inflammatory status at birth (before any malaria 
infection) predicts malaria severity during infancy. Wilson et al. have also shown in pregnant 
women that elevated levels of IL-10 and G-CSF are associated with asymptomatic malaria. 
Furthermore, the results of Perera et al. suggest that the high circulating TNF-alpha levels and 
the inadequate IL-10 response in severe malaria patients carrying TNF2 allele could 
contribute to the development of severe falciparum malarial disease. Previously, May et al. 
had shown that plasma Interleukin-10 Tumor Necrosis Factor (TNF)—α ratio was associated 
with TNF promoter variants and predicted malarial complications. This was confirmed by 
Zhang et al., who described that interleukin-10 (IL-10) polymorphisms are associated with IL-
10 production and clinical malaria in young children. CXCL9 expression is induced by IFN-γ, 
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and the strong association between birth weight and placental CXCL9 is consistent with 
previous observations relating IFN-γ to poor pregnancy outcomes. For these reasons, although 
being aware of the risk of over-adjusting, we decided to include inflammatory status in the 
model to take into account the different degree of inflammatory response that might be 
associated with different malaria clinical severity. This might account for the different degree 
of inflammatory response the individual would develop, which is specific at the individual 
level. This is one of the reasons for setting an individual intercept at the individual level in the 
model.
VI.1.2.b. Epidemiological evidence
We analysed the association of iron levels with malarial risk in a prospective longitudinal 
cohort through pregnancy considering both the possibility of having a positive blood smear 
and P.falciparum parasite density. Indeed, iron levels, measured by ferritin corrected for 
inflammation, were significantly associated with malarial episodes and P.falciparum density 
through the pregnancy period in the context of IPTp and ITN use. Furthermore, this 
association is strongly significant even after adjustment on inflammatory status. Moreover, 
iron levels are significantly associated with placental malaria even after adjustment on 
maternal infection. Literature shows PM is associated with increased infant’s susceptibility to 
the infection translating into increased number of clinical episodes. Consequently, the 
association of high iron with placental malaria might contribute to enhance its effect on 
malaria risk throughout the perinatal period. Finally, the association of maternal iron levels 
with LBW, possibly due to their relationship with PAM, suggests a broader impact of iron on 
infant health. Further details on the evolution of iron levels and anemia during pregnancy in 
this cohort are presented by Ouédraogo et al., but briefly, iron deficiency conferred protection 
against malaria through the entire follow-up. However iron levels were no longer associated 
with P.falciparum parasite density among iron deficient women, which suggests the possible 
existence of a threshold level above which iron levels become deleterious. Indeed there was 
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significant increased malarial risk above 30 days of supplementation in the stratified analysis 
of two African surveys with high antimalarial preventive measures (RR=1.42, 95% CI (1.09; 
1.84)). 
Our results are consistent with other studies. Although iron supplementation trials do not 
show augmented malaria morbidity associated with iron supplements, iron deficiency is 
correlated with lower odds of malarial episodes. Iron deficiency was statistically linked to 
reduced risk of placental malaria in Tanzania. Ferritin was also higher among placenta-
infected mothers in Gabon and zinc protoporphyrin in Malawi, but these differences were not 
statistically significant. Similar results were found in clinical trials in The Gambia or Kenya. 
The recent meta-analysis on malarial risk and iron status suggested a possible but not 
significant difference in placental malaria associated with iron supplementation depending on 
sickle cell genotype. However, as already said, these studies report iron levels only at 
enrolment, at delivery, or both, and the limited sample might be insufficient to show a 
statistically significant effect. 
Possible explanations for the increased malarial risk associated with iron levels found in our 
study are related to malaria pathophysiology in both the host and the parasite. At the host 
level, Plasmodium interferes with the physiological iron distribution and use through 
hemolysis, release of heme, dyserythropoiesis, anemia, deposition of iron in macrophages, 
and inhibition of dietary iron absorption Furthermore, the changes in iron metabolism during 
a malaria infection may modulate susceptibility to co-infections. In addition, iron inhibits the 
synthesis of nitric oxide by inhibiting the expression of inducible nitric oxide synthase 
(iNOS), and thereby interferes with macrophage-mediated cytotoxicity against Plasmodium . 
Moreover, non-transferrin bound iron (NTBI) is involved in the severity of malaria. Indeed, 
Plasmodium has the capacity of acquiring iron in a transferrin-independent pathway(42). 
VI.1.2.c. A comment on the specific characteristics of the individuals and their evolution 
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during pregnancy
The individual particularities of each pregnant woman and the physiopathological evolution 
of iron levels within the different periods of pregnancy need to be considered in the analysis 
of the association of iron levels with malarial risk. Therefore, a well-defined and concrete 
statistical approach is necessary: the multilevel model analysis. Multi-level models are 
particularly suited to the statistical analyses of prospective cohorts with repeated measures at 
the individual level, as they can take into account the specificities of each individual at 
different time measures. 
In order to treat the evolution of iron levels, we planned a multi-step statistical analysis. First, 
we assessed the association of iron with malaria risk by trimester, and high ferritin was 
significant in the observations of the different trimesters with regard to both the possibility of 
having a positive smear and also P.falciparum parasite density. Thereafter, in the context of 
the multilevel analysis we included a categorical variable to account for the specific 
pregnancy trimester of each observation and this variable was not significant. Ferritin levels 
may also differ from one trimester to the other also because women take iron supplements. 
Indeed, when we conducted the univariable analyses on the association between ferritin and 
the possibility of a positive blood smear or parasite density for each visit, the only case in 
which ferritin levels and a positive blood smear were not significantly associated (p-
value=0.07), still borderline, was in the visit following the iron supplements. However, the 
association between ferritin levels and parasite density for this same visit, i.e. before iron 
intake, was statistically significant (p-value=0.003). Then we tested the link between ferritin 
levels and gestational age and their association was significant, possibly due to the timing of 
the supplements. 
With regard to the specific characteristic inherent to the physiopathology of each individual, 
including its own immunity, we decided to use multilevel models with a random intercept at 
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the individual level. More precisely, for both the analysis of the possibility of a positive blood 
smear and for the analysis of parasite density, random beta estimate models were used as they 
were statistically better than fixed effects according to AIC and BIC criteria. The Akaike 
information criterion (AIC) and the Bayesian information criterion (BIC) compare maximum 
likelihood models. More precisely, AIC and BIC are defined as:  AIC = -2*ln(likelihood) + 
2*k, and   BIC = -2*ln(likelihood) + ln(N)*k, where k = number of parameters estimated,  N 
= number of observations.  AIC and BIC can be viewed as measures that combine fit and 
complexity.  Fit is measured negatively by -2*ln(likelihood); the larger the value, the  worse 
the fit.  Complexity is measured positively, either by 2*k (AIC) or ln(N)*k (BIC). 
In conclusion, random intercept was applied in both cases at the individual level and random 
slope was applied to gestational age, as the effect of the variables might differ between 
women and the effect of gestational age might also vary differently according to the timing of 
the measure. Certain variables were forced into the model because of their meaning in the 
analyses according to the literature: socio-economic status and rainfall in the case of malarial 
indicators, and BMI in the case of LBW.
VI.2. Effect of preventive public health interventions on malaria in 
infants: the determinant print? 
Public health interventions aim at improving the health status of the individuals and to 
avoiding the disease consequences. Pregnancy is a particular period in which the women are 
at special risk and the effect of diseases can harm both the mother and the foetus. Therefore, 
special caution needs to be paid when implementing any public health intervention during this 
critical period because of the possible long-term consequences. 
VI.2.1. Effect of IPTp on malaria in infants
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The case of pregnancy associated malaria is particularly sensible, as women are increasingly 
susceptible to malaria infection during pregnancy since Plasmodium falciparum, the most 
common parasite responsible for malaria, avoids spleen clearance through expression of 
proteins that bind to the chondroitin sulphate A (CSA) in the placental intervillous space. 
Consequently, the foetus is initially exposed to the effects of PAM in utero. Indeed, there is 
substantial epidemiological evidence that placental malaria is associated to increased 
susceptibility to malaria during infancy, possibly due to an ongoing immune tolerance 
process. Hence, it is reasonable that IPTp interventions, which have an impact on malaria 
parasitemia, would modify the immune tolerance process and thereby have an effect on 
malaria in infants.
VI.2.1.a. Epidemiological evidence
Indeed, our results show that IPTp has a significant effect on malaria severity in infants 
during the first year of life considering both the possibility of having a positive blood smear 
and P.falciparum parasite density.
PAM has been frequently correlated to an impaired health status of the offspring10. We found 
that the period of time between IPTp doses, i.e. the number of days between IPTp doses, is 
inversely correlated to malaria risk. When the period of time between IPTp doses is longer, 
infants have significantly reduced risk of malaria during the first year of life. 
Albeit their novelty, our results are coherent with the existing literature, that suggests that 
IPTp in general might be associated with malaria risk in the infant. Indeed, Borgella found 
infants born to a mother with PAM during the third trimester of pregnancy had a significantly 
increased risk of infection (OR=4.2, 95% CI (1.6; 10.5), p-value = 0.003) or of malaria attack 
(OR=4.6, 95% CI (1.7; 12.5), p-value = 0.003). In addition, Huynh found IPTp calendar is 
associated with secondary malaria indicators like LBW and anaemia. More precisely, at the 
beginning of pregnancy, peripheral infections were associated with a decrease in mean birth 
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weight (-98.5 g; p-value = 0.03) and an increase in the risk of anemia at delivery (aOR = 1.6; 
p-value = 0.03). Infections in late pregnancy were related to a higher risk of maternal anemia 
at delivery (aOR = 1.7; p-value = 0.001). Considering that PAM has a significant effect of 
malaria in infants and that IPTp has an impact on secondary malaria outcomes, such as LBW 
and anaemia, our results are consistent with those of other studies. The only discordant study 
is the cohort followed by Harrington in NE Tanzania. Surprisingly, IPTp was also associated 
with earlier first malaria episode among mothers with placental malaria and increased overall 
odds of severe malaria among all offspring in the cohort. However, there is a strong resistance 
against SP IPTp in NE- Tanzania, and the same team has shown that IPTp in this area is 
ineffective. In addition, women with placental malaria in this population, IPTp was associated 
with increased drug resistance alleles, placental parasite density, and inflammation. These 
findings are consistent with parasite competitive facilitation, a phenomenon where drug 
pressure eliminates drug susceptible parasites, allowing drug resistant parasites to overgrow. 
Indeed, the association between IPTp and time to first parasitemia was restricted to offspring 
of women with placental malaria, which suggests that the discordant results might be due to 
the ineffective IPTp, and would speak in favor of the immune tolerance hypothesis suggested 
by our results. 
Indeed, Dechavanne found in Benin increased susceptibility of infants to P. falciparum 
parasites with antigens to which they were previously exposed in utero, suggesting the 
existence of an in utero ongoing immune tolerance process. However, no evidence exists at 
present on its concrete physiopathological pathways. Following these results, an adjustment 
of IPTp calendar to enhance protection would be welcome in Benin. In effect, this 
intervention has already been recommended by WHO, which has recently outlined the 
convenience of a more frequent IPTp regime.
However, it is interesting to note that IPTp extent has an impact on malaria in infants whereas 
it has no effect on malaria clinical signs during pregnancy. Despite surprising, this might be 
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explained by the following reasons: first, the majority of women are multiparous, and even if 
they were not, clinical symptoms associated with PAM are rare or mild in this population. 
Hence, women might not come to the health centre during malaria episodes and we might 
have lost enough observations that could corroborate the association. Second, a recent article 
has shown that submicroscopic parasitemia has an impact on LBW, prematurity and maternal 
anemia but not with maternal malaria episodes. IPTp might clear numerous parasites and be 
effective enough to reduce PAM clinical episodes, but its protective effect on the infants 
might not last during the entire pregnancy period. During the time during which IPTp is no 
longer effective, even submicroscopic parasitemia might have an effect on the in utero 
exposition to the parasite and thereby an impact on immune tolerance and, consequently, on 
malaria in infants. Therefore, the extent of IPTp, i.e. the number of days between doses, 
which prolongs the time during which the foetus is protected, might entail a certain protection 
for the infant even if no significant protection is detectable on maternal clinical malaria.
VI.2.2. Effect of the infant iron levels on malaria in infants
As explained, the analysis of iron levels is really complex. Therefore, a consistent and multi-
technical statistical approach was necessary.  More precisely, we followed the same analytical 
approach that we used to analyse the maternal malaria risk.
VI.2.2.a. Statistical approach
First of all, exploratory and univariate analyses were realized to assess the association of all 
variables with both infant positive smear and peripheral P.falciparum density at each visit 
(systematic or unscheduled visit). Chi-squared and Kruskal-Wallis tests were used in the 
univariate analyses. When variables had several measures evolving during follow-up, 
univariate analyses were realized using a multilevel model with a random intercept at the 
infant level, as each infant has its own immunological, clinical and obstetric background. 
Thereafter, all variables with P values<0.2 were included in a multivariate multilevel model 
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with a random intercept at the infant level, and considering all visits for each infant. 
Multilevel models with a random intercept at the infant level were applied to explore the 
determinant of both the possibility of having a positive smear and peripheral P.falciparum 
density, respectively. More precisely, random intercept was applied in both cases at the 
individual level and random slope was applied to the infant age, as the effect of the variables 
might differ among infants and the effect of the infant age might also vary differently 
according to the timing of the measure. The statistical significance in the final multivariate 
models was set to P<0.05. 
VI.2.2.b. Epidemiological evidence
We have assessed the influence of iron levels on malarial risk throughout the first year of life 
with regard to the possibility of having a positive blood smear and P.falciparum parasite 
density, considering environmental, socio-economic, and PAM factors, such as placental 
malaria or gestational age. Indeed, iron levels, measured by ferritin corrected for 
inflammation, a consistent indicator of iron levels, were significantly associated with malarial 
episodes and P.falciparum density. Furthermore, like in the case of the mothers, this 
association was strongly significant even after adjustment on inflammatory status. Iron 
deficiency conferred protection through the entire follow-up period. More precisely, infants 
with iron levels in the first quartile were significantly protected against malaria. Indeed, iron 
deficiency has frequently been linked to a certain protection against malaria. Nevertheless, 
results on the effect of iron levels on malaria differ in the context of clinical trials with iron 
supplements. In a specific Cochrane review no significant difference in clinical malaria 
episodes was detected between iron alone and placebo (RR=0.99, 95% CI (0.90; 1.09)). 
However, the effect of iron deficiency was not assessed, and solid preventive measures 
against malaria were implemented in the clinical trials. Indeed, an increased risk of malaria 
with iron was observed in trials that did not provide malaria surveillance and treatment, and 
the risk of malaria parasitemia was higher with iron (RR=1.13, 95% CI (1.01; 1.26)). 
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Furthermore, in numerous studies included in the meta-analysis, iron was seldom determined 
longitudinally. 
Albeit the hereby reported results, iron supplements have undeniable benefits for infants. A 
2013 meta-analysis showed supplementation was associated to a reduced risk of anaemia 
(RR=0.61, 95% CI (0.50; 0.74), n=4825), of iron deficiency (RR=0.30, 95% CI (0.15; 0.60), 
n=2464), and of iron deficiency anaemia (RR=0.14, 95% CI (0.10; –0.22), n=2145). As 
pondering the advantages and risk of iron supplements is daunting because they are not 
epidemiologically quantifiable, the implementation of malaria protective strategies should be 
seriously encouraged. Indeed, the Cochrane review shows no increased risk of malaria in 
infants implementing protective interventions. 
VI.2.3. Supplementary factors associated with malaria in infants: the case 
of lead
VI.2.3.a. Epidemiological evidence
The high proportion of infants with elevated blood lead levels (BLL) (63%) and lead 
poisoning (19%) plead for the necessity of considering the possible influence of lead levels on 
the infant infectious morbidity, especially with regard to malaria, the main cause of mortality 
in children<5 years. In effect, high BLL were significantly associated with reduced malaria 
risk with regard to both the possibility of having a positive blood smear and P. falciparum 
density. Concern has been repeatedly raised up on the importance of alarmingly high anemia 
rates in West Africa, and both malaria and elevated BLL are associated with increased anemia 
rates.
Similar prevalence of elevated BLL has been found in other West-African regions. The mean 
BLL value for this study (7.4 µg/dl) is slightly lower than the mean BLL found by Nriagu et 
al in Nigeria in 2008 (8.9 µg/dl). In Jos, Nigeria, another study reported an average BLL of 
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11.2 µg/dl (range: 9.1–13.3 µg/dl), and that 55% had BLLs above 10 µg/dl. Indeed, the 
existing epidemiological evidence reveals the high prevalence of elevated BLL among 
African infants. However, there is very limited evidence on their effect on malaria. Nriagu et 
al described the inverse association of BLL and malaria in univariate analysis (p-
value=<0.001). Our results not only confirm this association in univariate analysis, but they 
are the first to evidence the significant effect of BLL on malarial risk. More precisely, these 
results show that elevated BLL are also associated with reduced probability of a positive 
blood smear as well as reduced P.falciparum parasite density. As a consequence, 
epidemiological evidence in our study rejects the possible sinergistic effect of lead on 
P.falciparum infection, but confirms its significant protective effect. Moreover, the high BLL 
present in our sample raise concern on their possible harmful consequences for the infant 
health. 
The mechanism by which lead might influence malaria infection has not been elucidated so 
far. However, Nriagu postulated that there are multiple levels at which lead can modulate the 
specific host response to Plasmodium infection including alterations in heme synthesis, 
immunoregulation, and iron metabolism.
Lead concentrates in red blood cells (RBC) in the context of lead poisoning. The toxification 
of the RBC, the main nutrition source of Plasmodium, may inhibit the development of the 
parasite. More precisely, the elevated intra-erythrocytic concentration of lead may interfere 
with the development from the ring form to the schizont stage and, consequently, lead 
exposure may be associated to reduced parasitemia in malaria-infected infants.
In addition, EBLL can exert a general effect on the immune regulatory function. In this 
respect, both lead poisoning and malaria favor the cytokine response which, in turn, has an 
influence on the Th1/Th2 balance. Indeed, a certain protection against severe malaria has been 
described as a consequence of the Th2 response following the alteration of the immune 
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system operated by lead poisoning. 
Alternatively, iron deficiency and hemoglobinopathies can foster the anti-parasite effect of 
lead in the context of the blood stages of P. falciparum. Indeed, iron deficiency may interfere 
with the proper use of iron by the parasite. However, iron deficiency was not significantly 
correlated with malaria risk in our analyses. Finally, high intra-erythrocyte lead concentration 
can inhibit protein synthesis, and thereby interfere with the correct iron utilization by 
Plasmodia. 
However, iron supplements are crucial to fight anemia especially in the context of elevated 
BLL. This is of special relevance, as iron deficiency is associated to increased lead 
absorption. Lead poisoning is the 6th most important contributor to the global burden of 
diseases measured in disability adjusted life years (DALYs) according to the Institute of 
Health Metrics, with Sub-Saharan African countries being predominantly responsible for the 
global DALYs. Lead poisoning entails severe consequences for the development of the 
children and is associated with major health problems highly prevalent in West Africa, such 
as anemia, having an important impact on the infants and their communities. In addition, iron 
is essential for the neurocognitive development of the child brain.
In conclusion, environmental factors, such as lead levels, need to be considered in the debate 
about iron supplements in malaria endemic countries. 
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VII.1. Effect of pregnancy associated malaria and intermittent 
preventive treatment on malaria in infants 
The impact of PAM on malaria in infants does not only involve placental malaria, prematurity 
or LBW. PAM entails increased risk of malaria in infants, possibly due to an ongoing immune 
tolerance process in utero. As a consequence, interventions tackling at PAM have also an 
effect on malaria in infants. Effective administration of IPTp clears placental parasitemia and 
consequently modifies the exposure to malaria antigens in utero resulting in a significant 
protection for malarial episodes during infancy. Indeed, the interval between IPTp doses, 
which might reflect the time during which the foetus might be protected, is associated to a 
reduced risk of malaria during infancy with regard to both the possibility of having a positive 
smear and P. falciparum parasitemia. However, IPTp timing (the moment of pregnancy when 
IPTp is given) does not seem to have a significant effect on malaria outcomes of the infant in 
our study. Moreover, there are no significant differences in malarial risk during pregnancy or 
infancy depending on the IPTp regime (either SP or MQ).  
The new WHO recommendations encourage IPTp with SP for all pregnant women as early as 
possible in the second trimester, and at each scheduled antenatal care visit at least one month 
apart in areas of moderate to high malaria transmission seems to improve the previous IPTp 
schedule (2 doses). IPTp strategies are however not yet completely deployed in malaria 
endemic regions and due to the insufficient implementation of IPTp the effect of this new 
policy on malaria in infants might be difficult to evaluate. In any case, the new 
recommendations are supposed to improve the disease burden associated to PAM.
VII.2. Effect of iron levels on malaria: evidence from pregnant women 
and infants. 
The interaction between iron levels and malaria is daunting because of the iron requirements 
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during pregnancy and infancy, and because of the fact that iron contributes to P.falciparum 
growth. In addition, this interaction is modified by malaria control interventions. For these 
reasons it is important to find out whether iron levels are associated with increased malarial 
risk in a prospective longitudinal cohort in the context of both supplements and IPTp in 
pregnant women but also in infants.
High ferritin levels are associated with increased malarial risk during pregnancy with regard 
to malarial episodes and P.falciparum parasite density in the context of IPTp and ITN use, 
even if positive smears diminish effectively after IPTp implementation. In addition, iron 
levels have also a significant association with important perinatal outcomes like placental 
malaria and LBW. Our data also suggest there might be a dose effect of iron levels on 
malarial risk. 
Even if infants are not supplemented with iron, malaria risk during the first year of life is also 
significantly associated with iron levels. High ferritin levels are associated with increased 
malarial risk throughout the first year of life with regard to malarial episodes and 
P.falciparum parasitemia considering other socioeconomic, environmental and clinical 
factors. We also find a dose effect of iron levels on malarial risk. 
In conclusion, we observe increased malaria risk associated with high iron levels in both 
pregnant women and infants. Furthermore, we find a certain dose effect of iron levels on 
malaria risk. This might be considered in the implementation of public health supplement 
strategies during pregnancy and infancy.
Additionally, we find high folate and lead levels are associated to reduced malarial risk.  
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VIII.1. The new WHO recommendations on IPTp in the context of 
increasing resistance 
The effect on maternal and infant health of the extension by WHO of IPTp regime to a SP-
dose at each ANV needs to be monitored. In theory LBW, prematurity and placental malaria 
but also malaria in infants should be carefully analysed to obtain an optimal timing and IPTp 
regime to optimize the protective effect of IPTp. However, operational research on the topic 
might be difficult to implement on the field, and the resulting data might be difficult to 
interpret. Protective strategies regarding iron levels should maybe start during the pre-
conceptional period to better protect both mother and infant. Operational research on different 
preventive IPT strategies should also be continuously conducted, and cost effectiveness 
analysis for community-level IST interventions should be further investigated, considering as 
well that IST has no effect on sub-microscopic parasitemia, which might be troublesome 
when targeting the elimination. 
In addition, as there is evidence of increased infant susceptibility to parasites carrying 
antigens to which they were previously exposed while in utero, further research should also 
tempt to explain the ongoing immune process. Furthermore, the role of protective maternal 
antibodies has not yet been clarified. An exploration of the influence of HLA-G 
polymorphisms on subsequent malaria symptoms would serve as well as an important 
contribution for infant malaria risk factors.
Finally, novel aspects of research on PAM should be further explored. Due to the long-term 
impact of placental malaria’s possible neuro-cognitive consequences, the scientific 
community should prioritize studies investigating this interaction. 
VIII.2. Iron supplements in malaria endemic settings 
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The significant association between iron levels and malarial risk in both pregnant women and 
infants appeals for additional epidemiological studies. Furthermore, the possible dose effect 
of iron levels for malaria risk, advocates for the evaluation of the effect of different doses of 
iron supplements on the infant infectious and haematological outcomes. Complementary 
interventional data are needed to determine the benefits and risks of differently dosed iron 
supplements, in order to ascertain their impact on infant health in malaria-endemic regions. 
Finally, the epidemiological comparison of cohorts in which iron is given as preventive 
intervention and cohorts in which iron is given solely on the purpose of treatment for anaemia 
or ID should be also analysed.
With regard to the difficulty of finding a gold standard for iron levels evaluation, a complete 
combination of iron markers is desirable. This evaluation should at least include the markers 
recommended by the joint WHO-CDC Technical Consultation for anaemia assessment 
(hemoglobin, mean cell volume (MCV), serum transferrin receptor (sTFR) concentration, 
serum ferritin concentration, and red cell protoporphyrin (measured by the zinc 
protoporphyrin/hemoglobin ratio (ZPP:H)) in addition to hepcidin, haptoglobin and 
inflammation  indicators (C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP). The 
index sTfR/log ferritin adjusted on CRP has also been recommended. 
In parallel, the association of iron with malaria risk might be different depending on malaria 
transmission patterns. Indeed, the dose-dependent effect, might be modified by the differences 
in the prevalence of Plasmodium falciparum, and this notable aspect has not been evaluated 
so far in clinical trials.
Finally, if women had sufficient pre-conceptual iron storages, iron supplements might not be 
necessary during pregnancy and the supplementary risk of adding iron, which could be used 
as a growing factor by the parasite, would not be necessary during that critical period.
In infants, iron storages depend on the mothers’, but other strategies like delayed cord 
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clamping can also contribute to increase them.
In any case, sufficient iron levels are crucial for both the mother and the infant, and they need 
to be reached in every possible manner. Therefore, malaria control interventions should be 
optimized to better ensure a minimal infective risk during pregnancy and infancy. 
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Appendix1: Score of Ballard to determine gestational age
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Appendix 2: Further details of the study APEC
The preparation of the APEC project started in 2008. Nineteen people (2 medical doctors, 8 
nurses, 5 lab technicians and 4 supporting agents) formed the APEC-MiPPAD research team. 
The study implied people from 33 different villages of the Allada region. Even if the follow-
up took place in three maternities (Sékou, Allada, and Attogon), the laboratory was in the 
centre of Sékou. In APEC the first woman was recruited on the 15th January 2009 and the last 
one delivered on the 10th January 2012. 
In case of illness each case has been managed according to Beninese guidelines.
Uncomplicated malaria has been treated in the different maternities and complicated malaria 
cases have been refered either to the Hospital of Calavi, to the Hôpital de la mère et de 
l’enfant Lagune, or to the Centre hospitalier universitaire-Hubert Koutoukou Maga in 
Cotonou, where they have received quinine.
In case of severe anemia the patients have been transfused and detected and treated the cause 
of anemia.
With regard to the lost-of follow-up, every trimester the entire cohort was controlled. A case 
was determined to be lost of follow-up when there were no news of the mother or the infant 
for longer than 3 visits. Each case was documented and the cause was also determined. In 
case of death, the date, the cause, and the previous treatments were also investigated.
HIV rapid tests were proposed to the pregnant women after HIV counselling at the 1st ANC 
visit. The tests realized were Determine® HIV-1/2 (Abbott Determine Kit HIV 1 and 2 
package insert) et Bioline (SD Bioline Kit HIV 1 and 2 3.0 package insert). When the result 
was positive, women were sent to the Hospital of Allada for an ELISA confirmation. In case 
of confirmation of the diagnostic, women were treated and followed according to the 
Beninese guidelines.
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With regard to the diagnostic of malaria, the technique of Lambarené was employed: it consist 
in the analysis of 10 μL of blood on a surface of 1.8 cm2 at the microscope. Afterwards the 
sample is colored with Giemsa. Then the mean number of parasites for each field is counted 
and then multiplied by a factor to obtain the mean number of parasites for each μL of blood. 
Parastiemia is determined by an estimation of the mean number of parasites per field. The 
number of fields to be counted depends on the parasite density: 
 more than 1000 parasites/ field: count 0.5 field
 100 to 999 parasites/ field: count 1 field
 10 to 99 parasites/ field: count 10 fields
 1 to 9 parasites/ field: count 100 fields  
The factor corresponds to the following microscopic factor: 
Parasites / μl = parasites / field * μL / field where μL / field 
Hemoglobin was determined by and hemoglobinometer needing 10 μL blood:
Hemo_Control® EKF Diagnostic, Germany). An internal control was realized every morning 
and an external control was realized by sending 10% of the samples to the health centre in 
Allada, where hemoglobin was dosed by an automat (Erma laboratory, Japan).
The hemoglobin type was determined by an electrophoresis on a cellulose acetate electric 
field using 50 μL blood (Helena Laboratories, USA).
To evaluate seric ferritin, folate and vitamine B12 the automate AxSYM (AxSYM, Abbott 
Diagnostic, USA) was used. An immunoenzymatic technique based on microparticules was 
used to determine the vitamine B12 concentration and a technique based on ionic capture was 
used to quatify the concentration of folate. Five-hundred μL serum were necessary to analyse 
these parameters.
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CRP was determined by a qualitative-semiquantitative kit (Cypress Diagnostic). It is a 
suspension of latex polystyrene particules covered with a specific anti-serum of IgG fraction 
anti-human CRP. The test is positive is the concentration is equal or higher than 6 mg/l. The 
sensibility of the test is 95,6% and the specificity 96,2%.
Helminth infections were analysed using the Kato-Katz technique. It consists in the 
examination of a calibrated film of fecale substance previously impregnated in a chemical 
solution. It can detect also eggs, especially ankylostome eggs, as well as the intensity of 
helminth infection. 
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Appendix 3: PNLP recommendations:
Since 2006, the programme national de lutte contre le paludisme (PNLP), recommends:
- daily supplement of 200 mg ferrous sulfate (containing 120 mg iron and 5 mg od folic 
acid) for all pregnant women starting at the 1st ANC visit until 3 months after 
delivery.
- In case maternal hemoglobin <110 g/l the quantity of supplements are doubled and if 
maternal hemoglobin <70 g/l maternal transfusion is then encouraged.
- Anti-parasitic treatment starting at the 2nd trimester of pregnancy consists in either 
one-dosed 500 mg mebendazole or 600 mg albendazole (100mg twice a day during 3 
days).
- IPTp with 1500mg sulfadoxine-75mg pyrimethamine twice during pregnancy, starting 
after the first trismester on month appart. The drug regime is augmented to 3 doses in 
case of HIV positive women.
- A rapid diagnostic test is realized to every pregnant woman in case of fever
- For uncomplicated malaria, since 2011, the PNLP recommends the ACT with 20mg 
artemether-120mg lumefantrine. In case of complicated malaria, the treatment consists 
in 8 mg/kg 3 times a day during one week.
- Insecticide treated nets. Since 2003 campaigns are organized to treat and repair ITN 
and/or change them.
- At each ANC visit, HIV screening is proposed for free.
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 A ces mots, il partit, et le laissa là, avec, dans le coeur, 
des pensées qui ne devaient pas se réaliser : Agamemnon se 
disait qu'il prendrait la ville de Priam ce jour-là, 
l'insensé, et il ignorait les desseins de Zeus, qui devait 
encore infliger bien des douleurs et des gémissements aux 
Troyens et aux Danaens, en de rudes mêlées. Il s'éveilla de 
son sommeil, et la voix divine s'écoula autour de lui.
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